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Abstract	
The	 high	 cost,	 complexity	 and	 multimodality	 of	 clinical	 data	 collection	 restrain	 the	datasets	 available	 for	 predictive	 modelling	 using	 machine	 learning	 (ML),	 thus	necessitating	 new	 data-efficient	 approaches	 specifically	 for	 limited	 datasets.	 This	interdisciplinary	 thesis	 focuses	 on	 clinical	 outcome	 modelling	 using	 a	 range	 of	 ML	techniques,	 including	 artificial	 neural	 networks	 (NNs)	 and	 their	 ensembles,	 decision	trees	(DTs)	and	random	forests	(RFs),	as	well	as	classical	 logistic	regression	(LR)	and	Cox	proportional	hazards	(Cox	PH)	models.	The	utility	of	ML	for	data-efficient	regression,	classification	 and	 survival	 analyses	 was	 investigated	 in	 three	 clinical	 applications,	whereby	 exposing	 the	 common	 limitations	 inherent	 in	 patient	 data,	 such	 as	 class	imbalance,	 incomplete	 samples,	 and,	 in	 particular,	 limited	 dataset	 size.	 The	 latter	problem	was	addressed	by	developing	a	methodological	 framework	for	 learning	 from	datasets	 with	 less	 than	 10	 observations	 per	 predictor	 variable.	 A	 novel	 method	 of	multiple	 runs	 overcame	 the	 volatility	 of	 NN	 and	 DT	 models	 due	 to	 limited	 training	samples,	 while	 a	 surrogate	 data	 test	 allowed	 for	 regression	model	 evaluation	 in	 the	presence	of	noise	due	to	limited	dataset	size.	When	applied	to	hard	tissue	engineering	for	 predicting	 femoral	 fracture	 risk,	 the	 framework	 resulted	 in	 98.3%	 accurate	regression	 NN.	 The	 framework	 was	 used	 to	 detect	 early	 rejection	 in	 antibody-	incompatible	 kidney	 transplantation,	 achieving	 85%	 accurate	 classification	 DT.	 	 The	third	 clinical	 task	 –	 that	 of	 predicting	10-year	 incidence	of	 type	2	diabetes	 in	 the	UK	population	 –	 resulted	 in	 70-85%	 accurate	 classification	 and	 survival	 models,	 whilst	highlighting	 the	 challenges	 of	 learning	 with	 the	 limited	 information	 characteristic	 of	routinely	 collected	 data.	 By	 discovering	 unintuitive	 patterns,	 supporting	 existing	hypotheses	 and	 generating	 novel	 insight,	 the	 ML	 models	 developed	 in	 this	 research	contributed	 meaningfully	 to	 clinical	 research	 and	 paved	 the	 way	 for	 data-efficient	applications	of	ML	in	engineering	and	clinical	practice.	
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Introduction	
 The	tacit	value	of	expert	insight	
In	his	1946	study	on	human	expertise,	Dutch	chess	master	and	psychologist	Adriaan	de	Groot	 came	 to	 a	 striking	 revelation	 that	 for	 a	 given	position,	 grandmasters	 evaluated	fewer	moves	than	less	experienced	players,	but	each	of	those	moves	were	among	the	five	best	possible.	The	grandmasters,	he	noted,	were	able	to	‘immediately	“see”	the	core	of	the	 problem	 in	 the	 position’	 [1].	 This	 ability	 of	 a	 practiced	 mind	 to	 eliminate	 poor	solutions,	before	they	reached	the	conscious	thought,	 is	attributed	to	 insight.	Defining	
information	 as	 value-added	 raw	 data	 in	 a	 usable	 context,	 and	 knowledge	 –	 as	 an	interconnected	 and	 structured	 system	 of	 information	 (Figure	 1.1),	 insight	 could	 be	described	 as	 a	 sudden	 change	 in	 knowledge	 representation,	 often	 leading	 to	 a	formulation	of	a	new	concept	or	awareness	of	a	solution	[2].	
	
Figure	1.1	Graphical	illustration	of	the	relationship	between	data,	information,	knowledge,	insight	and	
wisdom.	Adapted	from	[3].	
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For	 a	 society	 that	 has	 spent	most	 of	 the	 20th	 century	meticulously	 codifying	 existing	human	knowledge	into	computer	algorithms,	insight	presented	a	challenge:	it	is	difficult	to	reproduce,	systematise	or	even	explain	the	tacit	mechanisms	by	which	we	generate	insight.	 Without	 statistical	 backing	 and	 reproducibility,	 insight	 is	 often	 viewed	 as	intuition,	creative	genius,	or	luck,	therefore,	invalidating	its	use	in	systematic	decision-making	 in	high-risk	 applications	 and	expert	domains	 such	as	medicine	 [4].	 	Although	largely	a	product	of	 subconscious	processing,	 insight	originates	 from	 learning	complex	
patterns	 in	the	data,	that	results	in	an	often	spontaneous	awareness	of	the	underlying	knowledge	 structure	 [2].	 	 Whether	 in	 chess	 or	 radiography,	 the	 more	 practice	 we	undertake	 recognising	 relevant	 patterns,	 the	more	 efficient	 and	 focused	 our	 thinking	becomes,	to	the	point	where	we	are	able	to	ignore	non-essential	knowledge	pathways	and	come	up	with	an	insight	(Figure	1.1).			
Pattern	 recognition	 is	 a	 fundamental	 function	 of	 a	 human	 brain	 through	 which	 we	integrate	sensory	information	about	the	surrounding	world	to	generate	advantageous	behavioural	responses.	Whether	it	 is	 in	detecting	familiar	faces	and	creating	cognitive	maps	 of	 the	 environment,	 or	 piecing	 together	 sounds	 into	 a	 language,	 throughout	thousands	 of	 years	 of	 existence,	 humans	 have	 developed	 a	 remarkable	 capacity	 for	
pattern	 recognition	 from	sensory	 inputs.	We	are	even	capable	of	 identifying	 temporal	
patterns	when,	driven	by	our	rudimentary	aversion	of	uncertainty,	we	access	past	and	present	information	to	predict	and	model	the	future	[5].	Nevertheless,	our	perception	of	
numerical	and	abstract	patterns	 is	often	limited	by	three-dimensional	spatial	thinking,	making	 spontaneous	 insight	 improbable	 when	 multi-dimensional	 properties	 of	observations	 are	 involved,	 such	 as	 that	 in	 identifying	 a	 rare	 disease	 from	 sporadic	symptoms,	unrelated	tests	and	fragmented	medical	history.	
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 Teaching	machines	to	generate	insight	
From	drawings	and	clay	models	to	mathematics	and	physical	theories	–	we	have	always	used	 instruments	 to	 augment	 our	 perception	 of	 sensory,	 numerical,	 and	 abstract	patterns	and	aide	our	predictions.	Yet	only	with	the	advent	of	computers	we	have	been	able	to	overcome	the	limitation	of	our	three-dimensional	spatial	thinking.	This	became	possible	as	a	result	of	machine	learning	(ML)	–	a	paradigm	in	which	computers	are	taught	to	learn	patterns	from	data,	as	opposed	to	being	pre-programmed	with	equations	that	describe	 these	patterns.	 	By	 teaching	computers	 to	recognise	patterns	 in	 the	data,	we	have	 been	 able	 to	 augment	 our	 pattern	 recognition	 in	 higher	 dimensions,	 provide	statistical	backing	to	our	intuition,	and	make	probabilistically-founded	predictions	from	existing	observations	[6].		
Formally,	ML	refers	to	an	area	of	artificial	intelligence	that	enables	autonomous	learning	from	 input	 stimuli	 [7–9].	The	process	of	 learning	 in	 itself	 is	 a	 stepwise	 refinement	of	patterns	that	results	from	repeated	hierarchical,	parallel	and	recursive	computations	on	new	observations	 and	 experiences	 [4].	 As	with	 human	 learning,	where	we	 adapt	 our	behaviour	based	on	observed	information	in	order	to	achieve	a	set	goal,	computers	are	trained	 to	 generate	 adaptive	 responses	 to	 the	 input	 data	 when	 given	 an	 objective	function.	 	 This	 fundamental	 property	 allows	 ML	 systems	 to	 generate	 insight	 from	complex	patterns	through	exposure	to	data.		
The	 ML	 domain	 encompasses	 a	 diverse	 array	 of	 algorithms	 and	 modes	 of	 learning,	including	 supervised,	 unsupervised,	 hybrid,	 ensemble,	 reinforcement,	 active,	adversarial,	and	transfer	learning	[8–12].		In	predictive	modelling	that	is	the	focal	point	of	this	thesis,	much	of	the	success	of	ML	has	been	attributed	to	supervised	learning	[6,13],	in	which	machines	learn	to	map	inputs	to	pre-specified	desired	outputs	(ground	truth).	
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By	 comparing	 ML	 system	 predictions	 with	 the	 true	 outcomes,	 supervised	 learning	essentially	 reproduces	 the	 “trial	 and	 error”	 approach	 of	 human	 learning	 [4].	 Once	trained,	the	models	can	be	used	for	generalising	on	new	input	data,	i.e.	the	prediction	of	outputs	for	sets	of	data	not	previously	encountered	by	the	model.	Supervised	learning	has	proven	exceptionally	effective	in	solving	problems	that	involve	sorting	sets	of	data	into	previously	known	classifications,	mapping	trends	(function	fitting),	and	forecasting	the	output	from	sets	of	inputs	[14,15].	
Among	 numerous	 ML	 architectures,	 artificial	 neural	 networks	 (NN)	 are	 widely	recognised	for	their	ground-breaking	ability	to	derive	insight	from	complex	non-linear	patterns.	Originally	inspired	by	the	function	of	biological	neurons	in	the	central	nervous	system	 [16,17],	 NNs	 are	 regarded	 as	 universal	 function	 approximators	 capable	 of	working	 with	 both	 linear	 and	 non-linear	 systems	 [18,19].	 Various	 neural	 learning	algorithms	 and	 network	 configurations	 have	 been	 developed	 throughout	 NN	 history	[20],	allowing	NNs	to	be	tailored	to	the	demands	of	specific	analytical	tasks	ranging	from	classification,	 forecasting	 and	 time	 series	 analysis	 to	 combinatorial	 problem	 solving,	adaptive	 control,	 multisensory	 data	 fusion	 and	 noise	 filtering	 [21,22].	 Most	 recently,	Deep	Learning	[23]	resulted	in	NNs	mastering	speech	recognition	[24]	and	surpassing	humans	in	the	game	of	Go	[25].	Despite	their	adaptability,	NN	algorithms	are	sensitive	to	the	quality	and	size	of	the	training	data.	Precisely	for	this	versatility,	promising	future	potential,	and	realistic	 limitations,	 the	NN	was	chosen	 in	this	research	as	the	core	ML	architecture	 for	 exploring	 the	 challenges	 of	 predictive	 modelling	 with	 limited	information.	
In	 some	 high-risk	 clinical	 applications	 such	 as	 organ	 transplantation,	 where	 an	erroneous	decision	can	be	fatal,	the	black-box	nature	of	NNs	render	them	inadmissible	to	critical	decision	support.	In	applications	that	require	an	intuitive	model	to	be	used	by	
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the	 operating	 physician,	 decision	 tree	 (DT)	 learning	 offers	 an	 unprecedented	transparency	of	the	statistical	pattern	associations	with	transplantation	outcomes.		
Although	largely	focused	on	NNs	and	DTs,	the	methodological	approaches	developed	in	this	thesis	could	be	applied	to	other	ML	systems	for	clinical	risk	stratification,	including	kernel-based	 learning	 [318]	 and	 Bayesian	 inference	 models	 [200].	 However,	 these	systems	are	outside	of	the	remit	of	this	research	and	have	not	been	considered	in	this	thesis.	
 Machine	learning	in	healthcare	
In	medicine	 and	 clinical	 epidemiology,	ML	 is	 beginning	 to	 enable	 predictive	 decision	support	for	healthcare	professionals	in	diagnosing	diseases	[26],	predicting	mortality	or	relapse	 [27],	 informing	 treatment	 strategies	 [28–30],	 simulating	 potential	 outcomes	[31,32],	and	in	performing	numerous	other	patient-specific	analyses	[33].		ML	is	viewed	as	an	indispensable	tool	for	biomedical	problems	involving	complex	heterogeneous	data	when	conventional	statistical	 tools	 fail	 [34–36].	 In	applications	such	as	gene	selection	and	classification	[37],	screening	heart	murmurs	in	children	[38],	and	predicting	breast	cancer	 relapse	 [39],	ML	models	were	 able	 to	map	 highly	 nonlinear	 input	 and	 output	patterns	 even	when	mechanistic	 relationships	 between	model	 variables	 could	 not	 be	determined	due	to	pathologies	or	complexity.			
ML	is	largely	responsible	for	the	recent	breakthrough	in	human	genomics	[40,41]	and	drug	discovery	[42,43],	thus	accelerating	our	transition	to	precision	medicine		[44,45].	In	radiology	and	brain	imaging,	computer-aided	image	recognition	is	reshaping	the	clinical	practice	and	reaching	above-human	diagnostic	accuracies	[46,47].	In	other	areas,	clinical	researchers	equipped	with	ML	are	working	to	eradicate	AIDS	[28,32],	treat	diverse	types	of	 cancer	 [29,48–50],	 and	 improve	 the	 efficiency	 of	 critical	 care	 [51].	 	 Despite	 these	
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notable	 advances	 in	medical	 research,	 the	 uptake	 of	ML	 in	 clinical	 practice	 has	 been	slower	than	in	many	other	equally	high-risk	expert	domains	[52,53].	The	vast	potential	of	ML	for	predictive	modelling	in	healthcare	remains	largely	unexplored.	It	is	argued	that	the	further	development	of	ML	in	clinical	practice	is	impeded	by	limited	availability	and	quality	of	relevant	data	[33,51,52].	Thus,	to	extend	the	benefits	of	ML	to	a	wider	range	of	clinical	datasets,	it	is	essential	to	first	develop	methods	that	would	compensate	for	the	
limited	data.	This	brings	us	to	a	consideration	of	the	inherent	properties	of	clinical	and	biomedical	data	that	make	ML	particularly	challenging.		
 Why	clinical	data	are	limited	
The	limitations	of	clinical	datasets	are	two-fold:	limited	availability	of	high	quality	data	and	low	quality	of	available	data.		The	size	of	datasets	available	for	statistical	modelling	is	 often	 restrained	 by	 the	 cost	 and	 complexity	 of	 medical	 experiments.	 Most	experimental	datasets	stem	from	single-centre	studies,	and	do	not	meet	the	demands	of	data-intensive	ML	systems	designed	for	Big	data	[54].	Multicentre	data	collaborations	have	proven	to	possess	a	tremendous	potential	for	transforming	clinical	practice	[53],	yet	 integration	 of	 datasets	 across	 multiple	 institutions	 remains	 problematic.	Heterogeneity	 of	 study	 protocols,	 differing	 international	 and	 inter-institutional	standards,	concerns	over	patient	confidentiality,	and	technical	incompatibility	–	all	pose	barriers	to	an	open	sharing	of	medical	information	and	the	creation	of	the	substantive	datasets	required	to	train	ML	systems.	Finally,	 in	some	medical	domains,	for	example,	
hard	 tissue	 engineering	 or	 organ	 transplantation,	 where	 associated	 interventions	 are	invasive	and	potentially	harmful	 to	 the	patient,	 obtaining	 large	number	of	 samples	 is	altogether	unrealisable.			
Chapter	1.		Introduction	
7	
Routinely	collected	patient	data,	such	as	those	found	in	electronic	medical	records	(EMR)	and	clinical	data	management	systems,	are	generally	more	accessible	than	data	curated	for	 research	 purposes.	 By	 reusing	 the	 standard	 clinical	 databases,	 it	 is	 possible	 to	decrease	 the	cost	of	 large	volume	datasets	 for	 training	ML	systems.	Nevertheless,	 the	
quality	of	routinely	collected	data	is	often	limited	in	terms	of:		
• low	information	density	
• multimodality	and	heterogeneity	
• missing	values	and	censoring	
• class	imbalance	
• corruption	by	noise	and	errors		
Firstly,	 not	 all	 data	 are	 informative	 (Figure	1.1).	 Even	a	 large	EMR	database	may	not	contain	the	necessary	information	to	reliably	infer	complex	patterns	relevant	to	a	clinical	problem	at	hand.	For	 instance,	 in	order	 to	successfully	model	a	multifactorial	disease	such	 as	 diabetes	mellitus,	 the	 data	must	 carry	 sufficient	 information	 to	 describe	 the	pathophysiological	 mechanisms	 of	 the	 disease,	 to	 differentiate	 between	 patient	phenotypes,	and	to	account	for	confounding	factors	and	the	reverse	causality	of	diabetes	with	conditions	such	as	hypertension	and	obesity.		As	later	discovered	in	this	research,	such	intricate	detail	is	not	presently	available	in	the	UK	healthcare	EMR	systems.		Some	leading	groups	 in	clinical	ML	adaptation	argue	 that	 commercial	 clinical	 systems	were	designed	“to	document	clinical	activity	for	reporting,	liability,	and	billing	reasons,	rather	than	 for	 developing	 new	 algorithms”	 [51].	 The	 low	 information	 density	 of	 such	 EMR	systems	make	even	large	datasets	small.	
Multimodality	of	a	clinical	dataset	refers	to	its	heterogeneous	sources:	free-text	reports	by	 general	 practitioners,	 hospital	 discharge	 records,	 biochemistry	 tests	 and	 biopsies	from	 laboratories,	 DNA	 sequencing	 data,	 vaccination	 history,	 X-ray	 and	 MRI	 scans,	
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medication	 prescriptions,	 and	 even	 medical	 insurance	 claims.	 Multimodality	 poses	similar	problems	with	dataset	integration	as	the	multicentre	data	discussed	earlier,	but	requires	 technologically	 different	 ML	 solutions	 that	 cascade	 or	 combine	 multiple	learners	[55–57].	Variable	types	in	clinical	datasets	also	exhibit	heterogeneity:	discrete	(ex.:	 family	 size,	 number	 of	 previous	 transplants)	 and	 continuous	 (ex.:	 age,	 blood	pressure,	blood	glucose	 level)	numerical	variables,	nominal	 (ex.:	gender,	blood	group)	and	 ordinal	 (ex.:	 degrees	 of	 pain,	 classes	 of	 antibodies)	 categorical	 factors,	 including	binary	indicators,	as	well	as	image	matrices,	waveforms	and	time	series	–	all	of	which	necessitate	a	mixed	modelling	approach	and	non-trivial	pre-processing	[17,58]	.		
Clinical	database	records	and	EMR	are	rarely	complete.	Missing	values	arise	in	routinely	collected	datasets	for	reasons	such	as	unsystematic	recording,	equipment	failure,	time	constraints,	 human	 error,	 system	 blackouts,	 and	 patient	 no-show.	 Some	 unrecorded	values	 may	 be	 implicit	 (e.g.:	 sex	 of	 obstetrics	 patients,	 ethnicity	 in	 homogeneous	communities)	or	sparse	by	design	(e.g.:	historic	data	for	a	newly-introduced	variable).	A	particular	 type	 of	 missing	 data	 are	 right-censored	 observations,	 where	 the	 outcome	variable	is	unknown	due	to	loss	of	the	patient	follow-up.	Censored	population	data	are	particularly	 difficult	 for	 supervised	 learning;	 limited	 success	 has	 been	 achieved	with	supervised	ML	systems	and	right-censored	data	in	general	[6,27,59–62].	The	cumulative	effect	of	missing	values	across	several	variables	and	outcomes	of	interest	diminishes	the	reliability	and	information	density	of	routinely	collected	clinical	datasets	for	training	and	validating	accurate	ML	systems	[63–66].		
Class	imbalance	refers	to	a	limitation	where	one	type	of	outcomes	is	observed	in	a	dataset	more	frequently	than	another.	High	imbalance	is	common	in	medical	classification	tasks,	such	as	predicting	diseases	with	 low	prevalence	or	rare	variants	of	common	diseases,	monitoring	abnormal	response	to	treatment,	and	preventing	clinical	equipment	failures	
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[26,47,67,68].	 Imbalanced	 sets	 also	 abound	 in	 population	 screening	 data,	 where,	fortunately,	even	the	most	prevalent	diseases	such	as	diabetes,	only	affect	a	fraction	of	the	population.	Training	ML	classifiers	with	 imbalanced	data	reduces	 their	sensitivity	and	thus	overall	predictive	power,	unless	appropriately	accounted	for	[69–71].	
Finally,	 routinely	 collected	 patient	 data	 are	 inherently	noisy	 and	prone	 to	 errors.	 Any	locality	 specific	 variations,	 errors	 or	 omissions	 in	 EMR	 aggregate	 at	 scale	 when	combined	 with	 population-level	 datasets.	 An	 additional	 source	 of	 “noise”	 for	 ML	 in	multimodal	 and	 multicentre	 databases	 results	 from	 inconsistencies	 in	 how	 a	 given	disease	 symptom	 is	 coded,	 when	 certain	 variables	 are	 recorded,	 and	 how	 they	 are	interpreted		[44,72,73].	For	instance,	the	UK	National	Health	Service	(NHS)	EMR	system	accessed	 in	 this	 research	 utilises	 over	 300	 separate	 codes	 for	 direct	 identification	 of	diabetes	 mellitus,	 not	 including	 400	 additional	 product	 codes	 related	 to	 diabetic	medicine	prescriptions.	Even	smoking	status	identification	involves	analysis	of	over	120	read	 codes,	 which	 make	 distinctions	 as	 subtle	 –	 and	 perhaps	 as	 prone	 to	 arbitrary	assignment	 –	 as	 “137S.00	 Ex-smoker”	 and	 “137K.00	 Stopped	 smoking”.	 Despite	continuous	 standardisation	 of	 clinical	 databases	 in	 the	 UK	 and	 globally,	 noise,	inconsistencies	and	errors	have	remained	one	of	the	defining	limitations	of	a	domain	as	complex	and	diverse	as	human	healthcare		[47,51,74,75].	
Combined,	the	quality	limitations	reduce	the	predictive	value	of	clinical	and	biomedical	datasets.	Low	information	density,	high	heterogeneity,	missing	values,	class	imbalance	and	errors	explain	why	a	seemingly	vast	multicentre	dataset	may	not	contain	a	sufficient	number	 of	 observations	 to	 effectively	 approach	 the	 clinical	 problem	 at	 hand	 [53].	Whether	using	large	routinely	collected	multicentre	databases,	or	single-centre	datasets,	reductions	 of	 already	 scarce	 observations	 often	 result	 in	 datasets	 as	 small	 as	 10	
observations	per	predictor	variable.	
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 Challenges	of	learning	with	limited	information	
Small	datasets	jeopardise	the	predictive	potential	of	otherwise	powerful	ML	techniques.	Efforts	 towards	 data-efficient	 learning	 are	 presently	 nascent	 in	 the	 ML	 community,	which	has	been	traditionally	focused	on	solving	complex	problems	with	Big	data	[76].	Learning	efficiency	considerations	are	emerging	in	Bayesian	optimisation	[77–79]	and	reinforcement	 learning	 [80–82],	 however,	 the	 synthetic	 and	 real	 datasets	 implied	 in	those	applications	are	in	the	order	of	tens	of	megabytes	[83]	–	far	beyond	what	is	readily	available	 in	 many	 clinical	 applications,	 such	 as	 hard	 tissue	 engineering	 and	 organ	transplantation.		
As	a	result,	ML	models	trained	with	insufficiently	large	datasets	often	exhibit	unstable	behaviour	 in	 performance,	 i.e.	 sporadic	 fluctuations	 due	 to	 the	 sensitivity	 of	 the	 ML	models	to	initial	parameter	values	and	training	order	[84–86].	Model	initialisation	and	training	 algorithms	 commonly	 contain	 deliberate	 degrees	 of	 randomness	 in	 order	 to	improve	 convergence	 to	 the	 global	 minimum	 of	 the	 associated	 cost	 function	[14,85,87,88].	With	some	learning	algorithms,	the	order	within	which	the	training	data	are	fed	to	the	model	can	affect	the	level	of	convergence	and	produce	erratic	outcomes	[85,86].	 Moreover,	 limited	 test	 data	 availability	 poses	 a	 major	 obstacle	 to	 reliably	assessing	 the	model	generalisation	on	new	samples.	Such	 inter-model	volatility	 limits	both	the	reproducibility	of	the	results	and	the	objective	comparison	between	different	NN	designs	for	future	optimisation	and	validation.	Previous	attempts	[89]	to	resolve	the	stability	 problems	 in	 NNs	 demonstrated	 the	 success	 of	 k-fold	 cross-validation	 and	ensemble	 methods	 for	 a	 medical	 classification	 problem;	 the	 dataset	 comprised	 53	features	 and	1355	observations,	which	 corresponds	 to	25	observations	per	predictor	variable.	 	 To	 the	 author’s	 best	 knowledge,	 effective	 strategies	 for	 classification	 and	regression	tasks	with	less	than	10	observations	per	predictor	variable	have	not	yet	been	
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established,	 thus	 necessitating	 the	 development	 of	 a	methodology	 that	would	 enable	successful	learning	from	limited	information.	
 Aims	and	objectives	
The	aim	of	 this	 thesis	 is	 to	develop	and	validate	practical	models	 for	clinical	outcome	prediction	 and	 risk	 stratification	 based	 on	machine	 learning	with	 limited	 biomedical	information.	Three	 important	clinical	applications	are	addressed	by	adapting	existing,	and	 developing	 novel,	 supervised	 learning	 techniques	 for	 data-efficient	 regression,	classification,	and	survival	modelling.	
In	 hard	 tissue	 engineering,	 the	 task	 is	 to	 devise	 a	 scalable	 model	 for	 hip	 fracture	prediction	in	severe	osteoarthritis	based	on	a	small	secondary	dataset	of	35	trabecular	bone	 samples.	 If	 successful,	 the	 original	 contribution	 of	 this	 work	 is	 two-fold:	 (1)	enabling,	for	the	first	time,	an	accurate	and	non-invasive	estimation	of	the	mechanical	strength	of	a	trabecular	tissue	from	a	handful	of	structural	and	physiological	parameters	for	patients	suffering	from	a	severe	degenerative	bone	disease,	and	(2)	evidencing	that	a	small	 NN	 model	 is	 capable	 of	 capturing	 complex	 mechanobiological	 patterns	 and	 of	making	 inferences	 about	 the	 diseased	 bone	 quality	 that	 are	 inaccessible	 through	mechanistic	modelling.		
In	kidney	 transplantation,	 the	 aim	 is	 to	 reduce	 the	 long-term	 failure	 risk	 of	 donor-recipient	 antibody-incompatible	 transplants	 by	 providing	 nephrologists	 with	 an	accurate	and	transparent	decision	support	tool.	The	complexity	of	developing	such	a	tool	from	heterogeneous	single-centre	patient	data	is	that	it	must	combine	descriptive	and	predictive	modelling	in	order	to	first	establish	dangerous	antibody	levels	and	key	risk	factors,	 and	 then	 forecast	 the	 likelihood	 of	 acute	 and	 chronic	 transplant	 rejection.	 If	successful,	this	tool	for	the	early	detection	of	acute	graft	rejection	would	be	the	first	of	
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its	kind	in	antibody-incompatible	kidney	transplantation,	pioneered	in	Europe	by	clinical	collaborators	from	the	University	Hospitals	of	Coventry	and	Warwickshire.	
The	 diabetes	 screening	 project,	 conducted	 in	 collaboration	 with	 the	 Nuffield	Department	 of	 Primary	 Care	 Health	 Sciences	 (University	 of	 Oxford),	 is	 aimed	 at	modernising	the	existing	statistical	system	for	managing	the	early	prediction	of	diabetes	in	NHS	primary	health	care.	The	development	of	a	dynamic	NN	model	for	10-year	type	2	diabetes	 risk	 stratification	 from	 80,000	 routinely	 collected	medical	 records	 has	 been	stipulated	by	the	study	protocol	[90].	It	has	been	previously	hypothesised	that	inclusion	of	 blood	 glucose	 measurements	 can	 increase	 the	 prognostic	 value	 of	 the	 model.	 To	validate	 this	 hypothesis,	 the	 NN	 model	 will	 be	 implemented	 and	 evaluated	 in	 two	settings:	with	and	without	the	blood	glucose	information.		
It	is	important	to	note	that	the	ML	algorithms	developed	in	this	research	are	not	intended	to	 be	 decision-makers:	 they	 are	 merely	 statistical	 tools	 that	 allow	 healthcare	professionals	 to	 recognise	 non-trivial	 high-dimensional	 patterns	 that	 may	 exist	 in	complex	clinical	data.		
The	above	applications	represent	three	common	clinical	tasks:	regression,	classification	and	 survival	 analysis,	 respectively.	 They	 also	 reflect	 various	 aspects	 of	 limitations	inherent	in	clinical	data.	The	trabecular	bone	and	kidney	transplant	datasets	are	limited	by	size,	representing	single-centre	studies.	The	diabetes	dataset	is	of	a	large	size,	but	is	grossly	 incomplete,	 censored	and	 imbalanced,	 representing	 the	 common	attributes	of	routinely	collected	data.	
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The	objectives	of	this	thesis	are	listed	as	follows:	
1. to	identify	effective	strategies	for	managing	data	quality	limitations	in	the	three	applications;	2. to	 develop	 an	 application-independent	 methodological	 framework	 for	 small-data	learning	(less	than	10	observations	per	predictor	variable)	and	to	validate	the	framework	with	a	sufficiently	large	external	dataset;	3. using	existing	(1)	and	novel	(2)	methodology,	to	design,	implement,	optimise	and	test	 practical	 ML	 prototypes	 of	 the	 healthcare	 technology	 required	 for	 each	application:	a. an	 accurate,	 non-invasive	 diagnostic	 tool	 for	 depleted	 femoral	compressive	strength	in	osteoarthritic	patients	of	all	genders	and	ages;	b. an	 informative,	 statistically-grounded,	 and	 easy-to	 interpret	 decision	support	 tool	 for	 the	 prediction,	 prior	 to	 transplantation,	 of	 likely	transplant	outcomes;	c. a	prognostic	 tool	 for	 early	 indicators	of	 type	2	diabetes	 in	 the	general	population,	that	would	retain	high	sensitivity,	without	generating	a	large	number	of	costly	false	alarms;	4. to	use	the	clinical	insights	gained	from	the	ML	models	in	order	to	detect	patients	at	 risk	 and	 improve	 short-	 and	 long-term	 individual	 outcomes	 in	 all	 three	applications.		
 Thesis	structure	
The	 structure	 of	 the	 thesis	 is	 as	 follows.	 Chapter	 1	 introduces	machine	 learning	 and	predictive	modelling	in	healthcare	in	the	context	of	expert	insight	generation	and	clinical	data	limitations.	It	outlines	the	aims	and	the	objective	of	the	thesis.		Chapter	2	outlines	
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machine	learning	methodologies	relied	upon	in	this	work,	focusing	on	neural	networks,	decision	trees,	and	ensemble	learning.	Chapter	3	presents	a	novel	methodology	for	the	limited	 data	 underpinning	 this	 research,	 and	describes	 its	 validation	 using	 a	 publicly	available	civil	engineering	dataset.	Chapters	4	and	5	explore	the	utility	of	the	proposed	strategies	for	data-efficient	regression	modelling	on	hard	tissue	engineering	data,	and	predictive	 classification	 on	 kidney	 transplantation	 data,	 respectively.	 Chapter	 6	describes	the	challenges	of	modelling	diabetes	with	large,	routinely	collected	dataset	and	how	 they	 have	 been	 addressed	 with	 several	 classification	 and	 survival	 models.	 The	overall	contribution	and	key	discoveries	are	summarised	in	Chapter	7.			
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Methodology		
This	chapter	describes	the	underlying	methodology	for	the	design,	training,	optimisation	and	validation	of	the	machine	learning	models	developed	for	the	applications	in	Chapters	4,	 5	 and	 6,	 and	 serves	 as	 a	 foundation	 for	 the	 novel	 methodology	 for	 limited	 data	presented	in	Chapter	3.		
The	chapter	is	organised	as	follows.	Sections	2.1	and	2.2	provide	an	in-depth	explanation	of	 neural	 network	 and	 decision	 tree-based	 learning.	 Section	 2.3	 introduces	 ensemble	
learning	 and	 the	concept	of	 learner	diversity.	Section	2.4	presents	an	overview	of	 the	statistical	models	 implemented	 in	 Chapters	 5	 and	 6,	 specifically	 the	Cox	 proportional	
hazards	model	and	logistic	regression.	Section	2.5	describes	performance	validation	and	outlines	 the	 criteria	 for	 evaluation	 of	 regression,	 classification,	 and	 survival	 tasks.	Section	2.6	details	the	software	and	hardware	resources	utilised	in	this	research.	Finally,	the	sources	of	primary	and	secondary	data	are	acknowledged	in	Section	2.7.	
 Neural	network	learning	
2.1.1 Neural	network	topology	and	configuration	
NNs	 represent	 a	 set	 of	 highly	 interconnected	 neural	 computing	 elements	 called	
perceptrons	(also	known	as	neurons,	used	interchangeably)	that	respond	to	input	stimuli	
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by	 crudely	 imitating	 the	 non-linear	 learning	 that	 occurs	 in	 biological	 neurons.	 In	 the	biological	nervous	system,	an	input	signal	propagates	through	the	dendrites	to	the	cell	
body,	where	a	response	is	generated	if	an	excitation	(activation)	threshold	is	reached,	and	the	 response	 is	 then	 fired	 through	 the	 axon	 to	 the	 neighbouring	 neurons.	 The	connections	between	neurons,	called	synapses,	strengthen	or	weaken	depending	on	how	frequently	that	particular	synapse	is	used	to	compute	a	successful	response	[14,17].			
Imitating	 this	property	of	 the	 synapses,	NNs	adapt	 to	 changes	 in	 the	environment	by	varying	the	strength	of	individual	neural	links,	referred	to	as	weights	w,	and	the	inherent	inclination	of	each	neuron	to	produce	a	predefined	output,	termed	as	bias	b.	Figure	2.1	represents	 a	 single	 perceptron	 that	maps	 an	 input	 vector	 : = [: V 	: , … : C ]	 to	 an	output	vector		0 = [0 V 	0 , … 0 C ],	each	comprising	2	observations.		
	
Figure	2.1	Perceptron	The	perceptron	activation	function	consists	of	a	summation	operation	Y	and	a	transfer	function	Z.	Given	a	linear	Z,	the	perceptron	in	Figure	2.1	computes	the	output	as	follows:	
	 0 = :8 + b	 "].	2.1	
Given	 3	 predictor	 variables,	 the	 input	 becomes	 a	 2	x	3	 matrix		4 = :	V(V) ⋯ :	b(V)⋮ ⋱ ⋮:V(C) ⋯ :	b(C) ,	
where	 jth	column	with	2	observations	is	one	predictor	variable	:; = :;V 	:;, … :;C e .	
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Scaling	this	simple	mathematical	model	of	a	single	perceptron	into	a	multilayer	network	yields	a	powerful	predictive	model	capable	of	being	 trained	and	 learning	dynamically	from	new	stimuli	in	order	to	map	its	inputs	to	outputs	[14,91].			
	
Figure	2.2	Multilayer	perceptron	network	(secondary	paths	are	greyed-out	for	legibility)		The	diagram	in	Figure	2.2	is	an	example	of	a	multilayer	perceptron	network,	comprising	3	 inputs,	one	hidden	 layer	with	$	neurons	and	one	output	 layer	with	1	output	neuron.	The	 input	 to	 the	 NN	 does	 not	 strictly	 constitute	 its	 own	 layer,	 although	 there	 is	 no	unanimous	consensus	in	the	ML	community	regarding	reference	to	the	separate	“input”	layer	[14,17].	The	neurons	in	the	hidden	layer	connect	to	every	variable	:V, :,, … , :b	in	the	input	4	supplied	to	the	network.	The	number	of	hidden	layers,	as	well	as	their	size	(i.e.	the	number	of	neurons	$	in	the	layer)	are	NN	hyperparameters	that	can	be	tailored	for	a	given	 application.	 The	 number	 of	 neurons	 in	 the	 output	 layer	 is	 determined	 by	 the	number	of	output	variables	being	predicted.	In	the	network	depicted	in	Figure	2.2	the	output	layer	size	is	1,	since	the	applications	considered	in	this	thesis	only	required	one	
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output	0.		The	set1	of	biases	b	=	{. V , . , }	corresponds	to	the	number	of	neurons	in	the	network,	 which	 in	 this	 example	 is	 equal	 to	 $	 biases	. V = [	.VV 	.,V …	.hV ]	 for	 the	hidden	layer	and	one	bias	.(,)	for	the	output	neuron.		
The	matrix	of	input	weights	67 = 8VV ⋯ 8Vh⋮ ⋱ ⋮8bV ⋯ 8bh 	comprises	elements	8;i 	that	connect	the	jth	variable	:; 	with	a	kth	neuron	in	the	hidden	layer.	The	column	vector	of	layer	weights		89 = 8VB		8,B …8hB ecomprises	 elements	8iB 	 that	 connect	 each	 kth	 neuron	 in	 the	hidden	layer	to	the	output	neuron	(in	case	of	multiple	outputs	67 		is	a	matrix).	There	is	no	mathematical	distinction	between	how	8;i 	and	8iB	are	treated;	the	input	and	layer	weights	comprise	a	set	of	network	weights	6 = {67, 89}.	In	a	fully-connected	NN	every	neuron	in	a	given	layer	is	connected	to	every	neuron	in	the	next	layer,	but	not	to	other	neurons	in	the	same	layer	[17].	The	level	of	connectivity	can	be	customised	for	a	given	application,	producing	more	exotic	NN	topologies	such	as	convolutional	layer	networks	[92],	residual	networks	[93]	and	Echo	state	networks	[94].			
The	multilayer	perceptron	 in	Figure	2.2	 is	 referred	 to	as	a	 feedforward	NN,	due	 to	 its	acyclic	signal	flow	in	which	the	signal	is	propagated	from	the	inputs	to	outputs	and	the	connections	between	neurons	do	not	 form	 loops.	Other	 types	of	 flow	exist,	 such	as	 in	recurrent	 NNs	 [95],	 auto-encoders	 [96,97],	 Hopfield	 networks	 [98]	 and	 Boltzmann	machines	[99].		What	makes	feedforward	NNs	particularly	versatile	and	effective	in	the	applications	 considered	 in	 this	 research	 is	 that	 they	 are	 capable	 of	 approximating	arbitrarily	 closely	 any	 continuous	 function	 of	 real	 valued	 inputs.	 This	 notion	 of	feedforward	NNs	 	as	universal	approximators	has	been	elegantly	proven	by	Hornik	 in	1990	[19].	
																																								 																					1	Braces	{	}	denote	sets.	
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2.1.2 Neural	network	training	with	backpropagation	
NN	 training	 involves	 determining	 values	 for	weights	6	 and	 biases	.	 that	 reduce	 the	overall	network	cost	 function.	The	cost	 function	kZ(0, 1)	refers	to	the	error	/	between	predicted	0	and	target	1	output	value,	i.e.	/ = kZ 0, 1 .	In	supervised	learning,	a	training	dataset	l = {4, 1},	 comprising	 the	 pairs	 of	 input	4	 and	 target	 1	 = [1 V 	1 , … 	1 C ],	 is	supplied	to	the	network.	Hence,	the	aim	of	training	can	be	defined	as	using	observations	
in	l	to	determine	the	set	of	NN	parameters	%	 = 	 {6, .}		that	minimise	kZ(0, 1).	This	task	is	two-fold:	it	requires	an	optimisation	algorithm	to	minimise	kZ(0, 1)	and	a	mechanism	to	adapt	the	parameters	in	%	in	response	to	changes	in	kZ 0, 1 .	
In	the	NN	applications	considered	in	this	research,	i.e.	in	Chapters	3,	4	and	6,	the	task	of	training	NNs	 is	 solved	by	backpropagation	 –	 a	powerful	 algorithm	 that	has	 remained	dominant	 in	 NN	 development	 and	 proved	 its	 superiority	 through	 	 time	 [100–104].	Backpropagation	combines	the	chain	rule	[105],	to	propagate	the	slope	of	/	through	the	network,	 with	 an	 optimisation	 algorithm,	 such	 as	 gradient	 descent,	 to	 compute	 the	necessary	changes	to	network	parameters	in	%	to	reduce	/.	The	use	of	backwards	flow	through	 non-linear	 systems	 had	 been	 well	 known	 in	 control	 theory	 for	 many	 years	before	 Paul	Werbos	 proposed	 their	 application	 to	 NNs	 [101].	 	 The	 resulting	 process	created	 two	passes	of	 information	 flow	 through	a	network	 for	each	 training	 iteration	
(epoch).		In	the	forward	pass,	an	output	0	was	computed	from	the	training	sample	in	the	input	4.	In	the	backward	pass,	the	error	/	is	propagated	starting	from	the	output	layer	through	the	hidden	layers	to	the	input.	In	so	doing,	backpropagation	updates	the	values	of	 the	 weights	6	 and	 biases	 .	 for	 each	 neuron,	 while	 accounting	 for	 their	 overall	contribution	to	the	predicted	result.		The	forward	and	backward	steps	iterate	until	the	error	function	is	minimised,	as	described	in	Figure	2.3.		
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Figure	2.3	Stages	of	NN	training	with	backpropagation	What	 constitutes	 a	 single	 epoch	 depends	 on	 whether	 online	 (also	 referred	 to	 as	
stochastic)	or	batch	learning	is	involved.	In	online	learning,	each	data	sample	presented	is	 followed	 by	 a	 weight	 update,	 while	 for	 batch	 learning,	 all	 data	 samples	 from	 the	training	set	are	presented	to	the	NN,	and	the	weight	update	is	calculated	for	each	sample	and	 combined	 prior	 to	 every	 update	 event	 [106].	 Online	 learning	 requires	 less	computations	for	each	weight	update,	but	it	is	very	sensitive	to	the	outliers,	thus	making	it	impractical	for	the	clinical	applications	considered	in	this	research.	Despite	being	more	computationally	 demanding,	 batch	 learning	 yielded	 robust	 performance	 in	 the	 NNs	developed	in	Chapters	3,	4	and	6.		
2.1.3 Transfer	functions,	cost	functions	and	initialisation	
Sigmoidal	functions,	such	as	SmnNQn : = VVoEpq,	were	particularly	suitable	for	the	hidden	layers	of	the	NNs	developed	in	this	research,		due	to	their	flexibility	in	modelling	nearly	linear,	nearly	constant	and	curvilinear	functions	[17].	Alternative	transfer	functions	are	further	discussed	in	Appendix	A.1.	
The	error	function		/ = kZ(0, 1)		is	an	important	part	of	the	backpropagation	algorithm,	since	 it	 determines	 the	 dynamics	 of	 the	 learning	 process.	 For	 the	 regression	 tasks	addressed	in	this	research,	mean	squared	error	(MSE)	was	particularly	well-suited	for	its	
5.	Iterate	between		2-4	until	converged4.	Backward	pass
•adjusts	6 and	.in	response	to		FrFs
3.	Error	evaluation
•quantifies	the	prediction	error	/	 = 	kZ(1, 0)
2.	Forward	pass
•computes	the	output	y	from	input	4 layer	by	layer
1.	NN	initialisation
•sets	parameters	% = {6, .}	to	their	arbitrary	initial	values
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efficiency	and	ease	of	interpretability.	For	a	training	dataset	with	2	observations	in	batch	learning	MSE	is	defined	as:	
	 LM/ = 12 (1u − 0u),CuwV 	 "].	2.2	
Since	 the	 partial	 derivative	 of	 this	 squared	 error	 function	 is	 simply	 the	 difference	between	 the	 target	and	actual	output,	 i.e.	x//x0 = 1u − 0u ,	 this	 facilitated	 the	efficient	computation	of	weight	updates	during	numerous	iterations	of	NN	training.	
The	classification	models	developed	in	Chapter	6	used	cross	entropy	error,	defined	as:	
	 ?/ = − 1u ln 0u + 1 − 1u ln 1 − 0uCuwV 	 "].	2.3	
The	 logarithm	 term	ln 1 − 0u 	 in	 "].	 2.3	 accounts	 for	 the	 distance	 between	 the	continuous-valued	prediction	and	the	binary	target	class,	providing	superior	granularity	in	computing	the	classification	errors.	An	additional	advantage	of	cross	entropy	for	large	datasets,	as	encountered	in	Chapter	6,	is	that	the	rate	at	which	the	NN	learns	is	directly	controlled	by	the	magnitude	of	cross	entropy	in	the	output	[23,107].	
For	most	error	functions,	backpropagation	is	a	non-convex	optimisation	problem,	where		convergence	 to	 a	 global	 optimum	 is	 not	 guaranteed;	 instead,	multiple	 “good	 enough”	local	minima	are	often	considered	 in	practice	 [104,107].	 Since	NN	may	converge	 to	a	different	 local	minimum	for	diverse	 initial	 conditions,	NN	 initialisation	plays	a	crucial	role	in	the	optimality	of	the	solution	[21,22,107].	The	concept	of	NN	initialisation	with	
random	starting	values	of	6	is	rooted	in	the	symmetry	of	the	NN	topology:	if	the	initial	weights	are	equal	across	all	neurons,	then	at	any	given	layer	all	the	outputs	would	be	equal	too,	thus	stalling	the	training	process.	The	magnitude	of	starting	values	of	%	must	
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be	 chosen	with	 care:	 too	 small	 and	 the	 training	 does	 not	 proceed,	 too	 large	 and	 the	perceptron	 transfer	 function	 becomes	 saturated	 [104].	 In	 order	 to	 ensure	 that	 the	sigmoidal	neurons	were	 activated	 in	 their	 linear	 region,	Nguyen-Widrow	 initialisation	was	implemented	[108].	The	small	positive	and	negative	initial	values	of	%	generated	by	this	 algorithm	 spread	 the	 active	 region	 of	 each	 neuron	 evenly	 across	 the	 layer	 input	space.	The	advantage	of	this	approach	is	that	the	resulting	NN	learns	the	linear	part	of	the	4	to	0	mapping	first,	before	embarking	on	the	more	difficult,	non-linear	part	[104].		
2.1.4 Optimisation	algorithms	
An	optimisation	(training)	algorithm	defines	the	direction	and	the	magnitude	of	the	NN	parameter	update	in	response	to	the	derivatives	computed	in	the	backward	pass	[109].	The	choice	of	algorithms	defines	the	behaviour	of	a	given	backpropagation	network.	For	the	applications	considered	in	this	work,	two	backpropagation	algorithms:	Levenberg-
Marquardt	algorithm	 [110]	 and	 conjugate	 gradient	method	 [111],	 proved	particularly	effective.	 Understanding	 the	 algorithms’	 behaviour	 enables	 appropriate	 choices	 in	 a	given	NN	training	task.	Since	these	are	standard	optimisation	functions,	their	derivations	are	provided	in	Appendix	A.2	and	references	therein.	
The	 Levenberg-Marquardt	 algorithm	was	 used	 for	 the	 regression	 tasks	 addressed	 in	Chapters	3	and	4	because	it	combined	the	sensitivity	of	the	Gauss-Newton	method	[112]	with	 the	 speed	 of	 convergence	 of	 a	 simple	 gradient	 descent,	 making	 it	 suitable	 for	repeated	training	with	a	MSE	cost	function	on	small-sized	datasets.	This	was	useful	when	simulating	 thousands	 of	 NNs	 during	 the	 development	 and	 validation	 of	 the	 new	methodological	framework,	presented	in	Chapter	3,	without	sacrificing	accuracy.	
The	 conjugate	 gradient	method,	 known	 for	 its	 energy	 minimisation	 applications	 in	physics	[113,114],	was	an	obvious	choice	for	the	optimisation	of	the	cross	entropy	cost	
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function	used	by	the	classification	NNs	in	Chapter	6.	A	modification	introduced	by	Møller	[115]	was	implemented	to	the	standard	conjugate	gradient	method	by	scaling	the	step	size,	 therefore	 avoiding	 otherwise	 computationally-intensive	 line	 search.	 This	sufficiently	accelerated	the	algorithm	convergence	and	made	scaled	conjugate	gradient	(SCG)	feasible	even	for	the	large-data	ensemble	NN	simulations.		
With	finite	data,	determining	whether	the	NN	training	algorithm	has	converged	is	not	trivial	 [116–118].	 Instead,	 practical	 NNs	 employ	 a	 combination	 of	 several	 stopping	
criteria	which	have	been	used	in	the	NNs	developed	in	Chapters	3,	4	and	6.	These	are:	
• minimum	gradient	(usually	<0.00001)		
• minimum	error	(usually	<0.00001)	
• maximum	number	of	iterations	(usually	1000s)	
• maximum	training	duration	(pre-defined	time	in	seconds)	
Combined,	 these	 criteria	 ensured	 that	 the	 NN	 training	 process	 would	 terminate	eventually:	when	 the	 cost	 function	 ceased	 to	 change	 significantly	 or	 the	 value	 of	 the	prediction	 error	 became	negligibly	 small;	 or	 by	 simply	 timing	 out	 because	 either	 the	maximum	number	of	iterations	was	completed	or	the	pre-allocated	time	expired.		
The	stopping	criteria,	however,	do	not	prevent	overfitting,	 thus	necessitating	auxiliary	means	of	controlling	the	training	process,	which	enable	the	NN	to	generalise	beyond	the	training	cohort.	One	way	to	achieve	this	is	to	monitor	NN	performance	on	a	randomly	sampled	validation	cohort	and	to	stop	training	early	when	the	validation	error	ceases	to	decrease	 for	 -	 consecutive	 iterations	 –	 a	 technique	 aptly	 named	 early	 stopping.	Alternative	 methods	 for	 preventing	 over-parametrisation	 in	 NNs	 are	 regularisation	(Section	3.5.2)	 	which	penalises	 large	weights,	and	dropout	[119]	 	which	removes	 the	“weakest”	neurons.	
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 Decision	tree	learning	
In	 the	 context	 of	 ML,	 decision	 trees	 (DT)	 refer	 to	 hierarchical	 learners	 that	 map	 the	interrelated	consequences	(leaves)	of	given	decisions	(branches)	based	on	a	predefined	reasoning	process.		The	algorithm	for	classification	and	regression	trees	(CART)	was	first	formalised	by	Breiman	et	al.	[120]	and	has	since	been	used	for	descriptive	and	predictive	modelling	in	medicine	[121].	By	determining	the	answer	to	individual	decisions,	the	tree	makes	a	prediction	about	a	parameter	of	interest.	DTs	are	nonparametric,	i.e.	no	prior	assumptions	are	made	regarding	the	underlying	distribution	of	the	predictor	variables	[120].	
DTs	 produce	 a	 graphical	 mapping	 of	 input	 conditions	 to	 likely	 outcomes	 and	probabilities,	rendering	them	particularly	useful	when	decisions	have	to	be	taken	with	limited	information	and	reviewed	by	an	expert.	The	graphical	nature	of	DTs	makes	them	indispensable	 in	 clinical	 applications,	 where	 non-technical	 users	 might	 be	 seeking	intuitive	and	clear-cut	representations	of	the	complex	relationships	in	patient	data.	DTs	can	 be	 used	 in	 medical	 expert	 systems	 for	 decision	 making,	 classification,	 and	probabilistic	prediction	[121–124].		
2.2.1 Nomenclature,	topology	and	configuration	
Formally,	a	tree	is	an	acyclic	(no	loops)	directional	(top-to-bottom)	graph	with	nodes	and	edges	organised	in	a	hierarchical	structure	[125].	In	a	DT,	decisions	are	represented	by	
branches,	 which	 are	 arranged	 in	 a	 particular	 order	 starting	 from	 a	 root	 node	 and	terminating	at	a	leaf	node.		A	data	sample	traverses	through	the	tree	from	the	root	to	the	leaf	following	a	unique	path	determined	by	the	decisions	at	each	branch	along	the	way.		
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A	binary	DT,	such	as	that	used	for	the	two-class	prediction	tasks	described	in	Chapters	5	and	6,	 	 separates	 the	 input	data	4u 	 at	 a	 ith	parent	 node	2u 	 into	 two	subsets:	MuBE}~	 and		MuuÄÅ~ ,	 so	 that	4u = MuBE}~ ∪ 	MuuÄÅ~	 and	MuBE}~ ∩ 	MuuÄÅ~ = 	∅,	 i.e.	 the	 subsets	 are	 disjoint	(Figure	2.4).	The	child	nodes	2uoV	and	2uo,	operate	on	the		MuBE}~	and		MuuÄÅ~	and	divide	the	dataset	into	four	by	producing	further	child	nodes	2uoÑ,	2uoÖ,	2uoÜ	and	2uoá.	When	a	node	cannot	be	split	further,	i.e.		only	one	observation	remains	in	its	input	set	Mu 	or	when	a	 pre-defined	 degree	 of	purity	 is	 reached,	 it	 becomes	 a	 terminal	 leaf	 node.	 A	 node	 is	considered	pure	when	all	of	the	observations	in	that	node	are	of	the	same	target	value.	The	degree	of	impurity	is	measured	by	the	proportion	of	observations	in	the	node	that	do	not	agree	with	the	majority	target	value.	
The	binary	split	continues	until	every	branch	terminates	with	a	leaf	node,	i.e.	all	of	the	observations	 are	 assigned	 to	 a	 leaf.	 The	 target	 values	 could	 be	 continued-valued	(regression	DT)	or	categorical	(classification	DT).		The	binary	classification	tree	model	utilised	in	this	work	follows	Breiman’s	time-tested	CART	algorithm	[120]	as	described	below.	
	
Figure	2.4	A	binary	DT	topology:	a	root	node	(blue),	three	branch	nodes	(orange),	and	5	leaf	nodes	(green)	
across	3	levels.		
2V		
2,		 2Ñ		
2Ö		 2Ü		 2á		 2à		
2à		 2â		
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2.2.2 Decision	tree	training	
Training	 (or	 growing)	 a	 DT	 involves	 selecting	 which	 predictor	 variable	 is	 to	 be	considered	at	each	node,	and	how	this	variable	should	be	split.	In	order	to	determine	the	optimal	sequence	of	decisions	that	makes	a	fully-grown	DT,	the	CART	algorithm	employs	
recursive	 binary	 partitioning	 [17,120].	 In	 recursive	 binary	 partitioning	 an	 exhaustive	search	of	all	possible	split	values	is	performed	across	all	potential	predictor	variables.	This	greedy	algorithm	divides	the	predictor	variable	range	into	a	number	of	possible	split	points,	calculates	for	each	candidate	split	a	measure	of	quality,	and	chooses	the	best	one	to	 produce	 two	 child	 nodes.	 Split	 criteria	 are	 discussed	 further	 in	 Section	 2.2.3.	 The	process	is	repeated	in	a	recursive	manner	for	each	subsequent	child	node,	until	the	node	is	either	pure,	or	when	splitting	no	longer	increases	predictive	accuracy	[17].	This	top-down	 iterative	process	 for	DT	 learning	 is	 summarised	 in	Figure	2.5.	Since	not	all	 leaf	nodes	 in	a	DT	are	necessarily	pure,	 there	exists	 the	notion	of	a	classification	error	–	a	weighted	average	of	the	individual	leaf	impurities,	where	weights	are	the	proportions	of	records	in	each	leaf.		
	
Figure	2.5	Recursive	binary	partitioning	for	DT	learning	
1.	Determine	all	possible	splits	at	a	node
2.	Compute	a	measure	of	quality	for	each	split
3.	Choose	the	split	with	the	highest	quality
4.	Partition	the	node	into	child	nodes
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The	number	of	possible	 splits	 is	defined	by	 the	data	 themselves.	 In	 this	 research,	both	discrete	and	continuous	variables	were	considered.	A	continuous	variable	could	be	split	between	 any	 two	 adjacent	 values	 	 present	 among	 the	 observations,	 or,	 alternatively	categorised	 into	 a	 smaller	 number	 of	 ranges	where	 appropriate	 [17].	 For	 categorical	variables,	all	the	possible	combinations	of	categories	must	be	considered.	The	number	of	these	combinations	grows	exponentially	with	the	degrees	of	freedom	(levels)	present:	a	binary	 variable	 offers	 a	 single	 possible	 split,	 whilst	 a	 variable	 with	 S	levels	 could	 be	partitioned	 in	 2B–V– 1	 ways.	 Hence	 finding	 an	 optimal	 binary	 split	 for	 a	 continuous	predictor	 is	often	 less	 computationally	 intensive	 than	 for	a	 categorical	predictor	with	multiple	levels.		
2.2.3 Split	criteria		
The	quality	of	a	candidate	split	is	generally	determined	by	the	homogeneity	of	the	target	variable	in	the	child	nodes	it	produces	[17].	This	can	be	measured	in	a	number	of	ways.	For	regression	DTs,	the	most	common	split	criterion	is	mean	squared	error,	which	has	already	been	introduced	in	Section	2.1.3.	For	classification	DTs,	the	two	most	common	split	criteria	are	diversity	and	information	gain.		
Information	 gain	 (or	 entropy	 reduction)	 is	 based	 on	 the	 concept	 of	 entropy	 from	information	theory	[126,127].	Entropy	(also	known	as	Shannon’s	measure	of	uncertainty)	refers	 to	 the	 average	 length	 of	 the	 message	 required	 to	 transmit	 information	 in	variable	:.	The	entropy	of	:	whose	å	classes	have	probabilities	3V, 3,, … , 3i ,	is:	
	 ℎ : = −	 3D log,(3D)iDwV 	 "].	2.4	
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Note	 that	 the	 logarithm	of	base	2	 is	used	because	 the	message	 length	 is	measured	 in	binary	(0	or	1).	An	obvious	problem	arises	when	a	node	is	pure,	and	thus	the	probability	of	one	class	is	zero:	would	ℎ(:)	be	undefined?	An	analogy	with	signal	processing	–	where	information	 is	a	signal	 and	entropy	 is	equivalent	 to	noise	 –	 shows	 that	 the	amount	of	noise	in	a	crystal-clear	signal	is	zero,	as	is	the	entropy	of	a	pure	node.				
Based	on	 this	definition	of	entropy,	 the	 information	gain	êë	for	2u 	 is	computed	as	 the	difference	between	the	entropy	at	2u 	and	the	weighted	sum	of	entropy	of	its	child	nodes	2uoVBE}~	 and	 2uoVuÄÅ~ ,	 where	 the	 weights	 3BE}~	and	 3uÄÅ~	 represent	 the	 proportion	 of	observations	in	Mu 	that	reach	each	child	node:	
	 êë		 = ℎ :u − 	 [3BE}~	ℎ(MuBE}~) + 3uÄÅ~ℎ(MuuÄÅ~)]	 "].	2.5	
It	 is	 important	 to	 note	 that	 information	 gain	 is	 biased	 towards	 continuous	 :	 and	categorical	:	with	multiple	levels	[120].	The	bias	correction	for	information	gain	could	be	 achieved	 through	 a	 probabilistic	 3-value	 criterion	 with	 exact	 randomisation,	bootstrapping,	Monte	Carlo	simulation,	or	asymptotic	approximations	[128].	
Gini’s	Diversity	Index	(GDI)	is	a	measure	of	diversity	named	after	Corrado	Gini,		adopted	from	econometrics	 into	machine	 learning	by	Breiman	[126].	GDI	reflects	how	 likely	a	given	 observation	 in	 the	 input	 subset	 Mu 	 would	 be	 misclassified	 if	 it	 was	 labelled	randomly	according	to	the	class	distribution	in	Mu .	 	For	a	classification	problem	with	å	classes,	the	GDI	of	an	ith	node	with	observations	Mu 	is	given	by:	
	 ëGê = 	1 − 	 3D,iDwV 	 "].	2.6	
where	3D 	is	the	observed	probability	of	class	k	samples	that	reach	the	node	[126,127].	The	GDI	of	a	pure	node,	 i.e.	when	the	node	contains	only	observations	of	one	class,	 is	
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equal	to	0.	By	the	same	definition,	the	upper	boundary	of	GDI	is	always	less	than	1	for	any	å,	 and	 0.5	 for	 a	 å=2	 class	 problem.	 When	 applying	 GDI	 with	 recursive	 binary	partitioning,	 the	 split	 that	 results	 in	 a	 node	with	 the	 smallest	 GDI	 is	 selected	 as	 the	optimal	split.	
Despite	 the	 fundamental	 differences	 between	 GDI	 and	 information	 gain,	 a	 rigorous	analytical	comparison	by	Raileanu	et	al.	found	that	the	two	measures	disagreed	only	in	2%	of	cases	[126,127].	The	preliminary	analyses	of	the	DT	models	for	kidney	transplant	modelling	in	Chapter	5	also	demonstrated	no	difference	in	performance	associated	with	the	use	of	either	measures.	Given	that	there	was	no	advantage	of	using	information	gain,	GDI	was	used	as	a	split	criterion	for	all	models	described	in	Chapters	5	and	6,	saving	on	a	small,	but	recurrent	step	of	computing	logarithms.			
2.2.4 Controlling	leafiness		
Just	as	with	NN	training,	the	process	of	growing	DTs	was	monitored	closely	to	prevent	overtraining	 and	 avoid	 unnecessary	 complexity	 of	 a	 model.	 	 In	 DT,	 the	 degree	 of	complexity	is	determined	by	the	number	of	branch	levels	(“depth”)	and	the	number	of	leaves	 (“leafiness”).	 Note	 that	 if	 a	 tree	 is	 allowed	 to	 grow	 without	 restraints,	 it	 will	achieve	 100%	 accuracy	 (provided	 that	 samples	with	 identical	 attributes	 do	 not	 have	inconsistent	class	indicators)	by	fitting	every	available	training	sample	in	4	to	a	separate	leaf,	producing	a	“perfect”	 fit	 that	 is	bound	to	exhibit	poor	performance	on	additional	samples	[17].	A	drawback	of	deep	trees	is	that	with	every	new	branch	node,	the	subset	of	samples	available	for	analysis	becomes	smaller	and	less	representative	of	the	overall	performance.		
To	manage	the	size	of	the	tree,	the	following	parameters	have	been	constrained	in	the	DT	models	developed	in	this	research:	
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• maximum	tree	depth	–	the	number	of	branches	along	the	longest	path,	
• minimum	leaf	size	–	smallest	permitted	observation	count	per	leaf,	
• minimum	parent	size	–	observation	count	per	node	for	it	to	become	a	parent.	
The	constraints	prevented	splits	that	violated	the	set	limit,	and	forced	the	corresponding	parent	nodes	to	become	leaves	earlier	than	they	would	otherwise	do.	Nevertheless,	even	with	a	combination	of	several	stopping	criteria,	DTs	may	overfit	the	data.	This	limitation	is	inherent	in	DT	learning,	since	finding	a	globally	optimal	tree	requires	nondeterministic	polynomial	 time,	 i.e.	 the	problem	 is	np-complete.	 In	 contrast,	practical	DT	algorithms,	including	 CART,	 commonly	 employ	 heuristic	 searches,	 which	 yield	 locally	 optimal	decisions	 at	 each	 recursion.	 Thus,	 the	 convergence	 to	 a	 globally	 optimal	 tree	 is	 not	guaranteed.		
A	more	 direct,	model-based	method	 for	 controlling	 overfitting	 in	 DT	 is	pruning.	 It	 is	achieved	 by	 removing	 nodes	 that	 have	 the	 least	 effect	 on	 the	 overall	 classification	performance	[120].	Depending	on	when	the	node	in	question	is	discarded,	two	types	of	pruning	exist:	post-	and	pre-pruning.		
In	pre-pruning,	the	association	between	the	attributes	and	the	target	class	is	assessed	by	a	 statistical	 test	 (most	 commonly,	 +,	 test	 [129]),	 and	 only	 statistically	 significant	variables	are	considered	for	a	candidate	split.	Although	considerably	faster,	pre-pruning	it	is	less	frequently	used	in	practice,	as	it	terminates	the	learning	process	prematurely,	particularly	when	the	number	of	observations	is	small	[130].	
Post-pruning	 involves	simplification	operations	such	as	subtree	replacement	or	subtree	
raising.	 First,	 the	 tree	 is	allowed	 to	grow	until	 all	observations	 in	 the	 training	set	are	classified	correctly.	Then	the	classification	error	is	estimated	for	the	whole	tree.	Since	the	error	on	 the	 training	 set	does	not	 constitute	a	useful	 estimator,	 either	a	 separate	
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hold-out	set	is	required	for	assessing	the	pruning	error	(reduced	error	pruning)	or	the	upper	boundary	of	the	confidence	interval	derived	on	training	error	is	used	(pessimistic	
pruning)[131].	Pessimistic	pruning	further	adds	a	penalty	term	to	the	error	at	each	node,	known	 as	 error	 correction.	 As	 long	 as	 the	 error	 does	 not	 increase,	 entire	 subtrees	(combinations	of	connected	nodes)	may	be	pruned.	 In	subtree	replacement,	 the	nodes	with	the	weakest	class	discrimination	are	replaced	by	a	leaf	representing	the	majority	class	in	a	bottom-up	fashion.	Subtree	raising,	on	the	other	hand,	removes	a	node	with	the	largest	error	and	redistributes	its	observations	to	the	next	node	down	in	the	hierarchy.	The	 resulting	 tree	 represents	 the	 minimal-complexity	 model	 while	 maintaining	 the	predictive	 power.	 For	 a	 dataset	 with	 3	 attributes	 and	 2	 training	 instances,	 pruning	increases	 the	 complexity	 of	 the	 DT	 algorithm	 from	 Ο(32	log	2)	 to		Ο(32 log	2 ,).	Alternatives	to	DT	learning	with	pruning,	such	as	decision	lists	and	decision	graphs,	are	discussed	in	the	literature	[130].	
 Ensemble	learning	
The	accuracy	and	robustness	of	NN	and	DT	models	can	be	improved	by	combining	the	predictive	effort	of	several	learners	into	a	single	model,	known	as	an	ensemble	[132,133].	The	 principle	 behind	 a	 good	 ensemble	 is	 the	 diversity	 of	 its	 constituent	 models.	 By	generalising	over	different	subsets	of	an	input	space,	the	learners	offset	mutual	errors.	The	more	disagreement	there	is	between	the	learners	in	the	ensemble,	the	smaller	the	overall	generalisation	error.	This	relationship	between	the	diversity	of	an	ensemble	with	å	 learners	 and	 its	 generalisation	 performance	 	 was	 	 explored	 in	 detail	 	 by	 Krogh	 &	Vedelsby	[56].	Their	analytical	findings	demonstrate	that	the	error	for	an	input	sample	:	 in	 the	 ensemble	" : 	 depends	 on	 both	 the	 individual	 learner	 errors	 ìu : 	 and	 the	degree	of	diversity	P : ,	defined	as	the	variance	of	the	ensemble	around	the	mean:	
Chapter	2.		Methodology	
32	
	 " : = 1å ìu : −iu P : 	 "].	2.7	
Hence,	 when	 the	 learners	 in	 the	 ensemble	 are	 strongly	 correlated,	 i.e.	P : ≈ 0,	 the	ensemble	error	" : 	would	be	equal	to	the	average	of	the	errors	ìu : 	of	the	å	individual	learners.	As	the	diversity	P(:)	increases,	" : 	decreases.	By	increasing	learner	diversity,	the	 ensembles	 often	 yield	more	 robust	 predictive	models	 than	 any	 of	 its	 constituent	learners	and	offer	superior	generalisation	accuracy	[132,133].				
2.3.1 Increasing	ensemble	diversity		
The	most	popular	ensembling	strategies	for	 increasing	learner	diversity	are	bootstrap	
aggregation,	cross-validated	committee,	and	boosting,	as	described	below.		
Bootstrap	aggregation	(or	bagging)	involves	training	each	learner	in	the	ensemble	with	a	 different	 subset	 of	 samples	 drawn	 randomly	 from	 the	 original	 training	 set	 [134].	Sampled	with	replacement,	each	bootstrap	subset	may	contain	duplicate	observations.	All	models	in	a	bagged	ensemble	vote	with	an	equal	weight.			
To	 avoid	 bootstrapping	 duplicates	 in	 bagging,	 the	 original	 sample	 space	 could	 be	randomly	 divided	 into	disjoint	 subsets,	 producing	what	 is	 known	 as	 a	 cross-validated	
committee	[135].	Similar	to	å-fold	cross	validation	discussed	in	Section	2.5,	the	sample	space	 is	 partitioned	 into	å	disjoint	 subsets	 and	one	 subset	 is	withheld.	 Subsequently,	å	learners	are	each	trained	on	å-1	out	of	the	å	subsets,	with	the	subset	being	withheld	iterating	from	learner	to	learner.				
Boosting	is	similar	to	bagging,	but	instead	of	random	sampling,	the	individual	subsets	are	drawn	to	emphasise	the	samples	that	contributed	to	the	largest	error	[136].	The	process	is	 incremental:	 each	 new	 model	 is	 added	 to	 target	 the	 “weakest”	 samples	 of	 its	
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predecessor.	 This	 is	 achieved	 by	maintaining	 a	 set	 of	weights	 across	 all	 samples	 and	assigning	 a	 higher	 weight	 to	 the	 samples	 that	 produced	 the	 largest	 error.	 Thus,	 a	progressively	 more	 difficult	 problem	 is	 being	 learned	 by	 each	 new	 model.	 Boosting	allows	for	improved	performance	over	bagging	or	cross-validated	committees.	However,	by	emphasising	a	small	subset	of	samples,	it	is	also	more	prone	to	overfitting	on	noisy	data	[132].	
The	disadvantage	of	bagging,	boosting	and	cross-validated	committees	is	that	they	rely	on	sub-sampling,	which	reduces	the	amount	or	weight	of	the	training	samples	available	for	individual	learners	[133].	In	applications	where	datasets	are	already	small,	further	reduction	 of	 the	 sample	 space	may	not	 be	 feasible.	 Instead,	 for	 the	 applications	with	limited	data	considered	in	this	work,	the	learner	diversity	in	ensembles	was	achieved	by:	
• randomising	the	initial	model	parameters	(in	NN	ensembles)	
• combining	 small	 amount	 of	 bagging	 with	 random	 feature	 sampling	 (in	 DT	ensembles)	
2.3.2 Ensembles	of	neural	networks		
The	NN	ensemble	was	created	by	initialising	hundreds	of	NN	with	random	weights	and	biases.	 Each	 constituent	NN	 learner	was	 trained	 on	 the	 complete	 set.	 Optiz	&	Maclin	showed	 that	 this	 ensembling	 approach	 was	 “surprisingly	 effective,	 often	 producing	results	as	good	as	bagging”	[132].		
Once	individual	NNs	are	trained,	they	can	either	be	merged	into	a	single	NN	instance,	whose	weights	and	biases	are	a	parameter	average	of	the	constituent	NNs,	or	they	can	exist	 in	an	ensemble	by	combining	their	output	predictions	[137].	Several	approaches	
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were	 considered	 in	 this	 research	 for	 aggregating	 the	 individual	 outputs	0(u)	 across	å	learners	into	a	single	ensemble	output	0:		
• simple	output	averaging:	0 = 	 Vi 	 0 uiuwV 	
• weighted	 output	 averaging:	0 = 8(u)0(u)iuwV ,	 where	8(u)is	 proportional	 to	the	“trustworthiness”	of	the	learner	Q	measured	by	its	predictive	accuracy	
• voting	or	majority	consensus	(in	classicisation):	0 = 0(u)	if		 QiuwV > å/2	
In	 the	 applications	 addressed	 by	 the	 ensemble	 NNs	 in	 Chapters	 3,	 4	 and	 6,	 simple	averaging	proved	as	effective	as	weighted	averaging	and	voting.		
The	accuracy	of	the	NN	ensemble	generally	increases	with	the	number	of	learners	until	a	saturation	point	is	reached,	which	in	turn	depends	on	the	amount	of	noise	in	the	data	[118].	 Thus,	 the	 choice	 regarding	 the	number	 of	 learners	å	 to	 be	 included	 in	 a	 given	ensemble	is	a	design	trade-off	between	computational	efficiency	and	reproducibility.		
2.3.3 Random	forest	
An	ensemble	of	DTs,	aptly	named	random	forest	(RF),	involves	growing	a	number	of	DTs	and	aggregating	their	outputs	[138].	The	RF	algorithms	use	various	degrees	of	bagging	in	 tandem	with	 random	 feature	 sampling	 to	 further	 increase	 the	 diversity	 among	 its	constituent	DTs.	Each	tree	in	the	RF	is	developed	with	only	a	subset	3∗of	the	total	number	of	input	features	3,	sampled	at	random.	The	recommended	size	of	such	partial-feature	subsets	 is	 roughly	3∗ = √3,	 although	 empirical	 results	 show	 little	 sensitivity	 to	 this	choice	of	3∗[138].	RFs	do	not	tend	to	overfit	with	an	increased	number	of	trees,	instead,	the	RF	generalisation	error	reaches	a	limiting	value	[138].		
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By	design,	the	partial-feature	trees	are	unlikely	to	fit	the	entire	dataset	well,	hence	they	are	referred	to	as	“weak”	 learners.	 Instead,	 the	trees	 in	an	RF	developed	in	Chapter	4	were	 allowed	 to	 grow	 fully	 and	 specialise	 on	 their	 specific	 subset	 of	 samples	 and	features,	with	an	expectation	 that	when	a	 large	number	of	 them	was	combined,	 their	performances	would	benefit	from	the	cumulative	effect	across	the	entire	sample	space	[123,125].	This	property	allowed	 the	RFs	 to	handle	numerous	 input	 features	without	having	to	perform	preliminary	feature	selection	or	dimensionality	reduction.		
The	 built-in	 feature	 selection	 mechanism	 in	 RFs	 also	 enabled	 the	 quantification	 of	relative	variable	importance.	Variable	importance	scores	for	RF	are	defined	by	measuring	the	 increase	 in	 prediction	 error	 when	 the	 values	 of	 a	 variable	 under	 question	 are	permuted	 across	 the	 out-of-bag	 observations;	 referred	 to	 as	permutation	 test.	 	 These	scores	were	computed	 for	each	constituent	 tree,	averaged	across	 the	entire	ensemble	and	divided	by	the	standard	deviation.	
Finally,	the	predictions	made	by	the	individual	DTs	were	combined	by	voter	consensus,	in	which	each	constituent	DT	voted	for	the	corresponding	class	and	the	majority	of	votes	decided	 the	 overall	 RF	 output	 [121,123].	 This	 aggregate	 vote	 of	 several	 DTs	 proved	inherently	 less	 noisy	 and	 less	 susceptible	 to	 outliers	 than	 a	 single	 DT	 output,	 	 and	improved	the	robustness	of	predictions	[132,134,138].		
 Statistical	methods	
The	use	of	machine	learning	to	address	the	complex	research	questions	considered	in	this	work	was	driven	by	pragmatism,	not	by	design	preference.	Where	deemed	adequate	or	where	required	by	existing	clinical	practice,	classical	statistical	 techniques,	such	as	linear,	logistic	and	Cox	regression,	were	initially	considered.	For	example,	in	Chapter	5	the	 task	 of	 evaluating	 factors	 associated	 with	 long-term	 kidney	 graft	 survival	 was	
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accomplished	 using	 the	 Cox	 proportional	 hazards	 survival	 model,	 while	 logistic	
regression	was	used	for	discriminating	between	binary	rejection/non-rejection	patient	groups.	 In	Chapter	6,	 the	Cox	proportional	hazards	model	was	used	 to	 reproduce	 the	existing	 clinical	 benchmark	model,	 against	which	 the	NN	 ensembles	 and	 survival	 DT	models	 were	 subsequently	 assessed.	 Classical	 statistical	 models	 continue	 to	 play	 an	important	role	in	the	exploratory	analysis	and	model	benchmarking	of	modern	machine	learning	algorithms.	The	two	approaches	used	in	Chapters	5	and	6	are	described	below.	
Logistic	regression	(LR)	is	a	multivariate	parametric	model	that	has	been	widely	used	in	clinical	literature	due	to		its	ability	to	infer	categorical	outcomes	[139,140]	and	thus,	address	questions	such	as	Would	the	recipient	reject	the	transplant?	or	Would	this	patient	
be	diagnosed	with	diabetes	in	10	years?	LR	is	a	particular	case	of	generalised	linear	models	that	uses	logit	link	function	to	express	the	log-odds	of	dichotomous	outcome	0	in	terms	of	probabilities	I(:)	of	3-dimensional	input	: = :V	:, …	:b e 	[141]:	
	 log I :1 − I : = !ô +	 !;:;b;wV 	 "].	2.8	
The	solution	to	the	"].	2.8	is	presented	by	the	set	of	parameters	!	that	maximises	the	log-likelihood	HH	of	the	model	with	2	classes	containing	2V	and	2,	samples:	
	 HH = 	 log I :(u) + log	(1 − I :(u) )CöuwV,			sõwô
Cú
uwV,			sõwV 	 "].	2.9	
The	value	of	"#ù 	(known	as	the	odds	ratio)	explains	how	the	probability	of	the	outcome	0	being	positive	changes	as	variable	:; 	 	 increases	by	one	unit	 (if	 continuous),	or	by	a	factor	(if	categorical).		Unlike	least-squares	models,	logistic	regression	does	not	stipulate	strict	 assumptions	 on	 linearity	 between	 :; 	 and	0,	 nor	 the	 normality	 of	:; ,	 which	 is	
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particularly	advantageous	for	modelling	medical	and	biological	systems.	Nevertheless,	when	the	relationship	between	:; 		and	log	odds	of	0	is	linear	and	4	is	multivariate	normal,	logistic	regression	yields	more	stable	solutions	and	stronger	variable	significance	[140–142].	When	variable	 associations	 are	unreliable,	 such	as	 in	 cases	with	 limited	data,	 a	
likelihood	 ratio	 test	 can	 be	 used	 to	 assess	 the	 relative	 significance	 of	 the	 predictor	variables	given	a	model	fit	[141,143–145].	The	likelihood	ratio	test	measured,	for	every	variable	:; 	in	4,	the	chi-squared	+,	significance	[129]	between		HH	of	the	full	model	and	the	HH	of	the	nested	model	without	that	variable.	The	computation	of	+,	accounted	for	the	degrees	of	freedom	in	:; 	and	penalised	more	complex	models	[129,143,146].	
Cox	 proportional	 hazards	 (Cox	 PH)	 regression	 is	 a	 semiparametric	 multivariate	regression	model	 that	was	used	 in	this	research	for	problems	 involving	time-to-event	data	 [147,148].	 	 The	 risk	 of	 developing	 an	 event	û,	 such	 as	 transplant	 rejection	 or	diagnosis	with	a	disease,	at	time	1	is	expressed	by	a	hazard	'(1):	
	 ' 1 = '( 1 	"#ü 	 "].	2.10	
where	 baseline	 hazard	'( 1 		 corresponds	 to	 the	 overall	 model	 hazard	 when	 the	explanatory	 variables	 are	 absent,	 i.e.	 : = 0.	 By	 accounting	 for	 the	 length	 of	 survival	period	0,	Cox	PH	is	able	to	make	inferences	on	the	right-censored	data	that	are	common	in	longitudinal	clinical	studies,	where	patients	are	lost	to	follow-up.	The	solution	to	the	Cox	 PH	 regression	 is	 the	 set	 of	 parameters	 !	that	 maximises	 the	 probability	 of	 the	observed	event	û	occurring	in	ith	patient	(ûu = 1)	rather	than	any	other	kth	patient	,	given	by	the	log	partial	likelihood:	
	 HI = 	 (!:(u) − SmnCu:°õwV "#ü(¢)i:s¢£sõ )	 "].	2.11	
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The	 process	 of	 modelling	 with	 Cox	 PH	 and	 its	 extensions,	 including	 time-varying	covariates	 and	 non-proportional	 hazards,	 are	 described	 in	 detail	 by	 Singer	 &	Willett	[149]	and	references	therein.			
Model	selection.	With	a	limited	number	of	observations,	both	the	Cox	PH	and	LR	models	benefit	from	a	reduction	of	the	number	of	predictor	variables	to	the	most	parsimonious	set.	Since	a	priori	knowledge	of	which	variables	to	include	was	not	available	when	the	exploratory	analyses	were	conducted,	the	initial	Cox	PH	and	LR	regressions	were	fitted	on	 all	 clinically-relevant	 variables.	 Subsequently,	 using	 a	 popular	 technique	 of	model	selection	 known	 as	 backwards	 stepwise	 elimination	 [150],	 the	 variables	 that	 did	 not	contribute	to	the	improvement	of	the	models’	 log-likelihood	(log	partial	 likelihood	for	Cox	PH)	were	eliminated	from	the	models	one-by-one	in	an	automated	manner.	
The	statistical	hypothesis	tests	used	in	this	research	include	the	two-tailed	Fisher	exact	
test	 [151]	 for	 categorical	 variables,	 and	 the	 non-parametric	Wilcoxon	 rank	 sum	 (also	known	 as	Mann-Whitney	U)	 test	 [152]	 for	medians	 of	 continuous	 variables.	 The	 null	hypothesis	of	no	difference	between	the	groups	was	tested	at	the	5%	significance	level.		
 Performance	evaluation	
In	order	to	evaluate	a	predictive	ML	model,	the	validation	subset	of	data	must	be	separate	from	the	training	samples.	Popular	partitioning	strategies	[107]	considered	in	this	thesis	include	random	sampling,	å-fold	cross-validation,	and	leave-one-out	validation.		
With	random	sampling,	as	used	in	early	stopping	(Section	2.1.4),	the	validation	subset	is	formed	by	sampling	without	replacement.	In	å-fold	cross-validation	[56,153],	the	entire	dataset	 is	divided	into	å	disjoint	subsets	(folds),	out	of	which	å − 1	 folds	are	used	for	training,	and	the	remaining	fold	is	used	for	testing.	The	process	is	repeated	å	number	of	
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times,	until	all	folds	have	been	tested.	Leave-one-out	validation	[153]	is	equivalent	to	å-fold	validation	with	the	fold	consisting	of	a	single	sample:	the	model	is	trained	on	all	but	one	sample.	For	a	dataset	of	size	2,	the	process	is	repeated	2	times,	and	each	sample	is	tested	exactly	once.			
The	disadvantage	of	å-fold	validation	is	that	it	reduces	the	number	of	samples	available	for	model	training	and	produces	å	different	models.	Although	more	resourceful	with	the	data,	leave-one-out	validation	is	computationally	more	expensive	and	more	susceptible	to	outliers	 than	k-fold	cross-validation.	The	advantage	of	 random	sampling	 is	 that	 for	limited	data	it	allows	for	a	thorough	validation	if	repeated	multiple	times	with	different	combinations	of	samples,	even	when	the	validation	dataset	is	small	[47].	This	property	of	early	stopping	was	integrated	into	the	multiple	runs	method	developed	in	Chapter	3.	
The	 performance	 of	 the	 predictive	models	 developed	 in	 this	 research	was	 evaluated	using	the	following	standard	[17]	statistical	measures:	
(i) for	 regression	 models:	 coefficient	 of	 determination	 J		 and	 root-mean-square	error	JLM/			(ii) for	classifiers:	the	area	under	the	receiver	operating	characteristic	(ROC)	curve	=>?,	and	the	measures	defined	from	the	confusion	matrix	(Figure	2.6)	(iii) for	survival	models:	Harrell’s	?-index	and	Royston	and	Sauerbrei’s	G	and	JK, ,	in	addition	to	measures	in	(i).	
For	 classifiers,	 confusion	matrices	help	 distinguish	 True	 Positive	 (§I),	 True	 Negative	(§•),	 False	 Positive	 (¶I),	 and	 False	 Negative	 (¶•)	 observations,	 and	 define	 the	classifier’s	sensitivity	(§I	5P1"	also	referred	to	as	recall),	specificity	(§•	5P1"),	positive	and	negative	predictor	values,	and	the	overall	correct	classification	rate	(Figure	2.6).	
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Figure	2.6	Confusion	matrix	notation	and	definitions	for	a	binary	classifier	The	definitions	of	the	remaining	criteria	in	(i-iii)	are	detailed	in	Appendix	B.	
 Software	and	hardware	resources	
The	 applied,	 problem-driven	 nature	 of	 this	 machine	 learning	 research	 provided	 a	stimulating	 environment	 for	 the	 learning	 of	 several	 engineering	 programming	languages,	including	R	and	MATLAB™.	The	code	for	the	preliminary	data	analysis,	neural	network	 design,	 and	 the	 simulation	 of	 the	 new	 framework	 in	 Chapters	 3	 and	 4	 was	written	 in	 MATLAB™	 versions	 R2012b-R2015b	 for	 64-bit	 Microsoft	 Windows.	 The	research	 experiments	 on	 tree-based	 learning	 in	 Chapter	 5	 were	 implemented	 in	MATLAB™	 R2014b.	 The	 code	 for	 the	 programming,	 testing	 and	 visualisation	 of	 the	ensemble	 NN,	 Cox	 PH,	 LR	 and	 survival	 DT	 models	 in	 Chapter	 6	 was	 developed	predominantly	 in	 the	 open-source	 R	 environment	 (versions	 3.1.1	 to	 3.4.0),	 including	packages	attributed	to	several	authors	[154–159].			
By	most	conservative	estimates,	the	number	of	 individual	simulations	involved	in	this	research	 amounted	 to	 1,500,000	 neural	 networks	 and	 1600	 full	 and	 partial	 decision	trees.	The	computational	experiments	were	conducted	on	a	workstation	with	32	GB	RAM	
§I + §• + ¶I + ¶•	 = 	2	Correct	classification	rate	?	 = 	 (§I + §•)/2	Sensitivity	M2 = §I/(§I + ¶•)		Specificity	M3 = §•/(§• + ¶I)	Positive	predictive	value	IIß	 = 	§I/(§I + ¶I)		Negative	predictive	value	•Iß	 = 	§•/(§• + ¶•)	Balanced	accuracy	?@ABACDEF = (M2 + M3)/2	
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and	 an	 Intel®	 Core™	 i7-3770	 processor	 with	 base	 frequency	 of	 3.40GHz	 (3.90	 GHz	achieved	with	Turbo	Boost).		Where	possible,	the	simulations	were	parallelised	across	the	 four	 processor	 cores.	 The	 average	 simulation	 time	 for	 instantiating,	 training	 and	logging	a	run	of	2000	small-data	backpropagation	neural	networks	was	280	seconds.	
The	auxiliary	programs	that	supported	this	research		were	an	open-source	Plot	Digitizer	[160]	used	for	the	extraction	of	data	from	the	literature	sources	in	Chapter	4,	and	the	proprietary	 DTREG®	 [161]	 used	 to	 accelerate	 the	 computation	 of	 likelihood	 ratio	significance	 tests	 in	 Chapter	 5.	Mendeley	 Desktop	 version	 1.16.1	 [162]	was	 used	 for	referencing	and	maintaining	relevant	bibliographical	data.	For	parts	of	this	thesis,	Google	autonomous	speech	recognition	for	English	[24,163]	was	trialled		to	convert	the	author’s	voice	to	text.		
 Sources	of	data		
Four	clinical	and	engineering	datasets	were	used	for	the	training,	validation	and	testing	of	the	ML	systems	developed	in	this	research.	These	are	as	follows:	
(1) A	 civil	 engineering	 dataset	 comprising	 1030	 samples	 of	 concrete	 from	 the	experiments	of	Yeh	[164]	was	used	for	validating	the	generalising	performance	of	the	novel	 methodological	 framework	 developed	 in	 Chapter	 3.	 The	 dataset	 was	 obtained	through	a	publicly	available	Machine	Learning	Repository	at	the	University	of	California,	Irvine	[165].	
(2) A	 hard	 tissue	 engineering	 dataset	 comprising	 35	 trabecular	 bone	 samples	was	used	in	Chapter	4	for	the	development	of	a	patient-specific	hip	fracture	risk	stratification	model	 in	 severe	 osteoarthritis.	 This	 secondary	 dataset	 was	 extracted	 through	 plot	digitisation	from	the	original	study	by	Perilli	et	al.	[166].	
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(3) The	kidney	transplant	data	investigated	in	Chapter	5	were	obtained	as	a	result	of	meticulous	examination,	recording	and	follow-up,	spanning	14	years,	by	the	UK’s	leading	antibody-incompatible	renal	transplantation	group	at	the	University	Hospitals	Coventry	and	 Warwickshire	 (UHCW).	 The	 single-centre	 UHCW	 dataset	 containing	 baseline	characteristics	and	transplantation	outcomes	for	80	patients	was	provided	directly	by	the	clinical	collaborators	[167,168].		
(4) A	 UK	 primary	 care	 dataset	 comprising	 nearly	 80,000	 anonymised	 electronic	healthcare	records	was	used	in	Chapter	6	for	the	development	and	validation	of	novel	diabetes	 risk	 stratification	 models.	 The	 dataset	 was	 obtained	 through	 the	 Clinical	Practice	Research	Datalink	in	collaboration	with	a	team	at	University	of	Oxford	Nuffield	Department	of	Primary	Care	Health	Sciences		[90].	
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Strategies	for	limited	data	
As	discussed	in	Chapter	1,	limitations	on	data	quality,	such	as	missing	values	and	class	imbalance,	reduce	the	size	of	already	small	clinical	datasets,	often	below	10	observations	per	predictor	variable.	To	the	best	of	the	author’s	knowledge,	effective	ML	strategies	for	such	datasets	do	not	presently	exist	[169–171].	For	the	three	applications	considered	in	this	research,	existing	ML	approaches	for	managing	limited	data	[17,71,172]	did	not	offer	a	well-rounded	 solution	and,	 in	 some	cases,	were	 surpassed	by	biased	 complete	 case	analysis.	In	order	to	bridge	this	gap,	a	novel	framework	specifically	for	the	application	of	ML	 to	 small	 experimental	 datasets	 has	 been	 developed	 in	 this	 chapter.	 This	 original	methodology	 was	 pivotal	 to	 the	 successful	 development	 of	 ML	 models	 in	 the	 three	medical	applications	considered	in	Chapters	4,	5	and	6.	
This	chapter	commences	by	describing	the	strategies	for	improving	incomplete	(Section	3.1)	and	imbalanced	(Section	3.2)	data	used	in	this	research.	Sections	3.3	and	3.4	focus	on	the	development	of	the	novel	 framework	for	small	datasets	and	its	validation	with	real	 data.	 Section	 3.5	 demonstrates	 the	 efficacy	 of	 the	 proposed	 framework	 in	comparison	with	existing	state-of-the-art	techniques.			
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 Managing	incomplete	data	
Examples	of	incomplete	data	abound	in	medical	and	biomedical	databases.	Whether	it	is	a	nationwide	electronic	medical	record	system	or	a	collection	of	Excel	spreadsheets	from	a	 single	 centre,	 missing	 values	 are	 one	 of	 the	 defining	 characteristics	 of	 the	 clinical	datasets.	Before	we	can	discuss	the	strategies	for	handling	incomplete	data	in	predictive	modelling,	 it	 is	 important	 to	 highlight	 the	 mechanisms	 by	 which	 the	 data	 become	missing.	As	formulated		in	the	seminal	work	by	Rubin	[173],	depending	on	whether	the	missing	values	are	related	to	the	underlying	variables,	the	data	are	said	to	be:	
• missing	 completely	at	 random	 (MCAR),	 if	 the	probability	of	 the	data	missing	does	 not	 depend	 on	 any	 variable	 in	 the	 dataset,	 nor	 on	 the	 response	 being	predicted;	
• missing	at	random	(MAR),	if	the	probability	of	the	data	missing	is	independent	of	the	response,	but	may	depend	on	the	observed	values	of	other	variables	in	the	dataset;	
• missing	not	at	random	(MNAR),	if	missing	data	are	dependent	on	the	values	of	the	unobserved	data.		
Whilst	 with	 MCAR	 and	 MAR	 the	 missing	 data	 mechanism	 could	 be	 deemed	 to	 be	independent	 of	 the	 response,	 MNAR	 indicates	 that	 the	 missing	 data	 may	 contain	information	 about	 predicted	 response	 [65,172].	 Most	 algorithms	 for	 missing	 data	operate	under	MCAR	or	MAR	assumptions;	no	effective	approaches	exist	for	MNAR	data	unless	 the	 underlying	 missing	 data	 mechanism	 could	 also	 be	 specified	 and	 learned	[63,65,172].		Sections	3.1.1-3.1.4	describe	common	strategies	for	handling	missing	data	from	case	deletion	to	imputation,	and	model-based	induction	specific	to	decision	trees.	
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3.1.1 Complete	case	analysis	
When	the	missing	data	mechanism	is	MCAR,	the	observations	with	missing	values	could	be	safely	omitted	from	the	analysis	without	introducing	bias	[65].	Complete	case	analysis	considered	 in	Section	6.3.3	 illustrates	 the	potential	of	 small-data	NNs	when	routinely	collected	 patient	 records	 contain	 no	 missing	 information	 across	 a	 few	 variables	 of	interest.	 Such	 list-wise	 deletion	 is	 a	 simple	 yet	 appropriate	 solution	 for	 building	inferences	 on	MCAR	 data,	 but	 when	 the	 data	 fall	 under	MAR	 condition	 or	 when	 the	proportion	 of	 missing	 values	 is	 high,	 complete	 case	 analysis	 would	 produce	 biased	estimates	 of	 the	 response	 [63].	 In	 the	 case	 of	 MAR,	 the	 significance	 of	 the	 bias	 is	dependent	 on	 the	quantity	 of	missing	 values,	 and	on	 the	degree	of	 association	of	 the	missing	variable	with	other	confounding	variables	[63].		
3.1.2 Single	value	imputation	
Imputation	is	required	when	the	discarding	of	partially	incomplete	observations	is	not	feasible	due	to	the	high	historic	cost	of	collection	or	sensitivity	to	the	MAR	bias.		Single	value	imputation	aims	to	substitute	the	missing	values	with	an	estimate.	This	could	be	a	global	or	group	mean,	median	(or	mode	if	the	value	is	binary)	measured	on	the	observed	values	of	the	missing	variable,	or	a	value	estimated	through	a	model-based	algorithm,	such	as	linear	or	logistic	regression,	k-nearest	neighbours	or	expectation	maximisation	[63,65].			
Substituting	missing	values	 in	 a	 variable	with	 the	mean,	median	or	mode	 of	 observed	values	distorts	the	distributions	of	that	variable;	hence	the	technique	is	also	not	suitable	for	datasets	with	a	high	proportion	of	missing	values.	A	more	practical	approach,	which	has	been	used	in	Chapter	6,	is	to	complement	the	imputed	variable	with	an	additional	
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binary	indicator	flag	that	identifies	which	observations	in	that	variable	are	missing	[174].	This	 strategy	 is	 particularly	 effective	 with	 models	 that	 can	 incorporate	 variable	interaction,	such	as	Cox	proportional	hazards	and	neural	network	models	discussed	in	Chapter	6.		
Model-based	imputation	with	linear	or	logistic	regression	treats	the	incomplete	variable	as	dependent	and	regresses	its	values	based	on	all	other	variables	in	the	data	model.		The	quality	of	these	estimations	depends	on	the	quality	of	the	model	fit,	and	is	therefore	not	feasible	in	applications	where	a	well-fitting	model	could	not	be	defined	in	the	first	place,	as	is	common	with	physiological	models	[174–176].	The	quality	of	the	estimation	could	be	improved	using	an	iterative	expectation	maximisation	algorithm	[65,172],	but	it	was	also	 deemed	 inadequate	 with	 the	 level	 of	 incompleteness	 frequently	 observed	 in	routinely	 collected	 population	 data.	 	 For	 the	 diabetes	 data	 in	 Chapter	 6,	 expectation	maximisation	has	also	proved	prohibitively	slow,	since	its	rate	of	convergence	increased	exponentially	with	an	increasing	proportion	of	missing	information.	
Nearest	 neighbour	 technique	was	 another	 promising	method	 for	 handling	 incomplete	data,	with	some	resemblance	of	how	human	experts	complete	missing	data	[65,177].	For	each	 sample	 with	 missing	 values,	 the	 algorithm	 finds	 the	 k	 most	 similar	 samples	(neighbours).	The	missing	value	is	subsequently	substituted	with	the	mean	value	across	
k	 neighbours.	 The	 drawback	 of	 k-nearest	 neighbour	 imputation	 is	 that	 with	 a	 high	proportion	 of	 missing	 values,	 it	 alters	 the	 data	 distributions	 in	 a	 way	 that	 hinders	subsequent	response	prediction	[65,177].	This	 flaw	was	observed	when	the	k-nearest	neighbour	technique	was	implemented	for	the	diabetes	data	in	Chapter	6	and	eliminated	during	the	preliminary	data	analysis.	Nearest	neighbour	imputation	was	also	considered	for	the	kidney	transplant	patients	analysed	in	Chapter	5,	but	it	was	superseded	by	the	
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built-in	 mechanism	 for	 dealing	 with	 missing	 data	 in	 decision	 trees,	 as	 described	 in	Section	3.1.4.	
3.1.3 Multiple	imputation	
The	problem	with	single	value	imputation	is	that	it	does	not	account	for	uncertainty	in	the	 missing	 values,	 nor	 for	 biased	 interactions	 of	 multiple	 missing	 variables	 [63].	
Multiple	imputation	overcomes	these	issues	by	leveraging	on	the	predictive	distributions	of	 the	missing	 values	 and	 creates	multiple	 versions	 of	 the	 dataset	 [65,172].	 In	 other	words,	each	missing	value	is	replaced	by	an	m-dimensional	vector	of	imputed	values.	This	technique	 is	 more	 computationally	 intensive	 than	 single	 value	 imputation,	 but	 it	preserves	 the	 variance	 and	 uncertainty	 in	 the	 missing	 values	 required	 for	 realistic	modelling	of	the	response	[65].	Multiple	imputation	does	not	optimise	individual	sample	accuracy,	 but	 instead	 attempts	 to	 reproduce	 the	 overall	 resemblance	 to	 a	 complete	dataset	by	generating	multiple	datasets.	Among	numerous	practical	implementations	of	multiple	imputation,	Multiple	Imputation	with	Chained	Equations	(MICE)	has	been	shown	to	be	particularly	effective	for	clinical	applications	[178–180].	
For	the	clinical	application	described	in	Chapter	6,	MICE	was	used	for	imputation	of	the	three	continuous	variables	:V, :,, :Ñ	with	missing	values.	In	the	initial	step,	all	missing	values	 in	:V, :,, :Ñ	were	 filled	at	random.	Then,	:V	was	regressed	on	:,, :Ñ	and	all	 the	other	variables	:Ö, … , :b	present	in	the	model	(including	the	response	variable),	and	the	missing	values	in	:V		were	substituted	by	simulated	draws	from	its	posterior	predicted	distribution.	 Using	 the	 newly-imputed	 values	 of	:V,	 :,		was	 regressed	 on	:V, :Ñ, … , :b.	Similarly,	using	the	imputed	values	of	:V	and	:,,	:Ñwas	estimated	from	the	regression	on	:V, :,, :Ö, … , :i .	As	suggested	by	Van	Buuren,	the	cycle	was	repeated	20	times	to	refine	the	estimations	[178].	The	entire	procedure	was	repeated	® =100	iterations	in	order	to	
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account	 for	 the	 large	 proportion	 of	 missing	 values	 (60-70%).	 MICE	 resulted	 in	 100	individual	 datasets,	 each	 modelled	 separately.	 The	 parameter	 estimates	 and	 the	corresponding	 standard	 errors	 of	 the	 100	 individual	 Cox	 PH	 and	 LR	 models	 were	combined	according	to	Rubin’s	rules	[173],	and	the	outcomes	of	the	100	NN	models	were	combined	using	ensembling	approach.			
It	 is	 important	 to	note	 that	multiple	 imputation	operates	under	MAR	assumption.	For	MNAR	data,	 inclusion	of	additional	predictors	 that	affect	 the	missing	value	allows	 for	partial	approximation	of	MNAR	to	MAR,	but	only	to	a	certain	degree	[174].	The	potential	bias	with	MNAR	data	requires	careful	consideration,	since	the	response	variable	forms	part	of	the	MICE	imputation	model.	In	order	to	ensure	the	purity	of	test	samples,	model	derivation	and	model	validation	datasets	were	imputed	separately.			
3.1.4 Surrogate	splits	in	decision	trees	
In	DTs,	the	impact	of	missing	variables	could	be	mitigated	by	means	of	surrogate	splits		[121,181].	 For	 each	 primary	 split	 where	 the	 variable	 may	 be	 missing,	 “surrogate”	substitutions	are	constructed	from	other	predictor	variables	that	exist	in	the	model.	The	goal	 is	 to	 find	 a	 splitting	 point	 with	 child	 distributions	 most	 closely	 resembling	 the	primary	split.	The	surrogate	splits	are	then	ranked	according	to	misclassification	error,	and	any	split	that	does	not	perform	better	than	the	“go	with	the	majority”	rule	is	ignored.	The	split	with	lowest	misclassification	error	is	used	as	the	preferred	surrogate	split,	and	if	neither	the	primary	nor	the	surrogate	variable	are	available,	each	subsequent	ranked	surrogate	split	has	priority.	 If	no	surrogate	variables	are	available,	 the	data	sample	 is	classified	in	the	majority	direction	[181].		Surrogate	splits	allow	DTs	to	handle	missing	data	without	 imputation.	This	 important	advantage	of	DTs	over	other	ML	models	was	explored	in	two	medical	applications	considered	in	Chapters	5	and	6.	
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 Balancing	strategies	
The	problem	of	class	 imbalance	 is	 intrinsic	 to	medical	datasets,	and	occurs	when	one	type	of	outcome	is	observed	more	frequently	than	another,	thus	forming	a	majority	and	minority	classes.	An	imbalance	of	1:11,	such	as	that	observed	among	diabetic	and	non-diabetic	patients	in	Chapter	6,	skews	a	binary	classifier	to	null	accuracy	of	0.917,	meaning	that	 91.7%	 accuracy	 could	 be	 achieved	 by	 simply	 assigning	 every	 observation	 to	 the	majority	class.	 	 Significant	class	 imbalance	compromises	 the	 learning	success	of	a	ML	classifier,	 unless	 adjusted	 for.	 The	 methods	 used	 to	 address	 class	 imbalance	 can	 be	broadly	 grouped	 into:	 1)	 cost-sensitive	 training	 techniques,	 and	 2)	 data	 resampling	techniques,	including	synthetic	sample	generation.	
3.2.1 Cost-sensitive	training	
Cost-sensitive	training	prevents	overfitting	of	the	majority	class	instances	by	adjusting	the	classifier	cost	function.	An	obvious	way	to	implement	this	is	by	using	a	performance	metric	that	is	sensitive	to	the	underlying	class	distributions,	such	as	=>?	(see	Appendix	B)	or	the	weighted	harmonic	mean	of	the	classifier	sensitivity	and	specificity	known	as	¶-score	[71,182,183].	Yet,	successful	algorithms	for	optimising	=>?	or	¶-score	directly	are	scarce	for	NNs	[184,185],	and	non-existent	for	DTs.	This	is	due,	in	part,	to	the	nature	of	the	performance	measures:	in	contrast	to	LM/	or	entropy,	¶-score	and	=>?	are	global	measures	of	the	true	and	predicted	class	agreement,	and	are	not	a	direct	summation	of	the	error	in	individual	observations.	Moreover,	=>?	is	non-differentiable,	whilst	¶-score	is	not	concave,	thus	requiring	approximations	and	rendering	their	direct	optimisation	infeasible	[186–188].	Finally,	utilising	a	non-separable	global	cost	function	for	training,	meant	that	the	NN	models	would	lose	their	ability	to	adapt	incrementally	with	every	new	sample	–	a	key	criteria	for	making	medical	prognostic	models	scalable	with	future	data.	
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A	more	practical	approach	for	cost-sensitive	training	was	to	impose	a	weights	matrix	on	an	existing	cost	function,	so	that	false	negatives	are	penalised	more	severely	than	false	
positives	[71].	In	the	prognostic	models	developed	in	Chapter	6,	the	weighted	cost	matrix	approach	was	considered	for	classification	DT,	NN	and	LR.	The	weights	were	determined	from	 the	1:11	 ratio	 of	 diabetic	 and	non-diabetic	patients	 observed	 at	 10-years	 in	 the	model	derivation	cohort,	i.e.	the	cost	of	a	false	negative	predictions	was	stipulated	to	be	11	times	higher	than	the	cost	of	false	positives.	Such	weighted	cost	matrix	rectified	the	class	imbalance	issue	in	the	classification	DT,	although	the	overall	model	structure	was	deemed	inappropriate	and	the	classification	DT	was	replaced	later	in	the	study	with	a	specialised	survival	DT.		
Against	the	expectations,	the	cost-penalised	NN	and	LR	models	overfitted	the	diabetic	outcome	 patients	 and	 produced	 an	 overwhelming	 number	 of	 false	 positives.	 Poor	specificity	 in	models	 designed	 to	 predict	 a	 long-term	 incidence	 of	 diabetes,	 meant	 a	dramatic	 increase	 for	 the	NHS	 screening	 expenses,	 rendering	 such	models	 infeasible.	Lowering	the	cost	penalty	from	11	to	1	in	the	increments	of	1,	did	not	improve	the	overall	balanced	 accuracy,	 rendering	 the	weighted	 cost	matrix	 approach	 not	 suitable	 for	 the	applications	 where	 it	 is	 critical	 to	 achieve	 high	 sensitivity	 without	 jeopardising	 an	adequate	specificity.	This	left	the	author	and	her	collaborators	to	seek	data-resampling	techniques	for	balancing	the	class	representation	in	the	dataset.	
3.2.2 Sampling	techniques	for	imbalanced	data	
Another	approach	 for	balancing	a	dataset	 is	 to	 increase	 the	number	of	minority	 class	observations:	 either	 by	 resampling	 with	 replacement,	 or	 by	 generating	 synthetic	instances	[71].	Two	state-of-the-art	methods	of	oversampling	were	considered	for	the	imbalanced	dataset	 in	Chapter	6.	Synthetic	Minority	Oversampling	 (SMOTE)	generated	
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new	 samples	 from	 each	 minority	 observation	 and	 its	 nearest	 neighbours	 by	 linear	interpolation	across	each	input	dimension	[189].	The	method	is	considered	an	effective	remedy	against	severely	 imbalanced	data,	but	has	a	serious	drawback	of	blending	the	boundary	between	majority	and	minority	classes	[68,188,190].	An	extension	to	SMOTE	called	Adaptive	Synthetic	Sampling	(ADASYN),	in	which	the	density	of	the	new	instances	is	weighted	with	respect	to	the	class	boundaries,	was	proposed	by	He	et	al.	[191].		The	improvement	comes	with	a	price:	ADASYN	is	sensitive	to	outliers	[70,188,191],	which	makes	it	less	suitable	for	modelling	rare	events,	such	as	type	2	Diabetes	Mellitus	(DM)	considered	in	Chapter	6.		
The	 simplest	 and	 often	 overlooked	 approach	 for	 imbalanced	 data	 is	 majority	
undersampling,	 whereby	 majority	 class	 observations	 are	 removed	 from	 the	 training	dataset.	An	illustrative	comparison	of	SMOTE	and	majority	undersampling	is	shown	in	Figure	3.1.		
	
Figure	3.1	Effect	of	minority	oversampling	(centre)	and	majority	undersampling	(right)	on	imbalanced	data.	
Two	classes	of	patients	correspond	to	those	with	known	10-year	non-diabetic	(DM)	outcome	(red)	and	those	
who	had	been	diagnosed	with	type	2	DM	(teal)	during	the	10-year.	The	original	dataset	(left)	comprised	1431	
(278	DM)	patients	with	known	fasting	blood	glucose	(BG)	and	Body	mass	index	(BMI).			
2	 2	 2	
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Although	undersampling	has	been	shown	to	be	particularly	effective	 in	 large	datasets	with	low	variance	[69,70,188],	the	omission	of	a	part	of	the	dataset	inevitably	introduces	selection	 bias.	 Several	 techniques	 have	 been	 suggested	 to	 reduce	 this	 effect	 by	considering	majority	outliers	[190],	analysing	clusters	[68]	or	cascading	an	ensemble	of	classifiers	[192].		In	this	research,	majority	undersampling	was	combined	with	ensemble	learning,	allowing	for	all	majority	samples	to	be	considered	at	least	once,	thus	effectively	removing	 the	 inclusion	bias.	As	highlighted	 in	Section	6.3.2,	 this	approach	resulted	 in	prognostic	models	as	effective	as	those	built	with	more	complex	SMOTE	and	ADASYN.	
 Novel	framework	for	small	data		
In	 real	 world	 clinical	 applications,	 where	 missing	 values	 and	 class	 imbalance	 issues	cannot	be	effectively	addressed,	 the	number	of	samples	available	 for	ML	training	and	validation	is	 further	reduced.	As	mentioned	in	Chapter	1,	ML	models	trained	on	small	datasets	(less	than	10	observations	per	predictor	variable)	exhibit	sporadic	fluctuations	in	their	output,	and	are	difficult	to	validate.	In	order	to	address	these	issues	and	improve	usability	 of	 ML	 with	 small	 clinical	 datasets,	 developed	 in	 this	 thesis	 is	 a	 framework	consisting	of:	1)	the	method	of	multiple	runs	 for	model	development,	and	2)	surrogate	
data	 test	 for	 regression	 model	 validation.	 The	 method	 of	 multiple	 runs	 enabled	consistent	performance	comparisons	among	various	ML	designs,	despite	the	volatility	in	predicted	 outcomes	due	 to	 small	 data.	 	 Surrogate	 data	 test	 evaluated	 trained	models	under	small	data	conditions	and	provided	quantification	of	the	random	effects,	where	additional	test	samples	are	not	available.		
The	framework	was	developed	and	validated	for	NNs,	although	it	could	be	applied	to	any	regression	ML	system,	whose	training	and	initialisation	algorithms	contain	a	deliberate	degree	of	randomness.	The	method	of	multiple	runs,	in	isolation,	is	not	sensitive	to	the	
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nature	of	the	predicted	targets,	and	thus	it	is	applicable	to	both	regression,	classification	and	survival	problems.	This	novel	methodology	extends	beyond	the	task	considered	in	this	chapter	and	provides	a	general	framework	for	application	of	ML	to	medical	problems	characterised	by	limited	dataset	sizes.	
3.3.1 Method	of	multiple	runs		
The	 principle	 underpinning	 the	method	 of	 multiple	 runs	 is	 rooted	 in	 the	 simple	 yet	powerful	 idea	 of	 tackling	 the	 problem	 of	 insufficiently	 few	 samples	 with	 many	independent	 learners.	 A	 large	 number	 of	 NNs	 of	 the	 same	 design	 are	 trained	simultaneously.	In	other	words,	the	performance	of	a	given	NN	design	is	assessed	not	on	a	single	NN	instance,	but	repeatedly	on	a	set	(defined	here	as	run)	of	a	few	thousand	NNs.	Identical	in	terms	of	their	topology	and	neuron	functions,	NNs	within	each	such	run	differ	due	 to	several	 sources	of	 randomness	deliberately	embedded	 in	 the	 initialisation	and	training	routines.	For	instance,	for	feed-forward	NNs	with	early	stopping	these	are:		
• the	initial	values	of	the	layer	weights	and	biases,		
• the	split	between	the	training	and	validation	datasets,	
• the	order	with	which	the	training	and	validation	samples	are	fed	into	the	NN.		
In	 every	 run,	 several	 thousand	NNs	with	various	 initial	 conditions	are	generated	and	trained	in	parallel,	producing	a	range	of	successful	and	unsuccessful	NNs,	as	evaluated	according	to	criteria	set	in	Section	3.3.3.	Subsequently,	the	NN	performance	indicators	are	 reported	 as	 collective	 statistics	 across	 the	 whole	 run,	 thus	 allowing	 consistent	comparisons	of	performance	among	 runs	despite	 the	 limited	 size	of	 the	dataset.	This	helps	to	quantify	the	varying	effects	of	design	parameters,	such	as	network	size	and	the	training	duration,	during	the	iterative	parameter	estimation	process.	Finally,	the	highest	performing	 instance	 of	 the	 optimal	 NN	 design	 is	 selected	 as	 the	working	model.	 This	
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strategy	principally	differs	from	NN	ensemble	methods	(as	discussed	further	in	Section	3.5)	in	the	sense	that	only	the	output	of	a	single	best	performing	NN	is	ultimately	selected	as	the	working	model.	
In	summary,	the	following	terminology	applies	throughout	this	chapter:	
• design	parameters	are	NN	size,	neuron	functions,	training	functions,	etc.	
• individual	NN	parameters	are	weights	and	biases;	
• optimal	NN	design	is	based	on	estimation	of	appropriate	hyperparameters;	
• working	(optimal)	model	is	the	highest	performing	instance	selected	from	a	run	of	the	optimal	NN	design.		
The	 choice	 of	 the	 number	 of	 NNs	 per	 run	 is	 influenced	 by	 the	 balance	 between	 the	required	precision	of	the	statistical	measures	and	available	computational	resources,	as	larger	runs	require	more	memory	and	time	to	simulate.	In	the	extreme	case	of	dataset	size	 deficiency	 considered	 in	 Chapter	 4,	 where	 only	 35	 samples	 were	 available,	 a	consistency	 to	 3	 decimal	 places	 could	 be	maintained	 for	most	 performance	 statistics	(such	as	mean	regression	between	NN	targets	and	predictions)	with	2000	NNs,	which	was	deemed	sufficient.	For	 inter-run	consistency,	each	2000	NN	run	was	repeated	10	times,	 yielding	20000	NNs	 in	 total.	The	average	 simulation	 time	 for	 instantiating	and	training	a	run	of	2000	NNs	on	a	modern	PC	(Intel®	Core™	i7-3770	CPU	@3.40GHz,	32	GB	RAM)	was	280	seconds.		
3.3.2 Surrogate	data	test	
Where	 a	 sufficient	 number	 of	 samples	 is	 available,	 the	 efficiency	 of	 learning	 of	 the	interrelationships	 in	 the	data	 is	expected	 to	correlate	with	 its	 test	performance.	With	small	test	datasets,	however,	it	is	possible	for	even	poorly-designed	NNs	to	achieve,	at	
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random,	a	statistically	significant	performance.	In	order	to	distinguish	truly	effective	NN	learners	 from	 “lucky”	 coincidental	 fittings,	 it	 is	 important	 to	 be	 able	 to	 evaluate	 NN	generalising	 performance	 in	 spite	 of	 random	 effects.	 This	 is	 the	 aim	 of	 the	 proposed	
surrogate	data	test.		
First,	surrogate	data	are	generated	 so	 that	 they	mimic	 the	statistical	properties	of	 the	original	 dataset	 independently	 for	 each	 component	 of	 the	 input	 vector.	 Whilst	resembling	the	statistical	properties	of	the	original	data,	the	surrogates	are	not	meant	to	retain	 the	 intricate	 interrelationships	 between	 the	 various	 components	 of	 the	 real	dataset.	Subsequently,	the	NNs	trained	and	tested	on	surrogates	are	expected	to	perform	poorly.	Any	seemingly	high	performance	should	be	deemed	coincidental.		
The	model	accuracy	on	surrogate	data	informs	the	NN	designer	as	to	what	performance	could	be	achieved	by	a	particular	NN	design	due	to	“luck”.	By	repeating	these	estimations	with	 multiple	 surrogate-data	 NNs,	 the	 random	 effects	 on	 the	 real-data	 model	performance	can	be	quantified.	Training	and	evaluation	of	multiple	NNs	with	surrogate	data	is	made	possible	with	the	method	of	multiple	runs	proposed	in	Section	3.3.1.	The	highest	performing	surrogate	NN	instance	defines	the	lowest	performance	threshold	for	real	data	models.	Hence,	to	pass	the	surrogate	data	test,	real	data	NNs	must	outperform	this	threshold.	
The	surrogate	samples	can	be	generated	using	a	variety	of	methods	[170,193,194].	For	normally	 distributed	 data	 the	 surrogates	 were	 generated	 from	 random	 numbers	 to	match	the	truncated	normal	distributions,	e.g.	mean	and	standard	deviation	estimated	from	the	original	data,	as	well	as	their	range	and	size.	For	data	where	individual	variables	were	not	normally	distributed,	random	permutations	[195]	of	the	original	vectors	were	applied.	
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3.3.3 Model	evaluation	and	selection	
For	 the	regression	NNs,	 the	performance	of	 the	 individual	models,	 including	 the	best-performing,	was	reported	using	the	linear	regression	coefficients	J	between	the	ground	truth	 (targets)	 and	 predicted	 outputs.	 	 In	 particular,	 regression	 coefficients	 were	evaluated	 for	 the	entire	dataset	 (JABB),	 and	separately	 for	 training	 (J~AuC),	 validation	(J©AB),	and	testing	(J~E™~).		
The	 collective	 performance	 of	 the	 NNs	 within	 a	 multiple	 run	 was	 reported	 on	 the	following:	
• mean	µ	and	standard	deviation	*	of	J~E™~	and	JABB 	across	all	NNs	in	the	run	
• the	number	of	NNs	that	are	statistically	significant	(JABB ≥ 0.6)	
• the	random	effect	threshold,	J™Æ,ØAü ,	set	by	the	highest	performing	surrogate	NN,	in	terms	of	JABB 	and	J~E™~	
Under	small-data	conditions,	J©AB 	is	unreliable	on	its	own	for	model	selection.	Hence	in	the	proposed	framework,	both	J~AuC	and		J©AB 	were	considered	 in	order	to	select	 the	best	performing	model	 in	 the	multiple	 run.	Although	J~AuC	 does	not	 indicate	 the	NN	performance	on	new	samples,	it	provides	a	useful	estimation	of	the	highest	expected	NN	performance.		It	is,	therefore,	stipulated	that	J~AuC	must	be	generally	higher	than	J©AB 	for	a	well-trained	NN.	Subsequently,	when	selecting	the	best	performing	NN,	the	models	with	J©AB 	>	J~AuC	were	disregarded,	and	from	the	remaining	models	the	one	with	the	highest	J©AB 	was	chosen.	Note	that	J~E™~	should	not	be	involved	in	the	model	selection	as	it	reflects	the	generalising	performance	of	NN	models	on	new	data.	
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3.3.4 Summary	of	the	proposed	framework	
Combined,	the	method	of	multiple	runs	and	surrogate	data	test	comprise	a	framework	for	application	of	regression	ML	models	to	small	datasets,	as	summarised	in	Figure	3.2.		Multiple	runs	enable:		
i) consistent	comparison	of	ML	designs	during	design	parameter	estimation,		
ii) evaluation	of	surrogate	data	and	real	data	models	during	surrogate	data	test,	
iii) selection	of	the	working	model	among	the	models	of	optimal	design.			
Surrogate	data	test	provides	a	mechanism	for:	
iv) quantification	 of	 the	 random	 effects	 due	 to	 small	 data	 on	 regression	 ML	performance,		
v) validation	of	the	regression	ML	model	performance,	where	no	additional	test	samples	are	available.			
	
Figure	3.2	A	novel	framework	for	the	application	of	regression	ML	models	to	small	datasets.	
Chapter	3.		Strategies	for	limited	data	
58	
 Framework	validation	
The	 intended	 domain	 of	 application	 for	 the	 proposed	 framework	 was	 a	 tissue	engineering	 task	 of	 predicting	 compressive	 strength	 (CS)	 in	 bones	 affected	 by	osteoarthritis,	as	later	detailed	in	Chapter	4.		However,	the	small-data	models	enabled	by	the	framework	could	not	be	considered	as	valid	until	it	was	confirmed	that	such	models	were	able	to	generalise	on	larger	datasets.	Since	large	datasets	were	not	easily	available	in	hard	tissue	engineering,	alternative	data	sources	had	to	be	considered.		A	1030-sample	dataset	 [164]	on	CS	of	another	porous	solid	(concrete)	was	adapted	 in	 this	validation	study	from	civil	engineering	domain.	
This	dataset	enabled,	 in	a	principled	manner,	an	investigation	of	the	effects	of	dataset	size	on	generalising	ability	of	the	NNs	produced	by	the	framework.		Furthermore,	access	to	 more	 data	 meant	 that	 the	 small-data	 NNs	 could	 be	 rigorously	 assessed	 for	generalisation	on	a	large	independent	test	cohort,	subsequently	confirming	whether	the	multiple	runs	strategy	and	surrogate	data	test	were	effective.		
3.4.1 The	concrete	compressive	strength	data		
The	dataset	[164]	from	1030	concrete	samples	was	obtained	from	a	publicly	available	ML	 repository	 [165].	 It	 included	 the	 following	 variables	 (descriptive	 statistics	 are	provided	in	Appendix	C):		
• CS	of	concrete	samples	(in	MPa);	
• quantities	 of	 7	 components	 in	 the	 concrete	mixture	 (kg/m3):	 cement,	 blast	furnace	slag,	fly	ash,	water,	superplasticizer,	coarse	and	fine	aggregates;	
• duration	of	concrete	aging	(days).	
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CS	of	concrete	is	a	highly	nonlinear	function	of	its	components	and	the	duration	of	curing	[164],	 however,	 an	 appropriately	 trained	 NN	 could	 effectively	 capture	 that	 complex	relationship	between	the	CS	and	the	other	8	variables.	A	successful	application	of	NNs	to	CS	prediction	based	on	700	concrete	samples	has	been	demonstrated	in	an	original	study	by	Yeh	[164].		The	goal	of	this	work	was	to	establish	if	NNs	trained	with	smaller	dataset	could	achieve	comparable	performance.		
It	is	important	to	emphasise	that	the	concrete	CS	data	were	used	solely	for	the	purpose	of	validating	 the	proposed	modelling	methodology,	and	not	 for	 transfer	 learning	[11].	Concrete	 was	 chosen	 due	 to	 the	 similarity	 of	 the	 statistical	 nature	 of	 the	 output	(continuous	CS)	and	input	parameters,	but	 it	obviously	had	no	biological	relevance	to	trabecular	bones.	 In	principle,	 any	 large	dataset	with	continuous-valued	output	could	have	been	used.		
3.4.2 Effect	of	dataset	size	on	neural	network	performance	
The	dataset	 on	 concrete	CS	was	utilised	 to	 investigate	 the	 role	 of	 dataset	 size	 on	NN	performance	and	generalising	ability.	It	was	demonstrated	that	for	a	 larger	number	of	samples	the	optimal	NN	parameters	could	be	derived	without	 involving	the	proposed	framework,	yet	the	importance	of	the	framework	increases	as	the	data	size	is	reduced.	
First,	a	large-dataset	NN	model	was	developed	on	the	complete	dataset	(1030	samples).	The	samples	were	divided	at	random	into	training	(60%),	validation	(10%)	and	testing	(30%),	 i.e.	 out	 of	 1030	 available	 samples,	 630	 were	 used	 for	 NN	 training,	 100	 for	validation	 and	300	were	 reserved	 for	 testing.	 Each	 run	 comprised	 1000	 feedforward	backpropagation	NNs	with	3=8	inputs	and	$=10	neurons	in	the	hidden	layer.	The	NNs	were	trained	using	the	Levenberg-Marquardt	backpropagation	algorithm	[110,196,197].	The	cost	function	was	defined	as	the	mean	squared	error	LM/	between	the	output	and	
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actual	CS	values.	Early	stopping	on	an	independent	validation	cohort	was	implemented	in	order	to	avoid	NN	overtraining	and	to	improve	generalisation	[153].	The	validation	subset	was	sampled	at	random	from	the	model	dataset	for	each	NN,	ensuring	diversity	among	the	samples.	The	early	stopping	criterion	-	was	set	to	10.	
Secondly,	 a	 NN	was	 applied	 to	 a	 smaller	 subset	 of	 the	 original	 dataset.	 Out	 of	 1030	concrete	samples,	100	samples	were	sampled	at	random	and	without	replacement	[195].	The	descriptive	statistics	of	the	original	and	small	subsets	are	provided	in	Appendix	C.	The	proportions	for	training,	validation	and	testing	subsets,	as	well	as	the	training	and	initialisation	routines,	were	analogous	to	those	used	for	the	large	concrete	dataset	NN	with	an	exception	to	the	following	adjustments:	
i) the	 size	 of	 the	 run	 was	 increased	 to	 2000	 NNs	 to	 maintain	 inter-run	repeatability		
ii) the	hidden	 layer	 size	$	was	 reduced	 from	10	 to	5	neurons	 to	 adjust	 for	 the	smaller	dataset	
iii) the	early	stopping	criterion	-	was	reduced	from	10	to	6	to	reflect	the	changes	in	(ii)		
Finally,	an	extreme	case	with	even	smaller	subset	of	the	data	was	considered.	From	the	available	 1030	 samples,	 56	 were	 selected	 at	 random	 to	 yield	 the	 same	 ratio	 of	 the	number	of	observations	per	predictor	variable	as	in	the	bone	CS	dataset	(35	samples	and	5	predictors)	considered	in	Chapter	4.	Out	of	the	56	concrete	samples,	41	were	used	for	small-data	model	development,	and	the	remaining	15	were	reserved	for	model	testing.	The	descriptive	statistics	on	the	model	and	test	subset	are	provided	in	Appendix	C.		
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Figure	 3.3	 illustrates	 the	 changes	 to	 the	 regression	 coefficient	 distributions	 across	 a	multiple	run	as	the	size	of	the	dataset	decreased	from	(a)	1030	to	(b)	100,	and	to	(c)	56	samples.	 All	 large-data	 NNs	 (Figure	 3.3	 a)	 performed	 with	 statistically	 significant	regression	 coefficients	 (J	 ≥ 	0.6).	 As	 expected	with	 large	 data,	 the	 performance	was	highly	accurate,	with	)(JABB)	=0.95	and	)(J~E™~)=0.94	when	averaged	across	the	multiple	run	of	1000	NNs.	
For	smaller	dataset	NNs	(Figure	3.3	b,	c),	the	distributions	of	the	regression	coefficients	along	 x-axis	 were	 within	 substantially	 wider	 ranges.	 The	 standard	 deviations	 σ	 also	increased	 substantially	 for	 NN	modes	 based	 on	 smaller	 datasets	 compared	 with	 the	initial	 large-dataset	model	 (Figure	 3.3	 a).	 Distributions	 of	 the	 regression	 coefficients	achieved	 by	 the	 2000	 NN	 instances	within	 the	 same	 run	 (Figure	 3.3	 c)	 demonstrate	higher	intra-run	variance	when	compared	to	the	large-dataset	NNs	(Figure	3.3	a).		Over	half	 of	 the	NNs	 did	 not	 converge	 and	 only	 762	NNs	 produced	 statistically	 significant	predictions.		
The	 mean	 regression	 coefficients	 across	 the	 run	 decreased	 to	 )(JABB)=0.719,	 and	)(J~E™~)=0.542	(Figure	3.3	c).	 	When	considering	only	statistically	significant	NNs,	the	mean	 performance	 of	 all	 samples	 was	 )(JABB,™uÄCu})=0.839	 and	 individually	 for	 tests	)(J~E™~,™uÄCu})=0.736.	Despite	higher	volatility,	an	undesirable	distribution	spread	and	lower	 mean	 performance,	 the	 maximal	 R	 values	 for	 the	 small-dataset	 NNs	 were	comparable	with	those	for	the	large-dataset	NNs.		
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Figure	3.3.	Distributions	of	JABB 	and	J~E™~	across	a	run	of	NNs:	(a)	large-dataset	model	(1030	samples),	(b)	
intermediate	100	sample	model,	and	(c)	small-dataset	model	(56	samples).	The	inset	shows	the	enlarged	area	
highlighted	in	(a).	
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3.4.3 Surrogate	data	test	for	concrete		
As	expected,	NNs	trained	on	the	real	concrete	data	consistently	outperformed	surrogate	NNs.	Figure	3.4	demonstrates	how	the	difference	in	performance	between	the	real	and	surrogate	NNs	increased	with	the	dataset	size.		
For	the	large-dataset	NN	developed	with	1030	samples	(Figure	3.4	a),	the	surrogate	and	real-data	NN	distributions	did	not	overlap.	 In	 fact,	 the	 surrogate	NNs	 in	 this	 instance	achieved	 approximately	 zero	mean	 performance,	 which	 signifies	 that	 random	 effects	would	not	have	an	impact	on	NN	learning	with	a	dataset	of	this	size.		
The	100-sample	(Figure	3.4	b)	and	56-sample	(Figure	3.4	c)	surrogate	NNs	had	a	non-zero	mean	performance	of	)(JABB,™Æ,Vôô)	=0.219	and	)(JABB,™Æ,Üá)=0.187,	respectively.	They	were	also	characterised	by	a	higher	standard	deviation	of	* = 0.142	and	* = 0.145		compared	to	 large-dataset	NNs	(* = 0.048).	 	The	non-zero	mean	performance	of	NNs	suggests	 that	 random	 effects	 cannot	 be	 disregarded	with	 small	 datasets	 and	 require	quantification	offered	by	the	proposed	surrogate	data	test.	Figure	3.4	also	demonstrates	how	the	surrogate	data	test	becomes	progressively	more	conservative	with	decreasing	dataset	size.	
For	 56-sample	 datasets	 (Figure	 3.4	 c),	 the	 surrogate	 NNs	 performed	 with	 a	 mean	regression	of	)(JABB,™Æ,Üá)=0.187,	as	opposed	to	)(JABB,EAB,Üá)=0.715	for	real-data	NNs.	None	 of	 the	 2000	 surrogate	 small-dataset	 NNs	 achieved	 a	 statistically	 significant	performance	 (R	 ≥	 0.6).	 The	 surrogate	 threshold	 for	 the	 56-sample	 NN	 was	 below	statistical	significance:	the	highest	performing	surrogate	NN	achieved	J™Æ,ØAü,Üá=0.791,	largely	due	to	overtraining,	and	hence	its	corresponding	performance	on	test	samples	of	J™Æ,ØAü,Üá,~E™~		=	0.515	was	poor.			
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Figure	3.4.	Surrogate	(green)	vs.	real	concrete	data	(navy)	NN	performance	for	(a)	large-dataset	model	(1030	
samples),	(b)	intermediate	100	sample	model,	and	(c)	small-dataset	model	(56	samples).	
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3.4.4 Benchmark	model	
The	performance	of	one	of	1000	large-data	NN	from	the	run	in	Section	3.4.2	(Figure	3.3	a)	is	shown	in	Figure	3.5.	This	specimen	NN	achieved	JABB	=0.944	and	generalised	with	J~E™~=0.94	 on	 300	 independent	 test	 samples	 (Figure	 3.5	 d).	 It	 reflects	 a	 benchmark	performance	of	NNs	trained	with	abundant	samples	using	standard	techniques.		
	
Figure	3.5.	Linear	regression	between	target	and	predicted	compressive	strength	achieved	by	the	specimen	
large-data	(1030	samples)	concrete	neural	network	model.	Values	are	reported	individually	for	(a)	training	
(blue),	(b)	validation	(green),	(c)	testing	(red),	and	(d)	the	entire	dataset	(black).		3.4.5 Small-data	model	developed	with	multiple	runs	
Among	the	2000	small-dataset	(56-sample)	NNs,	the	best-performing	NN	was	selected	using	the	performance	criteria	defined	in	Section	3.3.3.	This	model	achieved	regression	
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coefficients	of	JABB=0.92	on	the	entire	dataset,	and	separately:	J~AuC=	0.96,	J©AB=	0.92	and	J~E™~=0.90	on	15-sample	test	(Figure	3.6	a-d).	In	comparison,	the	large-dataset	NN	developed	with	 1030	 samples	 performed	 only	 2.12%	higher.	 The	J	values	were	well	above	the	surrogate	threshold	)(J™Æ,ØAü,Üá)=0.791	determined	in	Section	3.4.3,	hence	establishing	that	high	performance	of	the	small-data	NN	was	not	due	to	random	effects.	
	
Figure	3.6.	Linear	regression	between	target	and	predicted	compressive	strength	achieved	by	the	small-
dataset	(56	samples)	optimised	concrete	neural	network.	Values	are	reported	individually	for	(a)	training	
(blue),	(b)	validation	(green)	and	(c)	testing	(red),	(d)	the	entire	dataset	(black),	and	(e)	for	300	independent	
test	samples	(purple).	To	further	confirm	that	the	proposed	framework	was	indeed	capable	of	producing	well-generalising	 models	 from	 limited	 data,	 the	 performance	 of	 the	 small-data	 NN	 was	assessed	on	300	additional	test	samples	(an	equivalent	number	was	used	in	the	large-dataset	 NN).	 These	were	 randomly	 sampled	without	 replacement	 from	 the	 available	dataset	of	1030 − 56 = 974	 samples	not	previously	seen	by	 this	NN.	Remarkably,	 the	small-data	NN,	modelled	with	only	41	samples,	was	able	to	predict	CS	on	300	new	test	samples	 with	J~E™~,Ñôô=0.865	 (Figure	 3.6	 e).	 The	 corresponding	RMSE	 (as	 defined	 in	
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Appendix	B)	was	9.5	MPa.	This	constitutes	a	7.5%	decrease	in	generalising	performance	compared	to	the	benchmark	NN,	which	used	18	(!)	times	larger	dataset	(Figure	3.5	c).		
In	 other	 words,	 the	 proposed	 framework	 enabled	 the	 development	 and	 validation	against	random	effects	of	an	86.5%	accurate	regression	ML	model	on	a	dataset	18	times	smaller	 than	 that	 required	 to	 achieve	 a	 comparable	 performance	 with	 standard	techniques.	 The	 remarkable	 cost-benefit	 trade-off	 made	 possible	 by	 the	 framework	highlighted	 its	 value	 for	 addressing	 the	 problems	 characterised	 by	 restricted	 dataset	sizes.	The	small-data	concrete	CS	NN	demonstrated	that	it	was	possible	for	accurate	and	robust	regression	ML	models	to	be	developed	with	as	few	as	56	samples.	This	finding	inspired	the	clinical	applications	in	Chapters	4-6,	which	were	not	previously	considered	possible	with	ML	due	to	restricted	availability	and	limited	quality	of	samples.		
 Comparison	with	alternative	techniques	for	small	data	
Although	there	are	no	existing	ML	techniques	for	analysis	of	such	extreme	cases	as	the	dataset	with	merely	56	observations,	some	ML	methods,	such	as	NN	ensembling,	leave-one-out	 cross-validation,	 and	 regularisation,	 are	 believed	 to	 work	 well	 in	 data-poor	situations	[198,199].			In	order	to	determine	their	suitability	for	datasets	as	small	as	10	observations	 per	 predictor	 variable,	 it	 was	 decided	 to	 implement	 each	 of	 the	abovementioned	techniques	and	let	the	practical	results	speak	for	themselves.		
3.5.1 Ensemble	of	neural	networks	
As	discussed	in	Section	2.3,	combining	predictions	of	a	series	of	individual	NNs	into	an	ensemble	often	increases	their	robustness	and	accuracy	[132,133].	In	this	section,	the	NN	 ensemble	 was	 compared	 and	 contrasted	 with	 a	 single	 small-data	 NN	 model	developed	with	the	proposed	framework	from	Section	3.4.5.		
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The	 initial	NN	ensemble	was	designed	by	combining	the	outputs	of	1000	NNs	trained	with	the	complete	dataset	(analogous	to	the	large-dataset	NNs	described	in	Section	3.4.2	and	presented	in	Figure	3.3	a).	As	anticipated,	this	NN	ensemble	was	able	to	achieve	a	superior	 generalisation	 accuracy	 of	 J~E™~	 =	 0.96	 when	 tested	 on	 300	 independent	samples.			
The	 second	 NN	 ensemble	 was	 designed	 by	 combining	 the	 2000	 56-sample	 NNs	(analogous	 to	 the	small-dataset	NNs	 in	Section	3.4.2).	This	ensemble	achieved	J~E™~	=	0.81	 on	 15	 independent	 test	 samples.	 In	 comparison,	 the	 small-dataset	 NN	model	 in	Section	 3.4.5	 achieved	 J~E™~	 =	 0.90	 on	 the	 same	 test	 samples.	 Subsequently	 the	generalising	ability	of	this	ensemble	was	assessed	on	300	additional	concrete	samples.		
The	ensemble	was	able	to	retain	its	generalising	ability	with	the	accuracy	of	J~E™~,Ñôô	=	0.81,	proving	its	robustness,	 irrespective	of	the	test	sample	size.	Despite	such	striking	consistency	between	J~E™~	and	J~E™~,Ñôô,	this	generalising	performance	was	found	to	be	8%	lower	than	that	of	the	single	small-data	NN	developed	with	the	proposed	framework	(J~E™~,Ñôô	=	0.87,	Section	3.4.5).	 	These	results	demonstrate	that	the	NN	ensemble	was	able	to	achieve	a	remarkable	performance	on	predictive	tasks	with	sufficient	data,	but	was	unable	to	perform	as	well	as	the	proposed	multiple	run	model	on	the	small	dataset	considered	in	this	experiment.		
3.5.2 Regularisation	
The	principle	behind	regularisation	is	to	penalise	NN	performance	for	large	weights	and	biases,	 thus	 preventing	 over-parametrisation	 and	 resulting	 in	 smoother	 response	[107,199].	This	 is	achieved	by	modifying	 the	NN	cost	 function	 to	consider	 the	sum	of	squares	of	the	NN	weights	and	biases.	Regularisation	with	Bayesian	regularisation	[200]	backpropagation	was	implemented	in	the	NN	models	as	an	alternative	technique	to	early	
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stopping.	The	validation	samples	required	for	early	stopping	were	now	made	available	for	 training.	Despite	 this	 increased	 training	 dataset,	 regularisation	 did	 not	 lead	 to	 an	increased	 generalisation	 performance,	 and	 instead	 it	 appeared	 to	 over-train	 the	NNs	(Table	3.1).	
Table	3.1	Controlling	overfitting	with	small	data:	Early	stopping	vs	Bayesian	regularisation	Median	J	across	a	run	of	2000	NNs	
Dataset2	 Early	stopping	 Regularisation	All	 0.760	 0.864	Training	 0.817	 0.950	Validation	 0.709	Testing	 0.734	 0.676		Changing	 regularisation	 parameters	 (such	 as	 increasing	 the	 minimum	 gradient,	
maximum	Marquardt	adjustment	parameter	 and	 the	 learning	rate	decrements)	did	not	improve	the	results.	Whilst	regularisation	did	not	prove	superior	to	early	stopping	on	the	extremely	small	dataset,	the	strategy	independently	verified	the	optimal	estimates	of	the	bone	CS	network	hyperparameters,	as	described	in	Chapter	4.	
3.5.3 K-fold	and	leave-one-out	cross	validation	
Cross-validation	is	used	to	ensure	that	the	results	produced	by	the	ML	models	do	not	depend	on	the	random	choice	of	 the	validation	set.	With	multiple	runs,	 the	validation	cohort	used	for	early	stopping	was	sampled	at	random	from	the	model	dataset	for	each	NN,	ensuring	diversity	among	the	samples.	This	validation	approach	cannot	be	strictly	called	 a	 k-folds	 cross-validation:	 the	 folds	 are	 overlapping	 and	 may	 not	 cover	 every	possible	combination.	The	resulting	validation	subsets	are	more	diverse	than	k-folds	due	to	the	random	sampling	in	each	run	of	2000	NNs.	
																																								 																					2	The	dataset	presented	here	bone	CS	data,	which	is	discussed	in	Chapter	4.		
Chapter	3.		Strategies	for	limited	data	
70	
Leave-one-out	cross	validation	was	useful	for	overall	inter-run	performance	evaluation	during	preliminary	design	parameter	optimisation.	However,	it	was	not	applicable	to	the	intra-run	model	 selection.	Medical	 applications	 considered	 in	 this	 research	 require	 a	stand-alone	predictive	model,	and,	therefore,	it	is	advantageous	to	be	able	to	single	out	a	best-performing	NN	 among	 those	 of	 identical	 designs.	 To	do	 so	without	 affecting	 the	purity	of	test	samples,	one	has	to	sacrifice	a	subset	for	a	validation	cohort.	Whilst	being	resourceful	with	an	already	small	dataset,	leave-one-out	cross	validation	does	not	provide	such	independent	subset	for	identification	of	a	single	best-performing	NN	in	a	run.		
 Chapter	conclusions	
This	 chapter	 demonstrated	 that	 no	 general	 “one-size-fits-all”	 strategy	 exists	 for	 ML	modelling	with	limited	clinical	data.	The	key	findings	are	summarised	as	follows:	
(1) The	existing	techniques	for	managing	incomplete	data	rely	on	missing	at	random	assumption	and	introduce	bias	when	mechanisms	of	missing	data	are	dependent	on	the	unknown	variables.			
(2) Relative	disadvantages	of	list-wise	deletion,	single	value	imputation	with	indicator	variable,	 and	multiple	 imputation	with	 chained	 equations	 have	 to	 be	 considered	 in	 a	practical	context.	
(3) Decision	 trees	 stand	out	 among	other	ML	 algorithms	 for	 their	 ability	 to	 handle	missing	data	without	imputation,	rendering	these	models	particularly	advantageous	for	analysing	incomplete	datasets.		
(4) Complexity	 of	 the	 class	 balancing	 technique	 does	 not	 necessarily	 translate	 into	superior	performance:	majority	undersampling	combined	with	ensemble	learning	was	
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as	effective	as	state-of-the-art	synthetic	minority	oversampling	techniques	for	data	with	1:11	class	imbalance.		
(5) A	novel	methodological	 framework	comprising:	 (1)	a	multiple	 runs	strategy	 for	predictive	model	 development	 and	 optimisation	with	 limited	 data,	 and	 (2)	 surrogate	data	test	for	regression	model	validation	in	the	absence	of	substantive	test	samples,	has	been	developed	to	address	the	limitations	of	small	datasets	(less	than	10	observations	per	predictor	variable)	in	ML	applications.		
(6) The	framework	enabled	the	successful	development	and	validation	of	a	regression	NN	with	as	few	as	8	observations	per	predictor	variable	and	outperformed	the	ensemble	NNs,	leave-one-out	cross	validation	and	regularisation	methods	in	experiments	on	small	data.		
(7) Using	the	proposed	framework,	a	NN	modelled	with	a	small	subset	of	56	samples	was	 shown	 to	 generalise	 on	 300	 independent	 test	 samples	 with	 86.5%	 predictive	accuracy.	 This	was	 comparable	 to	 the	performance	of	 the	NNs	developed	with	 an	18	times	 larger	 dataset	 using	 standard	 techniques,	 thus	 demonstrating	 the	 remarkable	potential	 of	 the	 proposed	 framework	 for	 improving	 the	 cost-benefit	 trade-off	 in	applications	restricted	by	dataset	sizes.	
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Bone	fracture	prediction	in	osteoarthritis	
The	compressive	strength	(CS)	of	a	trabecular	tissue	in	the	femoral	head	is	indicative	of	hip	 fracture	 risk	 [201–203].	 In	patients	 suffering	 from	severe	osteoarthritis	 (OA),	 the	relationships	between	the	CS	and	structural	parameters	of	trabecular	tissue	cannot	be	explained	with	the	existing	mechanistic	models	[201,204].	In	this	chapter,	a	two-layer	feedforward	NN	was	developed	 for	modelling	CS	 from	porosity,	morphology,	 and	 the	level	of	trabecular	interconnectivity	in	female	and	male	OA	patients	of	various	ages.		
Developed	with	only	35	specimens	using	the	novel	methodology	for	small	data	proposed	in	 Chapter	 3,	 the	 NN	model	 was	 able	 to	 accurately	 (J~E™~	 =0.983)	 estimate	 CS	 from	structural	and	physiological	properties	to	within	0.85	MPa.	Within	the	limitations	of	the	available	 dataset,	 the	 NN	 offered	 a	 predictive	 model	 for	 clinical	 and	 hard	 tissue	engineering	 decision	 support.	 The	 significance	 of	 this	 work	 is	 two-fold:	 its	 practical	application	allows	for	the	non-destructive	estimation	of	strength	to	femoral	fracture	in	OA	patients,	whilst	also	demonstrating	the	efficacy	of	the	proposed	framework	for	the	application	of	regression	NNs	to	small	biomedical	datasets.	
 Femoral	fractures	in	osteoarthritis	
Bone	 fractures	 account	 for	 more	 than	 20%	 of	 orthopaedic	 hospital	 cases	 in	 the	 UK,	among	which	 fractures	 of	 proximal	 femur	 (hip)	 are	 a	 growing	public	 health	 problem	
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[205–207].	With	 increasing	global	 incidence,	hip	 fractures	are	projected	to	affect	6.26	million	 people	 by	 2050	 [206],	which	 necessitates	 scalable	 screening	 programmes	 for	patients	at	risk	that	can	adapt	to	population	dynamics.				
A	fracture	occurs	when	excessive	mechanical	loading	is	exerted	on	areas	of	the	femora	during	accidental	falls	and	injuries.	Such	accidents	are	most	common	in	the	elderly	as	a	result	 of	 frailty,	 sensorial	 and	 neurological	 deterioration	 or	muscular	 atrophy	 [207].	Whether	 the	 femora	 would	 fracture	 at	 the	 traumatic	 impact	 is	 determined	 by	 the	mechanical	properties	of	 the	 femoral	 tissue	at	 the	 location	of	 impact.	The	mechanical	properties,	in	turn,	are	determined	by	the	quality	of	the	bone	tissue,	which	is	depleted	with	 age	 and	 hormonal	 changes	 in	 a	 process	 known	 as	 osteopenia	 and,	 in	 advanced	stages,	osteoporosis	 [208].	This	 is	why	 the	 residual	 lifetime	 risk	of	hip	 fracture	at	50	years	of	age	is	higher	in	women	(20%)	than	men	(5.6%)	[206].	Specifically,	osteoporosis	is	 characterised	by	 the	decrease	of	bone	mineral	density	 (BMD),	but	 it	 is	not	 the	only	degenerative	condition	that	affects	the	mechanical	strength	of	the	femur.		
Osteoarthritis	(OA)	is	a	degenerative	joint	disease	associated	with	the	degradation	of	the	articular	cartilage	and	hypertrophic	changes	in	the	bone	(Figure	4.1)	[209].	OA	is	a	life-long	condition	accompanied	by	pain	and	stiffness	in	the	affected	joint,	loss	of	dexterity,	and	reduced	mobility,	 thus	considerably	 limiting	 the	quality	of	 life	of	 the	patient.	The	etiological	 interplay	 in	OA	 is	 complex,	 but	 it	 is	 recognised	 that	OA	 in	 the	hip	 is	more	common	 in	 people	with	 high	 Body	Mass	 Index	 (BMI),	 advancing	 age	 (particularly	 in	women),	 previous	 joint	 injury,	 and	 genetic	 predisposition	 [201,209].	 In	 the	 UK,	 8.75	million	people	have	sought	treatment	for	OA,	which	translates	to	the	direct	annual	cost	of	£5.2	billion	to	the	healthcare	system	[210].	The	treatment	of	severe	hip	OA	is	partial	or	total	hip	arthroplasty	(replacement).		
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Whilst	it	is	well-established	that	osteoporotic	decrease	in	BMD	is	a	key	factor	in	fragility	fractures,	it	might	be	less	known	that	OA	is	often	associated	with	increased	BMD	around	the	 joints.	Several	groups	have	studied	 this	 inverse	association	between	OA	and	BMD		[201,211,212].	Evidence	indicates	that	hip	OA	modulates	the	age	dependence	of	BMD	in	the	proximal	 femora	 [213].	 It	was	also	observed	 that	hip	 fractures	 rarely	occurred	 in	patients	with	OA	[214],	although	OA	was	associated	with	higher	risk	fracture	in	the	knee	[215]	and	spine	 [216].	 It	 is	unclear	whether	 the	greater	BMD	 in	OA	could	be	directly	translated	into	a	reduced	risk	of	hip	fracture,	thus	necessitating	mechanical	modelling	of	the	OA-affected	tissue	from	structural	and	biological	parameters	[201].	
 Modelling	trabecular	strength	in	osteoarthritis	
Bone	is	a	living	cellular	solid	with	a	hierarchical	architecture,	formed	by	a	load-bearing	flexible	 matrix	 of	 collagen	 and	 other	 protein	 molecules	 layered	 with	 hydroxyapatite	nanocrystals	[217].	There	are	two	main	types	of	bone	architecture:	1)	cortical,	forming	the	outer	layer	of	long	bones	with	a	high	density	(90%	of	the	volume)	of	mineralization,	low	surface	to	volume	ratio	and	a	slow	metabolic	rate	(2.5%	annual	remodelling),	and	2)	
trabecular	(cancellous),	which	is	a	porous	lattice-like	structure	in	the	inner	bone	(Figure	4.1)	oriented	along	stress	lines	that	correspond	to	maximum	load-bearing	[208].	It	is	the	mechanical	strength	of	trabecular	tissue	that	determines	the	fragility	fracture	in	proximal	human	femur.	From	a	structural	point	of	view,	the	microarchitecture	of	trabecular	bone	is	characterised	by:		
• porosity,	which	 is	measured	by	 the	bone	volume	over	 total	volume	(BV/TV)	ratio	and	designates	the	percentage	level	of	BMD	in	a	given	volume;	
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• level	 of	 interconnectivity,	 indicated	 by	 trabecular	 thickness	 (Tb.Th)	 and	trabecular	spacing	and	which	shows	how	thick	trabeculae		are	and		how	large	the	pores	are,	respectively;	
• morphology,	 characterised	 by	 the	 Structure	 Model	 Index	 (SMI)	 and	 which	provides	the	3D	measures	of	the	trabecular	lattice	[218].	
These	structural	properties,	together	with	age	and	gender	related	quality	factors	such	as	collagen	content,	mineralisation	rate	and	damage	accumulation,	define	some	of	the	key	mechanical	indicators	of	bone	fracture	risk	such	as	compressive	strength	(CS),	hardness,	stiffness	and	Young’s	modulus.	
It	is	known	from	cellular	mechanics	that	CS	is	related	to	BMD	as	a	polynomial	function	(constant	 exponent	 of	 Ñ,Ü	 )	 [166,204,219].	 This	 mechanistic	 relationship	 explains	reasonably	 well	 the	 dependency	 of	 CS	 on	 BMD	 in	 healthy	 and	 osteoporotic	 patients	[220,221].	However,	for	patients	with	OA,	there	is	an	indication	that	higher	BMD	does	not	 increase	 the	 strength	 to	 failure	 in	OA-affected	 joints	 [201,211].	 Furthermore,	 the	improvement	 of	 BMD	 observed	 in	 OA	 patients	 may	 be	 misrepresented	 by	 the	heterogeneity	 of	 the	 femoral	 tissue	 itself,	 suggesting	 that	 higher	 bone	mineralisation	occurs	in	a	cortical	bone	whilst	trabecular	bone	suffers	from	osteoporotic	loss	of	BMD	[204,222].	The	task	of	modelling	trabecular	tissue	becomes	even	more	onerous	due	to	the	 dependence	 of	 CS	 on	 local	 variations	 in	 microarchitecture	 [223].	 Computational	techniques	such	as	finite-element	analysis	(FEA)	have	been	used	for	clinical	data	in	hip	fractures	with	limited	success	[203,224,225].	All	these	factors	not	only	highlight	the	non-intuitive	complexity	of	the	physiological	and	mechanical	properties	of	trabecular	tissue	in	OA,	but	also	emphasise	the	clinical	importance	of	modelling	femoral	CS	for	OA	patients,	who	have	been	overlooked	in	the	traditionally	osteoporosis-centred	fracture	screening	programmes	[201,213].			
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Figure	4.1	Osteoarthritic	hip	joint	Patient-specific	mechanical	CS	modelling	of	a	trabecular	bone	is	also	of	interest	to	hard	tissue	engineers,	who	are	often	faced	with	the	problem	of	selecting	the	most	successful	strategy	for	both	the	design	and	fabrication	of	synthetic	bioscaffolds	for	the	treatment	of	patients	 suffering	 from	 degenerative	 orthopaedic	 diseases	 triggered	 by	 OA,	osteoporosis,	trauma,	injury	and	metastatic	cancer	[84,226].	To	be	effective,	bioscaffolds	must	not	only	imitate	natural	trabecular	structure	for	improved	bone	regeneration,	but	also	match	precisely	the	mechanical	loading	of	the	diseased	tissue	that	is	being	replaced	[226,227].	 The	 latter	 task	 could	 be	 achieved	 with	 advanced	 3D	 printing	 techniques,	which	 are	 being	 increasingly	 adopted	 in	 hard	 tissue	 engineering	 [226,227];	 provided	that	the	target	values	of	load-bearing	CS	at	the	site	of	implantation	could	be	estimated	in	the	patient	femora	prior	to	the	CS-tailored	bioscaffold	fabrication.		
The	 clinical	 application	of	 screening	patients	 at	 risk	of	hip	 fractures	 in	OA	 requires	a	predictive,	 scalable	 and	 non-invasive	 CS	 model.	 Firstly,	 the	 model	 must	 enable	 the	prediction	of	the	dangerously	decreased	strength	to	fracture	of	OA	tissue	for	the	timely,	preventative	intervention	in	patients	of	different	age	and	gender	groups.	Secondly,	the	model	must	be	scalable	with	aging	population	dynamics	and	the	growing	incidence	of	hip	fractures.	Finally,	the	model	should	provide	a	non-invasive	estimation	of	trabecular	CS	from	the	structural	parameters	available	from	computer	tomography	(CT)	scans.	One	
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possibility	 of	 such	 modelling	 was	 addressed	 in	 this	 research	 using	 neural	 network	learning	from	a	small	secondary	dataset	obtained	from	a	published	study	on	the	effect	of	age	in	OA	[166].	
 Neural	network	for	bone	strength	prediction		
The	use	of	NNs	was	motivated	by	the	author’s	earlier	work	[84],	in	which	a	feedforward	backpropagation	 NN	 was	 able	 to	 infer,	 in	 multi-dimensional	 space,	 the	 complex	interdependency	between	the	mechanical	and	structural	parameters	of	trabecular	tissue	with	a	patient’s	age.	The	application	demonstrated	that	NNs	could	cope	well	with	a	lack	of	mechanistic	priors	and		the	non-linearity	of	parameters	and	determine	the	significant	correlation	of	CS	and	age	[84],	where	linear	statistical	analyses	and	polynomial	BMD-CS	models	had	failed	to	do	so	[166].		
The	 remaining	 obstacle	 for	 applying	NNs	 to	 trabecular	 CS	modelling	was	 the	 limited	availability	 of	 training	 and	 validation	data,	 since	 obtaining	 a	 labelled	dataset	with	CS	values	 involved	 the	destructive	 testing	of	 tissue	samples	extracted	 through	expensive	and	highly	invasive	hip	replacement	procedures.	Such	complexity	is	characteristic	of	the	tissue	engineering	domain,	where	generation	of	large-volume	and	high-quality	datasets	is	highly	 impractical	and	often	unrealistic.	Without	effective	strategies	 for	small	 sized	datasets,	such	as	the	novel	framework	developed	in	Chapter	3,	NN	modelling	remained	infeasible.	The	successful	application	of	the	framework	to	concrete	samples	presented	in	Chapter	3	demonstrated	the	small-data	potential	of	regression	NNs	to	CS	modelling	in	porous	 solids.	 The	 NN	 model	 for	 predicting	 trabecular	 CS	 presented	 in	 this	 chapter	follows	the	principles	of	design	optimisation	with	the	method	of	multiple	runs,	validation	with	 the	 surrogate	data	 test	 and	 comparison	with	 the	 ensemble	NNs	established	and	detailed	in	Section	3.3.	
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4.3.1 The	data	
This	work	focuses	on	a	single-centre	dataset	of	structural	and	mechanical	parameters	for	male	and	female	patients	of	various	ages,	adapted	from	a	study	on	trabecular	bones	affected	by	severe	OA	[166].		Patients	affected	by	secondary	OA	and	other	bone	and	joint	diseases	 were	 excluded	 from	 the	 original	 study.	 Trabecular	 tissue	 samples	 were	extracted	from	the	femoral	head	of	37	patients	undergoing	total	hip	arthroplasty	due	to	severe	 OA.	 The	 cylindrically	 shaped	 fragment	 (20	 mm	 in	 free	 height	 and	 10	 mm	 in	diameter)	of	trabecular	bone	was	chosen	from	the	principal	compressive	region	of	the	femoral	head	and	positioned	for	extraction	so	that	the	cylinder	axis	was	aligned	with	the	fixed	main	trabecular	direction	for	each	specimen.	Care	was	taken	to	ensure	consistency	of	shape,	location	and	alignment.	
The	physiological	data	reported	were	the	age	and	gender	of	the	patients.	The	structural	parameters,	 comprising	 trabecular	 thickness	 factor	Tb.Th	(μm),	bone	volume	 fraction	BV/TV	 (%),	 and	 SMI	 (dimensionless)	were	 estimated	 from	micro-CT	 scanning	 at	 the	isentropic	pixel	resolution	of	19.5	μm	with	a	complete	rotation	over	185°	through	voxel	analysis	and	spherical	estimation	[166].	Tissue	strength	to	compressive	failure	CS	(MPa)	was	 measured	 from	 the	 extensometer	 ultimate	 stress	 readings	 during	 deformation	testing	 of	 the	 extracted	 femoral	 specimen	 [166].	 Finally	 the	 tissue	 samples	 were	subjected	 to	 ashing	 at	 650°C	 for	 24	 hours	 with	 subsequent	 apparent	 density	measurements	in	order	to	confirm	the	BV/TV	values	estimated	from	micro-CT	images		[166].			
Since	 the	 apparent	 density	 and	 BV/TV	 values	 in	 Perilli’s	 experiments	 were	 the	characterisation	of	 the	 same	porosity	 parameter,	 they	were	 linearly	 correlated	 (R2	=	0.89,	p<0.01	[166].	Whilst	essentially	conveying	the	same	information	about	the	tissue	
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as	 BV/TV	 measured	 from	 micro-CT	 scans,	 the	 measurements	 of	 apparent	 density	involved	 invasive	 sample	 collection	 and	 ashing,	 and	 thus	 was	 excluded	 from	 the	 CS	model	proposed	in	this	study.		
The	model	dataset	comprising	BV/TV,	Tb.Th,	SMI,	CS	and	age	parameters	for	each	gender	was	extracted	through	the	digitisation	of	the	nine	plots	presented	in	the	primary	source	[166].	 The	 precision	 error	 of	 data	 extraction	 was	 less	 than	 0.7%	 for	 any	 given	measurement.	 CS	 data	 were	 not	 recorded	 in	 one	 specimen	 and	 BT/TV	 values	 were	missing	in	the	plots	for	another,	reducing	the	available	dataset	to	35	samples	(17	male	and	18	 female).	The	values	of	 the	 extracted	dataset	 are	provided	 in	Appendix	D.	The	dataset	was	divided	at	random	into	training	(63%),	validation	(17%)	and	testing	(20%)	subsets,	i.e.	22,	6	and	7	samples,	respectively.	The	relative	proportions	for	the	testing	and	validation	subsets	were	lower	than	in	the	small-data	concrete	CS	model	(Section	3.4.2),	since	further	reduction	in	the	number	of	samples	in	the	validation	set	was	not	feasible.	
4.3.2 Small-data	neural	network	design	
Considering	 the	 size	 and	 nature	 of	 the	 available	 data,	 a	 two-layer	 feedforward	backpropagation	NN	was	chosen	as	the	base	for	the	bone	CS	model,	with	5	input	features	and	1	output	(Figure	4.2).	The	hidden	layer	neurons	implemented	a	tan-sigmoid	transfer	function	[228],	while	the	output	neuron	computed	the	CS	output	from	the	input	by	using	a	simple	linear	transfer	function.	
For	every	sample,	 the	 input	vector	:	 	contained	5	predictor	variables	 in	the	following	order:	:V	 =	morphology	 (SMI),	:,	 =	 level	 of	 interconnectivity	 (Tb.Th),	 	:Ñ	 =	 porosity	(BV/TV),	:Ö	=	age	and	:Ü		=	gender.	The	5	x	$	input	weights	matrix	67 ,	the	$	x	1	column	vector	of	layer	weights	89 ,	and	sets	of	biases	.(V)	and	.(,)	corresponding	to	each	layer	
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were	 initialised	according	to	the	Nguyen-Widrow	method	[108]	 in	order	to	distribute	the	active	region	of	each	neuron	in	the	layer	evenly	across	the	layer's	input	space.		
	
Figure	4.2	The	bone	CS	NN	model	topology	and	layer	configuration	represented	by	a	5-D	input	vector,	1	
output	variable,	and	one	hidden	layer	of	η	neurons.		The	 NNs	 were	 trained	 using	 the	 Levenberg-Marquardt	 backpropagation	 algorithm	[110,196,197].	The	cost	function	was	defined	by	the	MSE	between	the	output	and	actual	CS	values.	Early	stopping	was	implemented	in	order	to	avoid	NN	overtraining	and	hence	ensured	 better	 generalisation	 [153].	 	 The	 final	 values	 of	 the	 NN	 parameters	67 ,	89 ,	.(V)	and	.(,)	 were	 determined	 during	 NN	 training	 and	 provided	 in	 Section	 4.3.4.	 For	every	sample	with	inputs	:,	the	resulting	NN	model	computed	the	output	0	(in	MPa)	as	follows:	
	 0 = 1P2NQn :67 + .(V) 89 +. , 	 "].	4.1	
During	each	iteration	(epoch),	the	performance	of	the	NN	on	training,	validation	and	test	samples	was	monitored	in	terms	of	its	cost	function.	Figure	4.3	shows	that	the	prediction	error	on	the	training	set	monotonically	decreased	with	each	epoch.	The	errors	on	the	validation	 and	 test	 samples	were	 sporadic	 until	 the	14th	 epoch.	At	 the	31st	 epoch	 the	validation	error	 failed	 to	decrease	 for	9	consecutive	 iterations	and	 the	early	stopping	criterion	was	triggered.	The	weights	and	biases	were	then	reverted	by	9	epochs	to	the	
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state	at	which	the	validation	error	was	the	lowest,	i.e.	the	final	state	of	the	trained	NN	weights	and	biases	corresponded	to	the	22nd	epoch.	It	is	important	to	note	that	the	22nd	epoch	 was	 not	 the	 state	 that	 minimises	 cost	 function	 for	 the	 test	 samples,	 as	 these	independent	test	samples	were	not	involved	in	the	model	training;	their	corresponding	cost	function	is	provided	for	illustrative	purposes	only.		
	
Figure	4.3	NN	cost	function	dynamics	during	the	31	epochs	of	training	(blue),	validation	(green)	and	testing	
(red).	The	training	was	completed	upon	reaching	the	minimum	validation	error	(green	circle).		4.3.3 Hyperparameter	optimisation	using	multiple	runs	
The	limited	availability	of	training	samples	stipulated	careful	selection	of	the	NN	design	hyperparameters,	 specifically,	 the	 size	 of	 the	 hidden	 layer	 η	 	 and	 the	 early	 stopping	criterion	ω,	in	order	to	achieve	efficient	training	and	improve	generalisation.	The	effect	
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of	 increasing	 the	 number	 of	 neurons	 η	 in	 the	 hidden	 layer	 on	 NN	 performance	 was	investigated	in	a	series	of	experiments	involving	20	short	runs	of	100	NNs.		
Reported	in	Figure	4.4	are	the	distributions	in	JABB 	achieved	when	varying	the	hidden	layer	size	from	η	=1	to	η	=	20	neurons.	Despite	the	inter-run	volatility	in	the	results,	it	was	 established	 that	 the	 performance	 was	 significantly	 lower	 in	 η	 =1	 configuration	(p<0.01	for	all	pairwise	comparisons)	signifying	undertraining.	Increasing	the	number	of	neurons	 past	 η	 =10	 did	 not	 improve	 the	 NN	 performance	 and	 instead	 resulted	 in	 a	gradual	 decrease	 in	JABB ,	 which	 signified	 overtraining.	 Between	 η	 =2	 and	 η	 =10,	 the	highest	median		JABB 	was	observed	in	η	=4	configuration,	although	it	was	not	statistically	different	 from	η	=3	 (p=0.192)	 and	only	marginally	 different	 from	 the	η	 =6	 (p=0.036)	configurations.	The	effect	of	η	=4	was	also	observed	on	J©AB .	Computed	from	the	leave-one-out	validation	cohort,	 it	 indicated	marginal,	but	statistically	significant	optimality	(p<0.05	for	all	pairwise	comparisons	apart	from	η	=3).		
	
Figure	4.4	Effect	of	hidden	layer	size	on	NN	performance		
J ABB	
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The	second	hyperparameter	considered	in	the	design	optimisation	was	the	NN	training	duration,	which	is	controlled	by	the	early	stopping	criterion	-.	This	criterion	specifies	the	 maximum	 for	 consecutive	 training	 epochs	 the	 NN	 validation	 performance	 could	decrease	before	early	termination	of	the	training	process	was	triggered	(Section	2.5).	
The	 effect	 of	-	 was	 investigated	 on	 NN	 performance	 when	 varied	 from	 1	 to	 20	 in	increments	of	1	and	from	10	to	100	in	increments	of	10.	When	investigated	with	the	total	28	runs	of	100	NNs,	J~AuC	was	found	to	increase	substantially	for	-		values	between	1	and	 10,	 and	 then	 grow	 monotonically	 for	 each	 value	 from	 10	 to	 100,	 signifying	 no	substantial	 increase	 in	 performance	 past	 -=10.	 Since	 large	 -	 directly	 affected	 the	computational	efficiency	of	the	training	algorithm	(Table	4.1),	only	-		values	between	1	and	10	were	further	investigated.	
	Table	4.1	The	timing	effects	of	early	stopping	criterion	ω	 Average	simulation	time	(seconds)	per	run	of	2000	NNs	on	standard	PC3	5	 240	10	 280	30	 590	100	 990		When	evaluated	on	J©AB 	at	η	=4,	the	early	stopping	criterion	-		had	a	marginal	effect	on	the	performance	of	the	NN	and	no	statistically	significant	median	differences	in	the	range	between	1 ≤ 	- ≤ 10	 (p>0.05	 for	 all	 pairwise	 comparisons).	 In	 the	 absence	of	 strong	evidence	for	choosing	a	specific	-,	the	value	of	-	=	9	that	gave	highest	J©AB 	was	chosen	for	the	final	NN.		
																																								 																					
3	PC	specifications:	Intel®	Core™	i7-3770	CPU	@3.40GHz,	32	GB	RAM	
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As	 highlighted	 in	 Section	 3.5.2,	 Bayesian	 regularisation	 [200]	 was	 considered	 as	 an	alternative	 approach	 for	 controlling	 the	 training	duration	without	 early	 stopping	and	determining	the	size	of	the	NNs.	By	penalising	NNs	for	large	weights,	the	regularisation	reduced	some	NN	weights	 to	near-zero	values.	The	remaining	non-zero	weights	were	counted	as	the	number	of	effective	NN	parameters,	irrespective	of	the	theoretical	NN	size.	By	varying	the	number	of	hidden	layer	neurons	$,	 it	was	possible	to	determine	which	hidden	layer	sizes	resulted	in	the	highest	number	of	effective	parameters.		
	
Figure	4.5	Effect	of	hidden	layer	size	on	the	number	of	effective	parameters		Reported	in	Figure	4.5	is	the	number	of	effective	parameters	for	a	NN	configuration	with		1 ≤ $ ≤ 20	across	20	runs	of	100	NNs.	The	median	number	of	effective	parameters	was	significantly	 (p<0.05	 for	 all	 pairwise	 comparisons)	 higher	 for	 a	 η	 =	 4	 configuration,	indicating	 that	 an	 increase	 in	 the	 hidden	 layer	 NN	 size	 above	 4	 neurons	 introduced	redundant	near-zero	weights,	whilst	a	smaller	hidden	layer	size	did	not	allow	maximum	NN	 potential.	 This	 observation	 further	 confirmed	 that	 for	 the	 dataset	 at	 hand,	 a	 NN	design	with	η	=	4	neurons	in	the	hidden	layer	was	optimal.		
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4.3.4 Optimised	neural	network	performance	
A	full	run	of	2000	NNs	of	optimal	design	was	trained	and	evaluated	using	the	multiple	runs	 strategy	 described	 in	 Section	 3.3.1.	 	 From	 the	 2000	 NNs	 considered,	 the	 best-performing	NN	was	selected	using	the	criteria	detailed	in	Section	3.3.3.	The	resulting	NN	model	was	 capable	 of	 predicting	 trabecular	 tissue	 CS	with	RMSE	 =	 0.85	MPa	 on	 test	samples.		
 
Figure	4.6	Linear	regression	between	target	and	predicted	CS	achieved	by	the	small-data	bone	NN.	Values	
were	reported	individually	for	a)	training	(blue),	b)	validation	(green)	and	c)	testing	(red),	and	d)	the	entire	
dataset	(black).		The	 linear	 regression	 coefficients	 between	 target	 and	 prediction	 achieved	 by	 the	NN	were	individually:	J~AuC=0.999,	J©AB=0.991,	J~E™~=0.983	and	in	total:	JABB=0.993	(Figure	4.6	a-d).	This	 indicated	a	high	accuracy	of	predictions	despite	 the	 limited	dataset	 (35	
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samples).	 The	 final	 values	 of	 the	 weights	 and	 biases	 of	 this	 fully-trained	 network	complete	the	unknown	terms	in	eq.	4.1:	
67 = 	 0.887 2.382 −0.888 −3.5841.301 −1.586 0.904 −3.841−3.268 0.632 −1.342 −0.144−1.216 −2.153 −1.380 −3.000−0.620 1.592 −0.379 −1.169 																			89 = 	
−0.698−0.1512.349−1.501 	
.(V) = 	 0.268 −0.006 −1.224 −4.972 		 	 									.(,) = 0.623	
4.3.5 Surrogate	data	test	
The	surrogate	data	test	proposed	in	Section	3.3.2	was	used	to	validate	the	NNs	trained	with	 real	 data	 against	 those	 trained	 on	 surrogate	 data	 and,	 therefore,	 establish	 the	minimal	performance	threshold	that	the	candidate	real	data	models	must	exceed.	The	surrogates	were	 generated	 using	 random	 sampling	 to	mimic	 the	 distributions	 of	 the	original	 bone	 data	 (Section	 3.3.2).	 The	 resulting	 surrogate	 dataset	 is	 provided	 in	Appendix	D.	When	analysed	across	the	total	of	20000	NNs	in	10	runs	of	2000	NNs,	the	real	dataset	NNs	consistently	outperformed	the	surrogate	NNs	with,	on	average,	a	35%	performance	increase	(Figure	4.7	a).		
The	median	JABB,™Æ=	0.38	and	median	JABB,EAB=0.78	across	20000	NNs	were	significantly	different	among	the	real	and	surrogate	data	NNs	(p	=	0,	Wilcoxon	rank	sum	test,	Figure	4.7	b).	Similar	differences	in	the	distributions	of	J~E™~,EAB 	and	J~E™~,™Æ	were	observed	for	the	NN	performance	on	test	samples	(Figure	4.7	c-d).	The	surrogate	threshold	for	the	bone	dataset	was	found	to	be	around	J™Æ,ØAü 	=	0.87.	By	quantifying	the	random	effects	in	training	and	initialisation	of	the	bone	CS	NNs,	the	surrogate	data	test	validated	that	the	performance	of	the	real	data	models	above	the	surrogate	threshold	was	not	due	to	noise.	
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Figure	4.7	Distributions	(a)	of	regression	coefficients	achieved	by	NNs	for	surrogates	(light	blue)	and	real	
bone	data	(navy)	and	(b)	Wilcoxon	rank	sum	test	for	medians	across	all	samples.		Distributions	and	Wilcoxon	
rank	sum	test	results	across	test	samples	are	reported	in	(c)	and	(d).		4.3.6 Comparison	with	a	neural	network	ensemble	
Ensemble	learning	was	implemented	by	combining	2000	small-data	NNs,	among	which	learner	 diversity	 was	 achieved	 through	 randomising	 the	 initial	 model	 parameters	(Section	 3.5.1)	 and	 aggregated	 using	 performance	 averaging	 (Section	 2.3.2).	 The	 NN	ensemble	 achieved	 J~E™~	 =	 0.882,	 which	 was	 11%	 lower	 than	 the	 accuracy	 of	 the	proposed	multiple	run	NN	model	 (J~E™~	=	0.983)	and	only	marginally	higher	 than	 the	surrogate	threshold	 	J™Æ,ØAü 	=	0.87	established	 in	Section	4.3.5	 for	the	bone	dataset.		
Chapter	4.		Bone	fracture	prediction	in	osteoarthritis	
88	
This	 result	 further	 confirmed	 that	 NN	 ensembles,	 when	 tasked	 with	 small-dataset	applications,	were	unable	to	realise	their	full	predictive	potential	and	were	inferior	to	NNs	 designed	 within	 the	 multiple	 runs	 framework.	 One	 possibility	 for	 improving	ensemble	diversity	was	to	train	constituent	NNs	with	different	versions	of	the	original	dataset,	 for	 instance,	by	 resampling	or	 repeating	 the	 source	plot	digitisation.	 Such	an	approach	was	investigated	in	Chapter	6,	whereby	each	constituent	NN	was	trained	on	a	different	version	of	the	imputation	dataset.		
 Clinical	significance	and	limitations	
The	application	of	NNs	for	hard	tissue	modelling	in	degenerative	conditions	was	a	novel	and	largely	unexplored	area.	Among	the	limited	number	of	relevant	studies	on	trabecular	bone	modelling,	only	a	few	adopted	NN-based	approaches	[229,230].	Habli		[230]	used	a	NN	model	 for	the	estimation	of	apparent	 fatigue	damage	accumulation	due	to	cyclic	loading	 in	 a	 trabecular	 bone	 from	FEA	 simulations.	 Zadpoor	 et	 al.	 [229]	 used	NNs	 to	analyse	FEA	data	and	model	the	mechanical	loading	effects	from	the	spatial	distribution	of	density	in	the	femur.	The	key	limitations	of	both	these	studies	were	the	dependence	of	 NN	 performance	 on	 the	 validity	 of	 the	 underlying	 FEA	model’s	 assumptions,	 thus	necessitating	 a	 stand-alone	 NN	 that	 could	 integrate	 the	 complex	 structural	 and	physiological	parameters	directly	into	a	single	model	of	a	human	femur.		At	the	time	of	publication	[84,231–233],	the	NN	model	developed	in	this	research	was	the	only	known	application	of	such	NNs	for	trabecular	tissue	modelling	in	severe	OA.		
The	 NN	 model	 offered	 98.3%	 accurate	 predictions	 of	 the	 strength	 to	 failure	 of	osteoarthritic	hip	joints	from	the	structural	and	physiological	parameters	of	the	femoral	trabecular	tissue	in	OA	patients.	In	the	absence	of	a	comparable	CS	model	specifically	for	OA,	the	power	model	from	cellular	mechanics,	with	Jb(∫E	Ø(FEB	=	0.916,	was	the	best	
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existing	 fit	 to	 the	 data	 [166].	 By	 inferring	 non-linear	 variable	 interrelations	 in	 the	heterogeneous	multi-dimensional	dataset,	the	NN	improved	Jb(∫E	Ø(FEBby	over	8%	on	all	samples	JABB	=	0.993.	
The	 high	 accuracy	 of	 the	 proposed	 CS	model	 enabled	 the	 early	 stratification	 of	 bone	fracture	 risk	 based	 on	 structural	 and	 physiological	 parameters	 that	 can	 be	 derived	without	invasive	tests	on	the	patient.	Hence,	by	predicting	how	CS	correlates	with	the	bone	volume	fraction,	trabecular	thickness	and	structure	model	index	for	OA	patients	of	various	age	and	gender	groups,	the	NN	model	provided	a	decision	support	tool	for	hard	tissue	engineers	and	clinicians	alike	[234].	The	potential	practical	applications	include:	the	estimation	of	bone	fracture	risk	in	OA	patients	from	CT-scans	and	basic	physiological	data,	 the	 load	modelling	 of	 synthetic	 bioscaffolds	 that	mimic	 natural	 trabecular	 bone	damaged	 by	 osteoarthritis,	 and	 the	 tailoring	 of	 bioscaffold	 designs	 for	 an	 individual	patient	to	match	the	damaged	trabecular	tissue	at	the	site	of	implantation.	
The	 predictive	 NN	 model	 can	 be	 adapted	 to	 larger	 datasets,	 extended	 to	 other	degenerative	bone	disorders,	or	scaled	for	modelling	new	anatomical	locations,	with	a	marginal	 increase	 in	design	effort	and	cost	 [14,26].	 Such	scalability	 is	 inherent	 in	 the	underlying	ML	nature,	which	enables	NNs	to	learn	and	improve	their	performance	with	new	data	[36,88,235,236].	Using	the	proposed	NN	model	for	OA	as	a	prototype,	future	predictive	NNs	could	provide	valuable	clinical	insights	for	the	early	detection	of	patients	at	risk	of	hip	fractures	and	for	the	preventive	treatment	of	bone	disorders,	thus	reducing	fractures	and	improving	surgical	effects.	
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 Chapter	conclusions	
The	key	findings	demonstrated	in	this	chapter	are	as	follows:	
(1) The	methodological	 framework	 for	 small	 datasets	 developed	 in	 Chapter	 3	was	effective	 in	 enabling	 NN-learning	 from	 35	 osteoarthritic	 specimens	 with	 an	 aim	 to	predict	 trabecular	 strength	 to	 hip	 fractures	 from	 structural	 and	 physiological	parameters.			
(2) The	regression	NN	developed	and	optimised	using	multiple	runs	achieved	98.3%	accurate	predictions	on	independent	test	samples.	Further	validation	with	a	surrogate	data	 test	confirmed	that	 the	accuracy	achieved	by	 the	NN	was	above	 the	 threshold	of	J™Æ,ØAü=0.87	attributable	to	random	effects	due	to	small	datasets.			
(3) The	NN	offered	an	accurate	and	scalable	predictive	 tool	 for	 the	non-destructive	estimation	 of	 femoral	 compressive	 strength	 in	 patients	 suffering	 from	 severe	osteoarthritis,	with	potential	extension	to	other	degenerative	bone	and	joint	disorders.	
(4) The	 proposed	 methodology	 confirmed	 that	 the	 size	 of	 datasets	 does	 not	necessarily	limit	the	utility	of	NNs	in	the	clinical	and	hard	tissue	engineering	domains.		
		
	
	91	
 	
Outcome	prediction	in	antibody-incompatible	kidney	transplantation		
Human	leukocyte	antigen	(HLA)	sensitisation	is	a	major	public	health	problem	that	limits	access	 to	 kidney	 transplantation	 for	 as	many	 as	 25%-47%	of	 the	 patients	 awaiting	 a	deceased	 donor	 transplant	 [167,237].	 The	 growing	 field	 of	 antibody-incompatible	transplantation	demands	novel	insights	into	the	complex	association	between	baseline	clinical	and	immunological	indicators	and	patient	outcomes	[167,238,239].		
The	 descriptive	 and	 predictive	 models	 developed	 in	 this	 chapter	 establish	 the	association	 of	 the	 dominant	 HLA	 isotype	 and	 its	 subclasses	 with	 both	 short-	 and	medium-term	renal	transplant	outcomes.	A	time-to-event	graft	survival	was	modelled	with	Cox	PH	(Section	5.4.1),	whilst	acute	graft	rejection	within	30	days	post-transplant	was	explored	using	logistic	regression	(Section	5.4.2).	A	granular	and	accurate	predictive	model	 for	early	 (acute)	antibody-mediated	 transplant	 rejection	was	developed	with	a	decision	tree	classifier	(Section	5.5)	using	the	multiple	runs	strategy	for	a	small,	single-centre	 dataset.	 This	 work	 demonstrated	 the	 potential	 for	 classification	 from	 small	clinical	data	(Section	5.6)	and	offered	novel	clinical	 insights	into	the	area	of	antibody-incompatible	transplantation	(Section	5.8).		
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 Antibody-incompatible	kidney	transplantation	
Organ	and	tissue	transplantation	is	recognised	as	an	effective	treatment	for	many	renal	(kidney)	pathologies	including	end-stage	renal	disease.	Transplantation	from	living	or	deceased	donors	can	dramatically	improve	the	recipients’	quality	of	life,	often	offering	the	only	solution	for	their	survival	[240].		In	the	UK	alone,	over	3100	life-saving	and	life-transforming	kidney	transplantations	were	performed	in	the	past	year	[237].			
For	a	successful	transplantation	outcome,	the	recipient	and	donor	should	be	matched	for	tissue	 proteins	 called	 human	 leukocyte	 antigen	 (HLA).	 HLA	mismatches	 between	 the	transplant	recipient	and	their	donor	may	cause	the	development	of	antibodies	against	HLA,	which	can	lead	to	transplant	(graft)	failure	and	endanger	the	option	of	a	subsequent	future	 transplant.	 HLA	 antibodies	 can	 also	 be	 stimulated	 by	 pregnancy	 and	 blood	transfusion.	Patients	with	preformed	HLA	donor-specific	antibodies	(DSAs)	have	longer	waiting	times	for	surgery	or	are	unable	to	receive	a	renal	transplant.	Current	NHS	Blood	and	Transplant	 data	 indicate	 that	 among	 the	 5233	 patients	 on	 the	 kidney	 transplant	register	in	March	2017,	32%	had	been	waiting	for	a	suitable	graft	for	over	3	years,	with	a	median	waiting	time	of	864	days	[237].	Between	25%	-	47%	of	patients	on	the	deceased	donor	 kidney	 programme	 in	 the	 UK	 are	 unable	 to	 receive	 a	 transplant	 due	 to	 HLA	sensitisation	[167].		
Antibody-incompatible	transplantation	(AIT)	was	pioneered	in	Europe	by	the	University	Hospitals	Coventry	and	Warwickshire	[241,242]	to	enable	transplantation	procedures	on	HLA	 senstised	patients.	 In	 the	past	 year	 alone,	HLA-incompatible	 transplantations	saved	and	 improved	 the	 lives	of	654	patients	 in	 the	UK	alone	 [237].	AIT	 is	becoming	increasingly	 feasible	 due	 to	 the	 advances	 in	 immunosuppressive	 drugs	 and	 surgical	techniques	 that	 allow	 for	 the	 recipient’s	 DSA	 levels	 to	 be	 decreased	 prior	 to	
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transplantation	 [243–245].	 Nevertheless,	 the	 complete	 elimination	 of	 DSAs	 and	immunological	memory	is	not	practical,	hence	AIT	is	considered	a	high-risk	intervention:	about	40%	of	HLA-incompatible	kidney	transplants	experience	an	episode	of	rejection,	which,	in	its	chronic		form,	leads	to	transplant	failure	[237].	The	ability	of		nephrologists	to	 identify	 patients	 at	 high	 risk	 of	 transplant	 rejeciton	 prior	 to	 transplantation	 is	diminished,	 because	 neither	 specific	 types	 of	 harmful	 HLA	DSAs	 nor	 their	acceptable	
levels		have	been	established.		
	
Figure	5.1	Immunoglobulin	G	molecule	structure	and	class	switching.	Adapted	from	[246].		Among	isotypes	of	HLA	DSAs,	Immunoglobulin	G	(IgG)	and	its	four	subclasses,	IgG1-IgG4	(Figure	 5.1),	 are	 recognised	 as	 principal	 agents	 for	 humoral	 (antibody-mediated)	rejection	 [247–249].	 The	 four	 subclasses	 of	 IgG	 exhibit	 structural	 and	 functional	differences	 that	may	be	 associated	with	 diverse	 clinical	 outcomes	 [246].	 In	 the	 small	number	 of	 studies	 that	 have	 investigated	HLA-specific	 IgG	 subclass	 associations	with	transplant	outcomes,	some	report	that	IgG1	subclass	DSAs	were	dominant	in	poor	graft	survival	 [250]	 and	 rejection	 [168],	 whilst	 others	 report	 	 the	 harmful	 effects	 of	 IgG4	subclass	 DSAs	 [167,247].	 Predicting	 AIT	 outcome	 from	 IgG	 subclass	 information	 is	further	complicated	by	the	class	switching	of	IgG3	to	IgG1	to	IgG2	to	IgG4	(Figure	5.1)	–	a	common	 phenomenon	 which	 occurs	 as	 the	 recipient’s	 immune	 system	 develops	 a	humoral	response	to	the	transplant	[246].		
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Determining	which	IgG	subclasses	are	particularly	dangerous	and	establishing	their	safe	levels	 prior	 to	 the	 surgery	 could	 prevent	 graft	 loss	 and/or	 excessive	 treatment	 	 by	harmful	and	expensive	immunonosuppresive	drugs.	Hence	the	field	of	AIT	requires	both	descriptive	 and	 predictive	models	 that	 could	 leverage	multidimensional	 associations	among	patient	and	antibody	characteristics	with	the	likely	transplant	outcomes.		
 Machine	learning	in	kidney	transplantation	
In	standard	(non-AIT)	kidney	transplantation,	the	task	of	outcome	prediction	has	been	considered	in	a	number	of	studies	using	machine	learning.	In	particular,	decision	trees	have	been	a	popular	choice,	likely	owing	to	their	graphical	interpretability	and	ability	to	supplement	nephrologists’	intuitive	insights	with	data-driven	statistical	evidence.		
Greco	et	al.	studied	long-term	kidney	graft	survival	and	concluded	that	“decision	trees	in	clinical	practice	may	be	a	suitable	alternative	to	the	traditional	statistical	methods,	since	it	 may	 allow	 one	 to	 analyse	 interactions	 between	 various	 risk	 factors	 beyond	 the	previous	knowledge”	[251].	Their	DT	model,	based	on	194	patients	with	9	known	clinical	indicators,	predicted	5-year	graft	survival	with	a	test	accuracy	of	74%-88%.		
Krikov	 et	 al.	 in	 their	 	 large-scale,	 multi-centre	 study	 [252]	 analysed	 92,844	 patient	records	 from	 the	US	Renal	 Data	 System.	 Their	DT	models	 for	 long-term	 kidney	 graft	survival	were	based	on	31	predictors	and	achieved	=>?	of	0.63,	0.64,	0.71,	0.82,	and	0.90	for	the	1,	3,	4,	5,	and	10-year	predictions,	respectively.	The	trend	–	the	further	into	the	future	the	forecast	scope	is,	the	better	its	accuracy	–	appears	unintuitive	to	those	working	with	 real-world	 forecasts.	 The	 phenomenon	 can	 be	 explained	 in	 part	 by	 the	way	 the	model	accuracies	were	measured,	and	how	this	was	influenced	by	reduced	follow-up	and	class	imbalance	dynamics	over	the	years	as	more	transplants	failed.						
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Decruyenaere	et	al.	compared	the	traditional	logistic	regression	method	with	8	different	ML	 algorithms	 for	 the	 prediction	 of	 delayed	 graft	 function	 (DGF)	 following	 kidney	transplantation	 [253].	 Their	 models	 were	 developed	 on	 497	 single-centre	 (Belgium)	patients	from	deceased	donors	and	used	24	parameters	related	to	donor	and	recipient	characteristics,	preservation	and	operation.	The	authors	found	that	tree-based	models	achieved	low	accuracy:	=>?	of	0.53	for	DT	and	0.74	for	RF	respectively,	which	again	can	be	attributed	to	DT	sensitivity	to	the	high	class	imbalance	between	DGF+	(12.5%)	and	DGF-	samples.	Out	of	10	classifiers,	a	linear	support	vector	machine	performed	best	with	=>?	of	0.84.	
The	models	 in	 the	above	 studies	were	developed	with	a	 few	hundred	 to	a	 few	 tens	of	
thousands	of	samples	 involving	national	databases.	 In	all	 four	datasets,	 the	number	of	observations	 2	 per	 3	 predictor	 features	 had	 ratio	 of	 2/3	 > 20.	 Datasets	 of	 such	magnitude	are	not	readily	available	in	HLA-incompatible	renal	transplantation,	which	is	inherently	a	high-risk,	low-volume	intervention.	The	data	are	further	limited	for	smaller	transplant	units	wishing	to	analyse	their	samples	without	having	to	wait	decades	until	enough	procedures	are	conducted.	Hence	outcome	prediction	in	AIT	often	falls	under	the	
small	dataset	condition	defined	in	Chapter	3,	as	2 3 < 10.	
Machine	learning	from	small	datasets	results	 in	high	variablitity	among	models	of	the	same	design.	In	the	previous	chapters	it	has	been	shown	that	identical	NNs	suffer	from	large	discrepancies	in	their	predictions	due	to	random	initial	conditions,	training	order	and	 the	 split	 between	 the	 training	 and	 validation	 samples.	 Such	 discrepansies	 are	common	for	other	ML	approaches,	including	DTs.		For	example,	Lofaro	et	al.	attempted	to	predict,	using	DTs,	chronic	graft	nephropathy	within	5	years	post-transplant	from	23	clinical	indications	based	on	only	80	samples	(2 3 = 3.5)	[254].	The	authors	reported	one	DT	model	with	=>? = 0.847,	62.5%	sensitivity,	7.2%	false	positive	rate,	and	another	
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tree	 with	=>? = 0.824,	 81.3%	 sensitivity	 and	 25%	 false	 positive	 rate.	 The	 volatility	among	 the	DT	 trials	was	 not	 explicitly	 disclosed,	 but	 the	 two	DTs	 presented	 showed	significant	variation	in	performance	and	structure,	thus	casting	doubts	on	the	robustness	of	the	overall	results.	Successful	applications	of	ML	to	small	single-centre	datasets	 for	outcome	prediction	in	AIT	are	presently	not	known.		
The	primary	aim	 of	 this	 research	was	 to	 confirm	which	donor-specific	 immunological	indicators	 and	 at	what	 levels	 were	 associated	 with	 short-	 and	 medium-term	 patient	outcomes	in	HLA-incompatible	transplantation.	The	secondary	aim	was	to	develop,	from	the	 small	 dataset	 of	 complex	 pre-transplant	 indicators,	 a	 predictive	 model	 for	 acute	transplant	rejection	that	would	support	the	clinical	decision	process.			
 Data:	patient	and	antibody	characteristics		
The	work	presented	in	this	chapter	examines	multivariate	associations	in	the	AIT	data	collected	by	the	clinical	collaborators	at	the	renal	transplant	unit	at	University	Hospitals	Coventry	and	Warwickshire	(UHCW).	Included	in	the	study	were	80	patients	(49	female	and	 31	 male)	 aged	 between	 18	 and	 68	 years	 (mean	 age	 of	 41.8	 ±	 11.6	 years)	 who	received	HLA-incompatible	renal	grafts	between	June	2003	and	October	2012.	 	At	the	time	of	transplantation	44%	of	patients	had	been	living	with	life-limiting	end-stage	renal	disease	(ESRD)	for	15	years	or	longer	(mean	ESRD	duration	11.3	±	8.2	years).	
The	patient	data	collected	at	the	UHCW	contained	information	on	the	type	of	transplant	(living	 or	 deceased),	 the	 number	 of	 HLA	 mismatches	 by	 class	 (I	 and	 II),	 including	particularly	dangerous	class	II	HLA	D-related	(DR)	mismatches,	patients’	progression	on	ESRD	 and	 other	 baseline	 characteristics.	 Additional	 immunological	 data,	 including	cytotoxic	crossmatching	and	HLA-specific	antibody	levels	by	IgG	subclass,	were	gathered	through	 advanced	 laboratory	 analyses	 [167,168].	 Flow	 cytometry	 and	 complement	
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dependant	cytotoxic	(CDC)	crossmatching	were	performed	prior	to	transplantation.	Pan-IgG	HLA	class	I-	and	class	II-specific	antibodies	were	identified	in	serum	obtained	before	the	immunosuppressive	treatment.		
The	pre-treatment	pan-IgG	DSA	levels	were	measured	using	fluorescence	immunoassay	and	 recorded	 as	 Median	 Fluorescence	 Intensity	 (MFI)	 values.	 	 In	 the	 immunoassay	analyses	 conducted,	 the	 positive	 reactive	 MFI	 threshold	 was	 set	 at	 1000.	 The	 MFI	threshold	 levels	 for	 each	 HLA-specific	 IgG	 subclass	 were	 five	 times	 greater	 than	 the	negative	 control	 incorporated	 into	 the	 immunoassay:	 120.6	 (IgG1),	 72.0	 (IgG2),	 62.7	(IgG3)	and	17.2	(IgG4)	 [167,168].	These	thresholds	presently	 lack	standardisation	and	vary	from	centre	to	centre.	
Combined,	 the	 following	14	baseline	 (pre-transplant)	parameters	were	established	as	potential	predictor	variables:	
• 7	continuous:	single	highest	pan-IgG	DSA	MFI	level,	patient’s	age	(years),	ESRD	duration	(years),	and	4	total	IgG	subclass	MFI	levels	(IgG1-IgG4)	
• 4	categorical:	cytometry	crossmatch	(1=bead,	2=flow	or	3=CDC),	total	number	of	HLA	mismatches	between	donor	and	recipient	(0-6),	the	number	of	class	II	HLA-	DR	mismatches	(0-2),	and	the	number	of	previous	transplants	(0-2)	
• 3	binary:	gender	(male/female),	the	presence	of	both	HLA	Class	I	and	Class	II	DSA	(yes/no),	and	an	indicator	for	donor	type	(live/deceased)	
The	transplantation	outcomes	of	primary	interest	were:	
• acute	antibody-mediated	rejection	(ABMR)		
• medium-term	graft	survival/failure	
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ABMR	was	defined	as	acute	graft	rejection	within	the	first	30	days	of	 transplantation.	ABMR	was	confirmed	by	renal	biopsy	in	the	ABMR+	group	(2 = 46),	except	in	four	cases,	where	anticoagulation	was	given	urgently	and	precluded	a	pre-treatment	biopsy	[167].	The	remaining	patients	(2 = 34),	who	did	not	experience	rejection	in	the	first	30	days,	were	categorised	as	the	ABMR-	group.	Owing	to	the	advances	 in	AIT,	even	in	patients	who	experienced	acute	rejection	the	graft	loss	could	be	prevented	by	timely	intervention.		In	 the	 UHCW	 centre,	 rejection	 was	 treated	 by	 a	 combination	 of	 immunosuppressive	drugs,	 plasmapheresis,	 and/or	 intravenous	 IgG	 injections	 for	 immunomodulation.	Among	the	80	high-risk	patients,	15	experienced	graft	failure,	6	died	with	a	functioning	transplant,	 and	 59	 were	 still	 alive	 with	 a	 functioning	 transplant	 at	 the	 time	 of	 this	analysis.		
Table	 5.1	 presents	 the	 results	 of	 the	 univariate	 comparison	 between	 the	 patients’	baseline	 clinical	 and	 immunological	 characteristics	 in	 the	 ABMR+/-	 and	 the	 graft	survival/failure	groups	[167].	The	null	hypothesis	of	no	difference	between	the	groups	was	 tested	 at	 5%	 significance	 level	 using	 two-tail	 Fisher	 exact	 test	 for	 categorical	variables	 and	 the	 Wilcoxon	 rank	 sum	 test	 for	 medians	 of	 continuous	 variable	distributions.	Signiﬁcant	differences	between	groups	(p	<	0.05)	are	highlighted	in	bold.	
Table	5.1	Baseline	clinical	and	antibody	characteristics	of	transplant	recipients	[167]		Variable	 Rejection	(within	first	30	days)	 Graft	outcome	(deaths	excluded)		 ABMR+		(n=46)	 ABMR-			(n=	34)	 p	 failure	(n=15)	 survival	(n	=	59)	 p	Age,	median	(range)	 42.5	(18-68)	 43	(22-67)	 0.83	 34	(22-50)	 43	(18-67)	 0.003	Male	gender,	N	(%)	 17	(37)	 14	(41)	 0.82	 7	(47)	 23	(39)	 0.56	Prev.	transpl.,	N	(%)	 16	(35)	 15	(44)	 0.49	 10	(67)	 36	(61)	 0.77	ESRD,	median	(range)	 13	(0-29)	 10	(0-31)	 0.60	 7	(0-21)	 13	(0-31)	 0.13	Living	donor,	N	(%)	 45	(98)	 30	(88)	 0.16	 15	(100)	 56	(95)	 0.58	DR	mismatch,	N	(%)	 38	(83)	 27	(79)	 0.78	 13	(87)	 47	(80)	 0.72	Total	mismatches,	median	(range)	 3(1-5)	 3	(0-6)	 0.13	 3	(2-5)	 3	(0-6)	 0.70	
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CDC	positive,	N	(%)	 12	(26)	 7	(21)	 0.61	 8	(53)	 10	(17)	 0.006	Single	highest	pan-IgG	DSA	MFI,	median	
(range)	 6058	(869	–13345)	 3492.5	(221-17660)	 0.03	 8987	(775-13345)	 3788	(221-17660)	 0.004	Total	pan-IgG	DSA	MFI,	median	(range)	 7797.5	(869-45612)	 5134	(306-37084)	 0.01	 11568	(775-45612)	 5793	(468-27187)	 0.02	IgG3	presence,	N	(%)	 22	(50%)	 13	(38.2%)	 0.36	 8	(53%)	 24	(42%)	 0.56	IgG3	MFI,	median	
(range)	 255.5	(76.5-2793)	 256.5	(75-1541)	 0.63	 521	(82-2793)	 204	(75-1541)	 0.24	IgG1	presence,	N	(%)	 35	(79.5%)	 18	(53%)	 0.01	 13	(86.7%)	 37	(65%)	 0.12	IgG1	MFI,	median	
(range)	 2393	(162-24589)	 2340	(175-16538)	 0.69	 6691	(175-24589)	 1121	(162-16538)	 0.03	IgG2	presence,	N	(%)	 24	(54.5%)	 14	(41.2%)	 0.26	 10	(66.6%)	 26	(45.6%)	 0.24	IgG2	MFI,	median	
(range)	 581.7	(87-9472)	 952.8	(75-5073)	 0.62	 1595	(102-9472)	 432	(75-4819)	 0.08	IgG4	presence,	N	(%)	 24	(52.2%)	 12	(35%)	 0.17	 12	(80%)	 23	(39%)	 0.008	IgG4	MFI,	median	
(range)	 113	(24-6505)	 30	(17.5-321)	 0.003	 53	(21-135)	 35	(17-6505)	 0.39	Class	I	&	II	DSA,	N	(%)	 24	(52)	 10	(29)	 0.07	 8	(53)	 24	(41)	 0.40	DGF,	N	(%)	 12	(26)	 4	(12)	 0.16	 1	(7)	 14	(24)	 0.28	Rejection,	N	(%)	 N/A	 10	(67)	 34	(58)	 0.57		For	the	ABMR+	patients	versus	the	ABMR-	group,	significant	differences	were	observed	in	IgG1	presence	(p=0.01)	and	IgG4	MFI	levels	(p=0.003)	[167].	In	addition,	the	patients	in	ABMR+	group	had	elevated	levels	of	single	highest	pan-IgG	DSA	MFI	(p=0.03)	and	total	pan-IgG	DSA	MFI	(p=0.01).	There	were	no	significant	differences	between	the	ABMR+/-	groups	 with	 respect	 to	 the	 presence	 or	 levels	 of	 the	 DSAs	 in	 the	 two	 remaining	subclasses,	IgG2	and	IgG3,	nor	in	the	CDC-positive	crossmatch	[167].	For	the	graft	failure	versus	survival	groups,	the	differences	were	significant	in	IgG1	MFI	levels	(p=0.03),	IgG4	presence	(p=0.008),	as	well	as	in	the	single	highest	pan-IgG	DSA	MFI	(p=0.004),	total	pan-IgG	DSA	MFI	(p=0.02),	age	(p=0.003),	and	the	CDC-positive	crossmatch	(p=0.006).	
The	univariate	analysis	(Table	5.1)	confirmed	the	initial	hypothesis	(Section	5.1)	of	the	association	 of	 pre-treatment	 IgG	 subclass	 presence	 and	 levels	 with	 ABMR	 and	 graft	failure	in	AIT.	However,	further	investigation	was	required	to	establish	whether	or	not	
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the	 effects	 of	 IgG1	 and	 IgG4	 subclasses	 remained	 significant	 in	 the	 presence	 of	confounding	factors	in	multivariate	space	[167].			
 Exploratory	data	analysis	
In	order	to	explore	the	effect	of	the	HLA	IgG	subclasses	on	acute	ABMR	and	medium-term	survival	in	the	presence	of	confounding	clinical	and	immunological	data,	the	following	multivariate	statistical	analyses	were	conducted	by	the	author:			
• Cox	PH	regression	for	medium-term	graft	survival		
• Logistic	regression	for	acute	ABMR	
5.4.1 Cox	proportional	hazards	model	for	graft	survival	
For	medium-term	 graft	 survival	modelling,	 early	 post-transplant	 outcomes	 (DFG	 and	rejection)	 were	 included	 in	 addition	 to	 the	 14	 baseline	 characteristics	 described	 in	Section	 5.3.	 The	 pre-treatment	 IgG	 subclass	 information	 was	 considered	 both	 as	continuous	MFI	values	and	as	a	binary	presence/absence	indicator	(based	on	the	cut-off	values	declared	in	Section	5.3).	The	outcome	was	modelled	as	time	(in	weeks)	until	the	event	(graft	failure).		
Among	 the	80	patient	samples,	6	were	excluded	due	 to	death-censoring	and	3	due	 to	missing	values.	57	out	of	the	remaining	71	samples	were	censored	at	the	study	end	date	(July	2014).		Backwards	stepwise	model	selection	[139]		was	used	to	eliminate	variables	that	did	not	improve	the	association	with	medium-term	survival.	The	final	Cox	PH	model	(Table	 5.2)	 comprised	 8	 variables:	 number	 of	 previous	 transplants,	 CDC	 crossmatch,	DFG,	single	highest	pan-IgG	DSA	MFI,	and	the	presence/absence	of	 the	4	 IgG	subclass	DSAs,	out	of	which	only	the	highest	pan-IgG	DSA	MFI	and	IgG4	subclass	DSA	presence	were	
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statistically	significant	(p<0.05).	 	The	hazard	ratios	(HR)	revealed	that	death	censored	graft	survival	was	significantly	worse	in	cases	with	positive	IgG4	DSA	(HR	=	5.8,	p=0.035)	and	elevated	single	highest	pan-IgG	DSA	MFI	levels	(HR	=	71,	p=0.012),	both	known	pre-treatment.	
Table	5.2	Cox	proportional	hazards	model	for	death	censored	graft	survival.	Highlighted	in	bold	are	p<0.05.		Variable	 p-value	 Hazard	ratio	 95%	CI	Lower	 Upper	Previous	transplant		 0.125	 0.443	 0.157	 1.253	CDC	crossmatch	positive	 0.598	 1.455	 0.362	 5.855	Highest	pan-IgG	DSA	(MFI)	 0.012	 70.999	 2.578	 1955.4	IgG1	(+/-)	 0.665	 0.641	 0.086	 4.789	IgG2	(+/-)		 0.282	 0.342	 0.048	 2.415	IgG3	(+/-)	 0.464	 1.694	 0.414	 6.932	IgG4	(+/-)	 0.035	 5.826	 1.129	 30.1	DGF		 0.165	 0.225	 0.027	 1.853		Separate	 Cox	 PH	 analyses	were	 carried	 out	 for	 IgG	DSA	 values	 at	 future	 time	 points,	including	peak	(around	14th	day)	and	30th	day	post-transplant.	These	time	points	are	of	great	 clinical	 importance	 and	 were	 considered	 in	 this	 interdisciplinary	 collaborative	study	with	 the	resulting	models	published	 in	 [167].	These	models,	however,	 relate	 to	post-event	information,	and,	therefore,	are	not	relevant	to	this	thesis,	which	focuses	on	
predictive	modelling	 as	a	means	of	 stratifying	 the	 risk	of	a	particular	 clinical	outcome	while	it	is	still	beneficial	for	the	patient.	
5.4.2 Logistic	regression	for	acute	rejection	
A	multivariate	LR	was	performed	to	determine	whether	the	pre-treatment	IgG4	and	IgG1	DSA	MFI	was	independently	predictive	of	acute	ABMR.	Three	cases	were	excluded	from	this	analysis	because	of	missing	baseline	data,	thus	leaving	77	samples,	43	in	the	ABMR+	group	and	34	in	the	ABMR-	group.		
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Included	 in	the	LR	model	were	the	14	baseline	characteristics	outlined	 in	Section	5.3.	Numerical	variables	were	mapped	to	the	interval	[0,	1]	in	order	to	normalise	the	varying	variable	 ranges.	 Backwards	 stepwise	model	 selection	 eliminated	 input	 variables	 that	reduced	the	quality	of	the	ABMR	model.	The	following	five	variables	were	not	found	to	be	statistically	significant	in	the	LR	model:		
1) recipient’s	age	2) ESRD	duration	3) number	of	class	II	HLA-DR	mismatches	4) number	of	previous	transplants	5) the	marker	of	whether	the	donor	was	a	live/deceased	
One	explanation	as	to	why	these	variables	did	not	add	value	to	the	ABMR	mode	is	that:	both	1)	 the	ESRD	duration	 and	2)	 recipient’s	 age	 carry	 the	 information	on	 long-term	effects,	whilst	the	outcome	in	question,	i.e.	acute	ABMR,	is	a	snapshot	in	time	at		day	30		post-transplant	and	was	influenced	predominantly	by	short-term	IgG	dynamics;	3)	the	number	 of	 class	 II	 HLA-DR	 mismatches	 is	 counted	 in	 the	 total	 number	 of	 HLA	mismatches,	 which	 was	 already	 included	 in	 the	 model;	 4)	 the	 number	 of	 previous	transplants	correlated	with	long-term	survival,	but	not	acute	ABMR;	5)	with	only	6	cases	of	deceased	donor	kidneys	(remaining	AIT	transplantations	were	from	living	donors),	it	is	likely	that	deceased	donor	incidence	was	too	rare	to	be	captured	in	the	available	80	sample	dataset,	yet	alone	used	to	predict	the	ABMR.	
The	 resulting	 LR	 model	 shown	 in	 Table	 5.3	 comprised	 8	 variables	 and	 a	 constant	(intercept).	The	regression	coefficients	β	were	statistically	significant	(3 < 0.05)	for	all	variables.	In	particular,	3	variables	yielded	odds	ratios	"# 	beyond	the	[0.5,	2]	interval,	namely:	the	number	of	HLA	mismatches	("#=	4.2,	p<0.0001),	single	highest	pan-IgG	DSA	MFI	("# =3.3,	p<0.0001),	and	total	IgG4	MFI	level	("# =3.0,	p<0.0001).		
Chapter	5.		Outcome	prediction	in	antibody-incompatible	kidney	transplantation	
103	
Table	5.3	Logistic	regression	model	for	acute	transplant	rejection.	Highlighted	in	bold	are	odds	ratios	outside	
[0.5,	2]	interval.	Variable	:	 		 Coefficient	!	 3-value			 Odds	ratio	"# 	 95%	CI		Lower	 Upper	Intercept	 -1.847	 <0.0001	 0.158	 0.089	 0.280	Number	of	HLA	mismatches	 1.435	 <0.0001	 4.199	 2.756	 6.396	Class	I	&	II	DSA	presence	 0.386	 <0.0001	 1.471	 1.260	 1.718	CDC	crossmatch	positive	 -0.413	 <0.0001	 0.662	 0.575	 0.762	Highest	pan-IgG	DSA	(MFI)	 1.185	 <0.0001	 3.269	 2.557	 4.180	IgG1	(MFI)	 0.547	 <0.0001	 1.727	 1.363	 2.190	IgG2	(MFI)	 -0.454	 <0.0001	 0.635	 0.598	 0.675	IgG3	(MFI)	 -0.235	 <0.0001	 0.791	 0.772	 0.810	IgG4	(MFI)	 1.088	 <0.0001	 2.969	 2.203	 4.000		Taking	into	account	the	scaling	of	the	numerical	variables,	these	odds	ratios	should	be	interpreted	as	follows:	
• Between	the	lowest	(1)	and	highest	(6)	number	of	HLA	mismatches,	the	odds	of	the	transplant	being	rejected	are	expected	to	increase	by	4.2	times.		
• For	every	1000	MFI	units	increase	in	the	highest	pan-IgG	DSAs,	there	is	13%	increase	in	the	odds	of	ABMR.	
• For	every	1000	MFI	units	increase	in	IgG4	levels,	the	expected	increase	in	the	odds	of	ABMR	is	30.5%.		
In	order	 to	establish	 the	relative	 variable	 importance	 for	ABMR	association	 in	 the	LR	model,	 the	 likelihood	 ratio	+,	significance	was	 evaluated	 for	 each	 variable	 using	Chi-squared	test	[143].	The	analysis	revealed	that	only	two	variables	resulted	in	a	significant	(p<0.05)	increase	in	the	goodness	of	fit	of	the	LR	model:			
• single	highest	pan-IgG	DSA	MFI	(+,=	4.3,	p=0.003)	
• total	IgG4	DSA	MFI	(+,=	7.6,	p=0.005)	
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The	number	of	HLA	mismatches	had	a	high	likelihood	ratio	(+,=11.9),	but	at	p=0.06,	it	fell	short	of	the	significance	threshold.	This	could	be	due	to	the	fact	that	the	Chi-squared	test	penalises	large	degrees	of	freedom,	hence	this	multilevel	(6	possible	HLA	mismatch	values)	variable	was	penalised	heavily	in	the	likelihood	ratio	significance	test.		
Accounting	for	confounding	baseline	indicators,	the	descriptive	Cox	PH	and	LR	models	confirmed	the	important	associations	of	the	single	highest	pan-IgG	DSA	and	the	total	IgG4	DSA	 subclass	with	 short-	 and	medium-term	 transplant	 outcomes	 [167,255].	 The	 key	immunological	 risk	 factors	 established	 in	 these	 exploratory	 analyses	 were	 further	confirmed	by	the	predictive	ML	models	described	in	the	subsequent	section.			
 Predicting	early	rejection	using	tree-based	learning	
As	stated	at	the	end	of	Section	5.2,	the	primary	purpose	of	this	research	was	not	only	to	establish	 the	key	 immunological	 indicators	of	 transplant	 rejection	and	 its	 subsequent	loss,	but	to	find	the	baseline	levels	of	DSAs	for	safe	transplantation,	i.e.	establishing	how	
much	of	DSAs	can	be	tolerated	before	the	donor	kidney	is	rejected.	The	solution	to	this	task	required	more	granularity	than	had	been	achieved	with	the	standard	Cox	PH	and	Logistic	regression	analyses,	hence	it	was	approached	with	machine	learning.			
The	 secondary	 goal	 of	 the	 research	 stipulated	 a	 predictive	model	 for	 acute	 rejection,	which	 clinicians	 could	 use	 to	 identify	 patients	 at	 risk	 of	 acute	 ABMR	 prior	 to	 AIT	interventions	 and	 to	 make	 timely	 and	 informed	 life-saving	 decisions.	 Accurately	classifying	 AIT	 patients	 into	 ABMR+/-	 groups	 –	 based	 on	heterogeneous	 (continuous,	categorical	 nominal	 and	 categorical	 ordinal	 variable	 types),	 multimodal	 (routine	collection	and	dedicated	laboratory	experiments),	incomplete	(a	few	samples	contained	missing	values),	and	small	data	–	constituted	a	non-trivial	task	that	also	necessitated	the	use	of	ML.		
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Among	various	ML	classifiers,	DTs	are	particularly	well	suited	for	clinical	classification	tasks,	where	interpretability	is	key.	DTs	are	easy	to	interpret	by	non-statisticians	and	are	intuitive	to	follow.	They	cope	with	missing	values	and	are	able	to	combine	heterogeneous	data	 types	 into	 a	 single	 model,	 whilst	 also	 performing	 automatic	 feature	 selection	[121,124].	When	 combined	 in	 a	 random	 forest	 (RF)	 ensemble,	 DTs	 lose	 part	 of	 their	interpretability,	but	benefit	from	increased	robustness	and	the	classification	accuracy	of	RFs.	 The	 exploratory	 power	 is	 partially	 restored	 in	 the	 RF	 by	 leveraging	 the	 built-in	variable	importance	estimation	(Section	2.3.3).		
As	has	been	demonstrated	in	Section	5.2,	tree-based	learning	has	been	successful	in	the	general	area	of	kidney	transplantation	where	training	samples	were	abundant.	The	new	challenge	was	 to	 develop	 equally	 successful	 DT	 and	 RF	models	 using	 only	 a	 limited,	single-centre	dataset.		The	novel	application	of	DTs	for	the	prediction	of	acute	ABMR	in	HLA-incompatible	kidney	transplantation	was	enabled	by	the	multiple	runs	strategy	for	small	data	proposed	in	Chapter	3.	
5.5.1 Decision	tree	and	random	forest	design	
From	the	80	available	patient	cases,	60	were	randomly	sampled	for	model	training	and	the	remaining	20	samples	were	reserved	for	independent	tests.	As	has	been	shown		in	Section	5.4,	 the	patient	 groups	were	well	 balanced	 (46	 in	ABMR+,	34	 in	ABMR-),	 but	contained	 3	 samples	 with	 partially	 missing	 values.	 In	 one	 of	 the	 samples	 the	 ESRD	duration	was	lost	upon	collection;	in	two	other	samples	the	IgG1,	IgG2,	and	IgG3	values	were	not	 recorded.	The	3	missing	 samples	were	 included	 in	 the	DT	and	RF	 inputs	 to	ensure	that	the	models	were	able	to	make	realistic	predictions	on	incomplete	data,	which	are	commonly	encountered	in	a	clinical	AIT	setting.		
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The	models	were	evaluated	using	confusion	matrices	and	ROC	curves	(as	described	in	Section	 2.5);	 the	 correct	 classification	 rate	?,	 sensitivity	M2,	 specificity	M3,	 and	 area	under	the	ROC	curve	=>?	were	evaluated	separately	for	training	and	test	cohorts.	The	same	test	cohort	was	used	for	both	the	final	DT	and	RF	models.		
Decision	tree	design	was	based	on	the	standard	CART	algorithm	implemented	using	MATLAB™	[120]	and	the	Caret	package	in	R	[157].	All	14	baseline	and	immunological	predictors	 described	 in	 Section	 5.3	 were	 included	 as	 the	 DT	 input	 feature	 space.	Throughout	the	training	process,	the	dataset	was	recursively	divided	according	to	the	Gini’s	Diversity	Index	split	criterion,	as	described	in	Section	2.2.3,	until	the	optimal	DT	hierarchy	of	nodes	was	reached.	In	order	to	control	leafiness,	the	following	constraints	defined	 in	 Section	 2.2.4	 were	 imposed	 on	 the	 DT:	 minimum	 parent	 size	 of	 10,	 and	minimum	 leaf	 size	of	1.	No	 separate	 validation	 cohort	was	 afforded	 from	 the	 already	limited	 number	 of	 available	 samples.	 Instead,	 pruning	 [120]	was	 applied	 in	 order	 to	penalise	the	complexity	of	the	DT	and	prevent	overfitting,	thus	ensuring	that	only	the	most	significant	splits	were	discovered	by	the	model.	
Using	the	multiple	runs	strategy,	the	experiments	with	DT	were	repeated	600	times	and	each	 time	 a	 different	 model	 subset	 was	 sampled	 from	 the	 original	 samples.	 	 It	 was	expected	that	the	performance	of	those	600	DTs	would	be	highly	volatile,	reflecting	that	not	all	DTs	would	be	able	to	learn	from	the	limited	training	data.	It	was	also	expected	that	some	DTs	would	be	initialised	to	the	training	subsets	which	was	more	conducive	to	generalisable	 patterns	 in	 the	 ABMR+/-	 patients,	 as	was	 the	 case	with	 the	 small-data	neural	network	models	in	the	concrete	and	bone	applications	[232,233].	The	sufficient	size	 of	 the	 multiple	 run	 was	 estimated	 from	 the	 initial	 design	 exploration,	 where	increasing	the	size	above	600	trees	did	not	result	in	observable	changes	in	the	=>?	and	?	distributions.			
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Random	forest	design.	A	RF	comprising	600	constituent	trees	was	developed	in	order	to	increase	the	robustness	of	the	stand-alone	DT	predictions	to	the	degree	required	by	a	practical	 clinical	 support	 system.	This	 number	 of	 trees	was	 selected	due	 to	 the	 same	considerations	as	in	the	multiple	runs	above.	Although	it	was	expected	that	the	RF	would	produce	substantially	more	robust	results	than	the	600	individual	DTs,	the	experiment	with	RF	was	repeated	10	times	to	monitor	the	variance	due	to	small	data.	 In	order	to	reduce	its	input	dimensionality,	the	predictive	RF	system	leveraged	the	findings	of	the	exploratory	LR	analysis	conducted	in	Section	5.4.2.	The	5	variables	that	lacked	significant	association	with	 the	 acute	 ABMR	 in	 the	 LR	model	 were	 removed	 from	 the	 RF	 input	feature	space,	thus	reducing	it	to	9	baseline	predictors,	all	of	which	were	known	prior	to	the	transplantation.		
A	constituent	tree	in	RF	was	different	from	a	DT	in	the	following	ways:	
• Overfitting	was	controlled	by	out-of-bag	validation	with	90%	of	the	samples,	as	opposed	to	DT	pruning.	
• To	compensate	for	otherwise	excessively	large	trees	grown	without	pruning,	the	minimum	number	of	samples	per	leaf	node	was	increased	to	3.	
• Out	of	the	9	input	features,	6	were	sampled	at	random	for	each	partial-feature	tree	in	the	RF.		
5.5.2 Decision	tree	model	results	
The	DT	classifier	in	Figure	5.2	was	developed	after	considering	a	multiple	run	of	the	600	DTs,	each	modelled	on	a	different	subset	of	the	data	by	permuting	the	test	and	training	datasets	 with	 each	 other.	 The	 models	 were	 analysed	 in	 a	 semi-automatic	 manner	whereby	 the	 high-performing	 (=>?~AuC ≥ 	0.8)	 DTs	 were	 monitored	 for	 repeating	patterns	of	variables	in	the	branches.	In	the	absence	of	a	separate	validation	cohort,	the	
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final	model	was	selected	as	the	highest	performing	(measured	by	=>?~AuC,	?~E™~,	?~AuC,	and	?~E™~)	 from	the	subset	of	DTs	with	a	repeating	pattern.	As	expected,	considerable	volatility	in	performance	and	structure	was	observed	among	the	600	DTs.	Out	of		the	600	DTs,	a	persistent	pattern	was	observed	in	14	high-performing	DTs,	which	used	the	same	6	variables	(in	differing	order)	as	the	model	in	Figure	5.2.			
	
Figure	5.2	DT	schematic	showing	the	split	hierarchy	with	7	branch	nodes	and	8	leaves	based	on	6	variables		A	 further	 comparison	 of	 these	 14	 DT	 instances	 with	 the	 remaining	 586	 DTs	 in	 the	multiple	run	was	carried	out	with	the	Wilcoxon	rank	sum	test	for	medians	of	?~E™~ .	Figure	5.3	shows	that	despite	the	overall	large	variance	(*	 = 	0.013)	across	the	multiple	run,	the	14	DTs	based	on	the	6	variables	 identified	 in	Figure	5.2	had	a	significantly	higher	predictive	 power	 (p<0.002).	 This	 indicated	 that	 the	 training	 cohorts	 of	 these	 trees,	containing	high-risk	patient	groups,	were	more	conducive	to	learning	the	associations	between	the	input	variables	and	acute	ABMR	[232].		
0	=	ABMR-	
1	=	ABMR+	
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Figure	5.3	Wilcoxon	rank	sum	test	for	median	?~E™~	based	on	600	DTs	and	on	the	subset	of	DTs	with	the	
repeating	pattern.			Out	of	the	14	baseline	predictors,	6	variables	were	identified	by	the	DT	as	the	primary	splits	for	ABMR	prediction.	These	were:	the	single	highest	pan-IgG	DSA	MFI	level,	total	IgG4	MFI	level,	number	of	HLA	mismatches,	total	IgG2	MFI	level,	the	total	IgG1	MFI	level,	and	cytometry	crossmatch.		The	remaining	8	were	not	used	by	the	final	DT	(Figure	5.2)	in	either	the	primary	or	surrogate	splits.	Thus,	the	DT	model	independently	confirmed	that	none	of	 the	5	baseline	parameters	 eliminated	by	 the	LR	model	 (Table	5.3)	were	instrumental	to	acute	ABMR	prediction.	
Importantly,	the	node	splits	in	the	DT	model	(Figure	5.2)	provided	an	indication	as	to	what	specific	levels	of	HLA	DSA	antibodies	were	statistically	associated	with	each	of	the	ABMR+/-	 groups.	 The	 DT	 identified	 that	 all	 patients	 with	 the	 highest	 pan-IgG	 levels	below	 MFI	 1062	 belonged	 to	 the	 ABMR-	 group	 (no	 rejection),	 while	 those	 with	 the	highest	pan-IgG	level	≥	1062	and	the	IgG4	MFI	level	≥	80	had	a	high	(85%)	likelihood	of	early	transplant	rejection.	Similarly,	85%	of	patients	with	4	or	5	HLA	mismatches,	the	highest	pan-IgG	 level	≥	1062,	 and	 IgG4	MFI	 level	<	80	belonged	 to	 the	ABMR+	group	[256,257].	
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Figure	5.4	Confusion	matrices	for	the	training	dataset	(left)	and	test	samples	(right)	of	the	DT	model.	
The	cells	provide	the	performance	metrics	described	in	Section	2.5.		The	DT	was	able	to	correctly	predict	the	incidence	of	ABMR	in	85%	cases	on	both	training	and	test	datasets	(Figure	5.4).	When	evaluated	on	the	test	cohort,	the	DT	identified	ABMR+	patients	with	81.8%	sensitivity	and	ABMR-	cases	with	88.90%	specificity	(Figure	5.4).	The	classifier	ROC	curves	show	=>?~AuC 	= 	0.849	on	training	samples	and	=>?~E™~ 	= 	0.854	for	DT	predictions	on	test	samples	(Figure	5.5).		
	
Figure	5.5	ROC	curves	for	DT	accuracy	on	the	training	dataset	(left)	and	test	samples	(right).	
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5.5.3 Random	forest	model	results	
The	 RF	 of	 600	 partial-feature	 trees	was	 built	 on	 the	 same	 training	 cohort	 as	 the	 DT	presented	 in	 Figure	 5.2.	 It	 achieved	 ?~AuC	 =	 91.7%	 during	 the	 training	 phase	 and	correctly	classified	85%	of	test	cases	(Figure	5.6),	which	was	analogous	to	the	DT	model	performance	on	the	same	test	cohort.	The	RF	was	able	to	identify	ABMR+	patients	with	a	 higher	 sensitivity	 (M2	 =	 92.3%)	 than	 the	 DT,	 but	 its	 ABMR-	 predictions	 were	 less	specific	(M3	=	71.4%).	=>?~E™~	=	0.819	of	this	RF	was	equal	to	that	of	the	DT	(Figure	5.7).	
	
Figure	5.6	Confusion	matrices	for	the	training	dataset	(left)	and	test	samples	(right)	of	the	RF	model.	
	
Figure	5.7	ROC	curves	for	RF	classification	accuracy	on	training	(left)	and	test	(right)	samples.	
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Ten	RFs	were	 generated	 [256]	 in	 order	 to	 determine	whether	 the	 consistency	 of	 the	predictions	 improved	 compared	 to	 the	 DT	 run.	 The	 results	 (Figure	 5.8)	 showed	significantly	reduced	variance	(*	 = 	0.002),	and	consistently	high	performance.	
	
Figure	5.8	Distributions	of	performance	measures	?~AuC, ?~E™~, =>?~AuC, =>?~E™~	for	10	RFs.	The	 variable	 importance	 scores	 (Figure	 5.9)	 were	 computed	 in	 order	 to	 identify	 the	principal	 factors	 of	 ABMR	 among	 the	 9	 input	 variables	 used	 by	 the	RF	 classifier.	 	 As	shown	 in	 Figure	 5.9,	 the	 total	 IgG4	 MFI	 level	 was	 the	 single	 most	 important	 factor,	followed	by	the	highest	MFI	IgG	level,	and	the	number	of	HLA	mismatches.	This	result	independently	 confirms	 the	 finding	 of	 the	multivariate	 analyses	 that	 IgG4	 was	 a	 key	contributor	to	the	risk	of	kidney	rejection	in	the	early	post-transplant	period	[255–257].	
	
Figure	5.9	Variable	importance	scores	evaluated	by	a	permutation	test	across	10	RFs	
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Both	 the	 DT	 and	 RF	 models	 enabled	 accurate	 predictions	 of	 acute	 ABMR	 from	 the	baseline	 indicators	 in	 the	 UHCW	 data.	 However,	 the	 two	 tree-based	 models	 offered	distinct	auxiliary	functionality.		Despite	its	volatility	to	limited	training	samples,	the	DT	model	had	an	added	advantage	of	descriptive	modelling:	its	numerical	branches	enabled	quantification	of	dangerous	HLA	DSA	levels,	whilst	its	clear	graphical	representation	is	easy	to	follow	by	non-statisticians.	The	RF	did	not	offer	such	ease	of	interpretation,	since	it	comprised	600	individual	partial-feature	trees.	This	drawback	in	interpretability	was	compensated	by	 the	reduction	 in	 the	RF	performance	volatility,	making	the	RF	model	more	 suitable	 as	 a	 practical	 clinical	 risk	 stratification	 system.	 The	 quantitative	comparison	of	the	two	predictive	models	is	provided	in	Table	5.4.	
Table	5.4	Predictive	performance	of	the	DT	and	RF	models	
Performance	measures:																																												
DT	 RF	
training	 test	 training	 test	Correct	classification	rate,	C	(%)	 85.0	 85.0	 91.7	 85.0	Sensitivity,	Sn	(%)	 85.7	 81.8	 93.9	 92.3	Specificity,	Sp	(%)	 84.0	 88.9	 88.9	 71.4	Positive	Predictive	Value,	PPV	(%)	 88.2	 90.0	 91.2	 85.7	Negative	Predictive	Value,	NPV	(%)	 80.8	 80.0	 92.3	 83.3	Area	under	the	ROC	curve,	AUC	 0.849	 0.854	 0.914	 0.819			
 Methodological	significance	and	limitations	
The	accuracy	achieved	by	the	DT	classifier	in	Section	5.5	demonstrated	that	tree-based	ML	could	be	effectively	applied	to	predictive	modelling	in	AIT	despite	the	small	number	of	observations	and	heterogeneous	input	parameters.	Developed	with	only	60	cases,	the	DT	model	for	acute	ABMR	correctly	classified	85%	of	the	patients	in	both	the	training	and	test	cohorts.	Although	no	similar	ML	model	for	acute	ABMR	existed	at	the	time	of	
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publication	[256,257]	to	make	a	direct	comparison,	the	proposed	DT	outperformed	in	its	accuracy	(=>?	=	0.854)	some	of	the	highest-performing	large-data	ML	models	in	the	area	of	kidney	transplantation	discussed	in	Section	5.2	[251–254].	
In	 addition	 to	 providing	 patient-specific	 ABMR	 risk	 predictions,	 the	 DT	 was	 also	 a	
descriptive	model.	 Its	 branch	 nodes	 determined	 the	 optimal	 set	 of	 6	 pre-treatment	indicators	 associated	with	 acute	ABMR,	which	 confirmed	 and	 expanded	 the	 previous	findings	of	the	LR	model	(Section	5.4.2).	The	superiority	of	the	DT	model	was	in	further	granularity:	 not	 only	 had	 it	 identified	which	 IgG	 subclasses	 were	 highly	 pertinent	 to	ABMR,	but	also	what	levels	of	these	IgG	DSAs	could	be	safely	tolerated	[256,257].		
The	 limitation	 of	 the	 DT	 model	 was	 its	 sensitivity	 to	 the	 subset	 of	 training	 data	 it	received.	 Without	 an	 additional	 validation	 cohort	 it	 is	 unknown	 whether	 the	 DT	performance	 on	 the	 test	 cohort	 was	 also	 subset-dependent,	 or	 whether	 it	 was	generalisable	 to	 new	 samples.	 The	 model	 provided	 in	 Figure	 5.2	 was	 not	 a	 unique	solution	 to	 the	 classification	 of	 ABMR.	 Instead,	 it	 represented	 one	 of	 several	 DT	hierarchies	that	could	explain	the	association	of	the	samples	in	the	training	cohort	with	acute	 ABMR.	 Due	 to	 this,	 no	 claims	 on	 the	 DT	 model	 generalisation	 for	 the	 patient	samples	outside	of	the	UHCW	data	could	be	reasonably	made.	
The	RF	ensemble	provided	an	extension	to	the	DT	model,	with	the	purpose	of	improving	its	robustness	as	a	classification	tool.	It	has	been	widely	accepted	that	an	aggregate	vote	of	several	DTs	was	inherently	less	noisy	and	less	susceptible	to	outliers	than	a	single	DT	output	[132–134,138,258].	The	RF	ensemble	 in	 this	study	was	not	developed	with	an	intention	of	improving	the	already	high	DT	model	accuracy,	but	to	factor	in	possible	noise	in	 the	 training	 samples	 the	 DT	 model	 received,	 and	 thus	 increase	 its	 generalisation	potential.	The	RF	offered	a	better	consistency	of	results	and	lowered	the	volatility	of	the	DT	predictions,	albeit	at	the	expense	of	reduced	interpretability.	It	remains	for	further	
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study	to	confirm	that	the	reduction	in	volatility	was	due	to	ensemble	learning	and	not	the	training	data,	and	whether	the	RF	model	would	indeed	be	able	to	generalise	on	the	patient	cohort	outside	of	the	UHCW	centre.	
Small	dataset	size	was	not	the	only	limitation	of	the	clinical	data	explored	in	this	work.	Despite	 being	 meticulously	 collected	 and	 maintained	 by	 largely	 the	 same	 team	 of	nephrologists,	the	single-centre	dataset	contained	3	incomplete	samples.	These	samples	with	partially	missing	baseline	and	immunological	information	could	not	be	integrated	into	the	Cox	PH	survival	and	logistic	regression	analyses	without	one	of	the	imputation	strategies	discussed	 in	Chapter	3.	On	 the	 contrary,	 the	DT	and	RF	models	were	well-equipped	to	handle	partially	missing	data	and	managed	to	classify	correctly	all	3	cases	with	 incomplete	 data.	 	 This	methodological	 superiority	 of	 the	 tree-based	ML	models	further	 adds	 to	 their	 descriptive	 and	 predictive	 significance	 for	 classification	 from	limited	clinical	data.		
 Clinical	impact	
At	 the	 time	of	 	publication	 [167,232,233],	 this	research	was	 the	 first	 in	 the	UK	to	use	machine	learning	for	the	prediction	of	acute	ABMR	from	HLA	donor-specific	IgG	subclass	data	in	antibody-incompatible	renal	transplantation.		It	was	also	the	first	demonstration	of	the	potential	prognostic	value	of	the	HLA	DSA	IgG4	in	AIT	[167,255,257].	
The	independent	association	of	IgG4	DSAs	with	the	graft	outcome	was	first	confirmed	by	the	Cox	PH	model	(Table	5.2).	The	multivariate	model	revealed	a	strong	association	of	pre-treatment	IgG4	DSA	presence	with	medium-term	graft	loss.	Accounting	for	multiple	confounding	factors,	this	association	was	independent	of	IgG1	and	pan-IgG	DSA	levels,	revealing	that	IgG4	DSAs,	even	in	isolation,	could	be	highly	pathogenic	to	the	graft.	It	is	also	possible	 that,	being	 last	 in	 the	 IgG	class-switching	sequence,	 IgG4	represented	an	
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already	mature	immune	response	to	the	donor	organ	by	the	recipient’s	immune	system.		The	 importance	 of	 IgG4	was	 also	 detected	 in	 acute	 graft	 rejection	 by	 the	 exploratory	logistic	 model	 (Table	 5.3).	 The	 LR	 model	 confirmed	 a	 significant	 association	 of	 pre-treatment	 IgG4	DSA	 levels	with	 acute	ABMR.	A	 similar	 association	was	 independently	confirmed	 by	 the	 relative	 variable	 importance	 scores	 in	 the	 subsequent	 RF	 model.	Combined,	 the	 analyses	 strongly	 supported	 the	 discovery	 of	 IgG4	 DSAs	 as	 the	 key	prognostic	indicator	for	short-	and	medium-term	AIT	outcomes.		
Conventional	statistical	models	were	unable	to	determine	how	much	of	IgG4	DSAs	could	be	safely	tolerated	before	the	transplant	was	rejected	by	the	recipient’s	humoral	system.		It	was	 the	DT	model	 that	 revealed	 the	dangerous	 levels	 of	 antibodies	 associated	with	ABMR.	The	harmful	levels	of	IgG4	DSA	and	the	single	highest	pan-IgG	DSA	were	identified	to	be	at	80	MFI	and	1062	MFI,	respectively	(Figure	5.2).	Whilst	the	threshold	of	around	1000	MFI	for	the	single	highest	pan-IgG	had	been	intuitively	used	by	transplant	experts	[75,239,248,259],	the	threshold	for	IgG4	discovered	by	the	DT	model	on	the	UHCW	data	presented	an	entirely	novel	insight.		
By	integrating	known	and	novel	associations,	the	tree-based	ML	classifiers	developed	in	this	work	enabled	accurate,	patient-specific	outcome	predictions	for	acute	ABMR.	They	provided	the	means	for	the	early	stratification	of	ABMR	risk	from	pre-treatment	clinical	and	 immunological	 indicators,	 leaving	 clinicians	 with	 more	 time	 to	 make	 essential	adjustments	to	treatment.		The	granularity,	with	which	the	DT	model	determined	which	IgG	 subclasses	 were	 particularly	 dangerous,	 and	 to	 what	 degree,	 added	 invaluable	statistical	evidence	 to	support	 the	expert	clinician’s	decision	making.	These	outcomes	are	summarised	by	the	workflow	schematic	in	Figure	5.10.	
By	 informing	 clinical	 decisions,	 tree-based	 ML	 has	 the	 potential	 to	 transform	personalised	care	 in	AIT,	preventing	 life-threatening	graft	 loss	and	over-treatment	by	
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costly	 and	 harmful	 immunonosuppresive	 drugs.	 Before	 the	 DT	 and	 RF	 prototypes	developed	in	this	work	on	the	UHCW	data	can	be	used	as	a	practical	decision	support	tool,	they	require	extensive	validation	with	external	datasets.	Through	dissiminations	at	multiple	 international	 conferences	and	 leading	AIT	 fora,	 requests	 to	 collaborate	were	discussed	with	multiple	groups,	including	the	Paris	centre	[260].	A	grant	application	to	obtain	additional	HLA-incompatible	and	blood-group	incompatible	transplant	data	was	submitted	 to	 the	UK	Transplant	Registry	 [261]	and	access	has	 recently	been	granted.		Thus,	the	research	underpinning	this	thesis	forms		the		foundation	for	an	extensive	multi-centre	collaboration	with	the	potential	to	transform	the	field	of	antibody-incompatible	renal	transplantation.		
	
Figure	5.10	From	raw	data	to	clinical	insight:	summary	of	the	workflow		
 Chapter	conclusions		
The	key	finding	of	this	chapter	are	as	follows:	
(1) Single-centre	 renal	 transplant	 data	 were	 explored	 for	 novel	 multivariate	associations	 and	 the	 potential	 for	 data-driven	 predictive	 modelling	 of	 early	transplantation	outcomes.	
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(2) A	multivariate	Cox	PH	model	established	the	independent	association	of	the	single	highest	pan-IgG	DSA	MFI	levels	(HR	=	71,	p=0.012),	and,	specifically,	IgG4	DSAs	presence	(HR	=	5.8,	p=0.035)	with	medium-term	graft	loss.		
(3) An	exploratory	LR	model	confirmed	that	the	single	highest	pan-IgG	DSA	MFI	level	("#=	 3.3,	 p<0.0001)	 and	 total	 IgG4	 DSA	 MFI	 level	 ("#=	 3.0,	 p<0.0001)	 were	 also	associated	with	early	transplant	rejection.	
(4) A	 predictive	 DT	model,	 developed	 on	 60	 patient	 samples	 using	 the	 method	 of	multiple	 runs,	 independently	 confirmed	 the	 confounding	 factors	 used	 in	 LR	 and	predicted	early	ABMR	with	85%	accuracy.	
(5) By	providing	a	quantification	of	dangerous	DSA	levels,	 the	DT	identified	that	all	patients	with	the	highest	pan-IgG	levels	below	MFI	1062	belonged	to	the	ABMR-	group,	while	those	with	the	highest	pan-IgG	level	≥	1062	and	the	IgG4	MFI	level	≥	80	had	an	85%	chance	of	early	ABMR+.	
(6) Within	 the	 limitations	 of	 the	 test	 cohort,	 the	 predictive	 RF	 ensemble	 model	improved	DT	robustness	and	maintained	85%	predictive	accuracy.	The	relative	variable	importance	scores	of	the	RF	ensemble	further	confirmed	the	LR	and	DT	findings	of	the	key	immunological	and	clinical	factors	for	acute	ABMR	in	HLA	sensitised	patients.		
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Diabetes	type	2	risk	stratification	from	routinely	collected	NHS	data	
The	research	presented	in	this	chapter	stems	from	a	3-year-long	collaboration	with	the	Nuffield	Department	of	Primary	Care	Health	Sciences,	University	of	Oxford.		The	overall	aim	 of	 the	 project	 was	 to	 explore	 the	 possibilities	 of	 improving	 the	 existing	 type	 2	diabetes	risk	stratification	system	used	in	NHS	primary	care,	through	the	adoption	of	ML	and	 inclusion	 of	 blood	 glucose	 information.	 The	 author’s	 contribution	 to	 this	collaboration	 was	 the	 development,	 implementation,	 and	 validation	 of	 a	 novel	 ML	prototype	 that	 predicted	 the	 10-year	 risk	 of	 acquiring	 type	 2	 diabetes	 in	 the	 UK	population	based	on	routinely	collected	primary	care	data.	The	study	protocol	specified	for	 the	model	 to	 be	 based	 on	 artificial	 neural	 networks,	 although	 alternative	models	using	 logistic	 regression	 and	 survival	 decision	 trees	 were	 also	 explored	 and	 are	presented	in	this	chapter.	
 Diabetes	in	the	UK	and	globally	
Diabetes	 mellitus	 (DM)	 is	 a	 chronic	 hormone	 deficiency	 condition	 that	 significantly	impacts	on	the	lives	of	an	estimated	422	million	people	globally	[262].	The	key	feature	of	DM	is	the	relative	or	absolute	absence	of	insulin	–	the	hormone	involved	in	controlling	
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and	critically	 lowering	 levels	of	glucose	 in	 the	blood.	Elevated	 levels	of	blood	glucose	(hyperglycaemia)	produce	serious	short-term	as	well	as	 long-term	complications	 that	have	significant	impacts	on	the	quality	of	life	and	health	of	diabetic	patients	and	lead	to	increased	 mortality	 [263].	 In	 severe	 cases,	 patients	 can	 suffer	 from	 hyperglycaemic	hyperosmolar	state,	and	in	instances	of	absolute	insulin	deficiency,	lead	to	ketoacidosis,	loss	 of	 consciousness	 and	 coma.	 In	 cases	 of	 long-term	 hyperglycaemia,	 the	microvasculature	 of	 a	 patient's	 kidney,	 eye,	 nerve,	 and	 larger	 arteries	 are	 affected,	leading	to	blindness,	neuropathy,	and	end-stage	renal	failure	[263].	Hypoglycaemia	(low	blood	glucose)	caused	by	improper	glycaemic	management	in	diabetic	patients	can	also	lead	 to	 mortality	 [263].	 The	 World	 Health	 Organisation	 estimates	 that	 DM	 and	 its	complications	 caused	 1.5	 million	 deaths	 in	 2012	 (2016).	 In	 England	 alone,	 DM	 is	responsible	for	over	48,000	hospital	admissions	and	5,500	deaths	annually	[264].		
As	alarming	as	its	complications,	is	the	accelerating	rate	at	which	DM	continues	to	strike	modern	society.	The	worldwide	prevalence	of	diabetes	type	2	has	doubled	since	1980		and	this	trend	is	expected	to	continue	with	a	forecasted	592	million	diabetic	people	by	2035	[262,265].	Weber	and	Narayan	call	it	the	“epidemic	of	diabetes”	(2008).	In	the	UK,	the	number	of	adults	living	with	DM	is	3.9	million,	corresponding	to	a	prevalence	rate	of	6.2%	[267,268].	 It	 is	estimated	 that	 there	are	also	around	850,000	people	 in	England	who	have	diabetes	but	have	not	been	diagnosed	[267].	Those	undiagnosed	patients	may	have	experienced	diabetic	complications,	such	as	a	heart	attack	or	renal	failure	without	warning	symptoms.	
The	 rapid	 growth	 in	 DM	 incidence	 is	 a	 serious	 public	 health	 priority	 [262,264].	Fortunately,	 the	 past	 few	 decades	 have	 also	 brought	 about	 two	 paradigms:	 (1)	widespread	 computerisation	 of	medical	 systems	 in	 industrialised	 countries	 that	 have	resulted	 in	the	collection	of	vast	(and	often	convoluted)	digital	repositories	of	patient	
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data,	and	(2)	 the	emergence	of	hardware	and	machine	 learning	algorithms	capable	of	dealing	with	these	data.	Combined,	these	technological	advances	offer	an	unprecedented	opportunity	 to	 better	 understand,	 monitor	 and	 manage	 DM.	 By	 analysing	 routinely	collected	primary	 care	data	using	NNs	 and	DTs,	 this	work	 contributes	 to	 the	nascent	niche	for	machine	learning	application	in	the	early	prediction	of	DM	in	the	UK	population.	
6.1.1 Disease	pathology,	diagnosis	and	treatment	
Despite	 the	 rapid	 growth	 in	 incidence	of	DM	 in	 the	past	 century,	 the	disease	 is	not	 a	phenomenon	unique	to	modern	society.	The	term	diabetes	can	be	traced	back	to	the	2nd	century	AD	Greece,	and	 the	distinction	between	 the	different	 types	of	DM	 is	 found	as	early	as	the	5th	and	6th	centuries	AD	in	the	work	of	multiple	Hindu	physicians	[263].	Yet	our	understanding	of	the	complex	metabolic	and	biochemical	processes	in	DM,	as	well	as	the	policy	around	diagnosing	and	managing	DM,	is	still	evolving.		
DM	is	diagnosed	on	the	basis	of	chronic	hyperglycaemia	determined	by	a	blood	glucose	(BG)	 test.	A	 fasting	glucose	 level	≥7	mmol/L	 in	plasma	or	≥6.1	mmol/L	 in	a	 capillary	blood	sample	define	DM.	 	Where	 fasting	BG	 is	not	available,	2-hour	BG	 level	of	≥11.1	mmol/L	(either	in	plasma	or	capillary)	are	used	as	a	sufficient	diagnostic	criteria	for	DM	[263].	In	2011	the	World	Health	Organisation	recommended	a	supplementary	diagnostic	measure	based	on	glycated	haemoglobin	(HbA1c)	above	48	mmol/mol	or	6.5%	[267].	
DM	is	categorised	into	two	main	types:	type	1,	caused	by	autoimmune	responses	within	the	pancreas	 (absolute	deficiency),	 and	 type	2,	 associated	with	 insulin	 resistance	and	impaired	secretion.	There	are	a	range	of	other	forms	of	DM,	such	as	neonatal	DM,	mature	onset	 diabetes	 of	 the	 young	 (type	 MODY),	 and	 Alström	 and	 Wolfram	 syndromes.	However,	over	90%	of	all	incidences	of	DM	correspond	to	type	2	[264].	 	This	work	on	routinely	collected	data	from	the	general	UK	population	focuses	solely	on	type	2	DM.	
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Type	2	DM	is	caused	by	a	combination	of	genetic	and	environmental	factors,	such	as	low	physical	activity,	imbalanced	diet,	chronic	stress	and	polygenic	inheritance	patterns.	It	is	a	life-long	condition	that	can	rarely	be	reversed,	although	the	risk	of	complications	and	the	severity	of	the	disease	can	be	considerably	reduced	by	life	style	interventions,	such	as	weight	 loss,	 increased	physical	 activity,	 and	 cessation	of	 smoking	 [265].	These	 life	style	changes	have	to	be	adopted	early	and	carried	out	persistently	to	be	effective,	thus	timely	detection	of	DM	or	pre-DM	conditions	is	highly	advantageous	[264,266,269].		
Unlike	 type	1	DM,	 type	2	diabetic	patients	are	not	necessarily	dependent	on	external	insulin.	However,	 type	2	DM	 is	a	progressive	 condition	 that	often	deteriorates,	 to	 the	point	where	exercise	and	healthy	diet	alone	are	not	sufficient	to	control	BG	levels.	The	patient	is	then	prescribed	insulin	and	a	number	of	medications	to	stimulate	and	protect	insulin-producing	 cells	 in	 the	 pancreas	 or	 to	 inhibit	 the	 absorption	 of	 starch	 in	 the	intestine	and	the	absorption	of	glucose	by	the	kidneys	and	the	blood	[268].	The	ability	to	maintain	BG	outside	 the	dangerous	hyper-	or-	hypoglycaemia	 thresholds	 is	 critical	 to	reducing	 the	 risk	 of	 serious	 macro-	 and	 micro-vascular	 complications	 and	 death	[263,269,270].	The	longer	the	patient’s	body	is	exposed	to	uncontrolled	hyperglycaemia,	the	 higher	 the	 risk	 of	 the	 irreversible	 damage	 of	 insulin-producing	 cells	 [263].	 Early	detection	of	DM	is	therefore	key	to	preventing	severe	morbidity.	
6.1.2 Managing	type	2	diabetes	risk	in	primary	care	
With	49.1	million	 items	prescribed	each	year	 for	DM	 in	England	alone,	 the	burden	of	monitoring	and	managing	type	2	DM	falls	on	primary	care	[264].	The	risk	of	type	2	DM	can	be	identified	through	correlated	(but	not	necessarily	causal)	factors	observable	in	primary	care,	including:	
• high	BMI	and	obesity	
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• first-degree	relative	with	DM	
• smoking		
• hypertension	
• conditions	requiring	the	prescription	of	corticosteroids	
• gestational	diabetes		
The	net	effect	of	these	risk	factors	is	not	straight	forward.	Obesity	in	itself	is	a	summary	measure	of	multiple	health	conditions	that	reflect	both	lifestyle	and	genetic	factors	[265].	Cardiovascular	 conditions	 such	 as	 hypertension	 and	 DM	 are	 mutually-cofounded:		patients	with	hypertension	have	increased	insulin	resistance,	while	75%	of	DM	patients	also	have	hypertension	[271].	Some	risks	are	associated	with	patient	demographic.	For	instance,	among	the	UK	population	type	2	DM	is	found	to	be	more	common	in	people	of	South	 Asian,	 African,	 Afro-Caribbean	 and	 Chinese	 family	 origins	 and	 in	 people	 from	regions	associated	with	a	high	Townsend	index	of	multiple	deprivation	[264].	General	practitioners	are	encouraged	to	screen	 for	DM	risk	 factors,	and	to	refer	patients	 for	a	blood	 biochemistry	 test	when	 a	 combination	 of	multiple	DM	 risk	 factors	 is	 observed	[264,267].	
Population	screening		for	high-risk	groups	is	set	in	place	across	UK	primary	health	care	practices		[264,267].	The	official	guideline	of	the	National	Institute	for	Health	and	Care	Excellence	[267]	recommends	the	use	of	computer-based	risk	assessment	tools	based	on	routinely	collected	data,	including	the	QDiabetes®	risk	calculator	[272],	the	Cambridge	dataset	risk	score	[273],	the	questionnaire-based	Finish	Diabetes	Risk	Score	[274],	and	the	Leicester	practice	score	[275].	These	four	risk	assessment	tools	predict	the	10-year	risk	of	being	diagnosed	with	type	2	DM	and	use	5	common	variables	(age,	gender,	BMI,	family	history	of	diabetes	and	hypertension)	and	2-5	additional	variables,	such	as	waist	
Chapter	6.		Diabetes	type	2	risk	stratification	from	routinely	collected	NHS	data	
124	
circumference,	self-reported	 fruit	and	vegetable	 intake	and	gestational	diabetes,	all	of	which	can	be	measured	in	primary	care	without	expensive	laboratory	tests.		
It	 is	 unrealistic	 that	 a	 handful	 of	 predictor	 variables	 can	 capture	 the	 entirety	 of	 the	possible	DM	risks	and	variance	in	population,	but	it	is	important	to	establish	the	small	number	of	variables	that	account	for	most	of	the	variance.	In	a	systematic	review	of	14	type	2	DM	risk-prediction	models,	Noble	et	al.	advised	against	including	more	than	10	components	to	the	risk	model	in	order	to	sustain	its	usability	[276,277].	
The	Finnish	Diabetes	Risk	Score	and	Leicester	risk	scores	use	questionnaires	that	sort	patients	into	appropriate	categories	of	risk	of	developing	type	2	DM	in	a	10-year	period.	The	Cambridge	risk	score	and	QDiabetes®	use	data	already	available	 in	primary	care	systems,	 but	 the	 algorithms	 for	 computing	 the	 risk	 differ:	 QDiabetes®	 uses	 the	 Cox	proportional	hazards	model	to	compute	percentage	risk	of	developing	type	2	DM,	while	the	Cambridge	risk	score	utilises	logistic	regression	to	express	the	likelihood	of	having	undiagnosed	diabetes.	
Importantly,	these	four	validated	and	routinely	used	risk	assessment	algorithms	were	recently	found	to	produce	dissimilar	risk	scores	[278].	For	an	individual,	this	carries	an	implication	that	their	predicted	risk	is	dependent	on	which	risk-prediction	tool	is	used	and	 could	 be	 altered	 if	 a	 different	 assessment	 is	 adopted.	 The	 National	 Audit	 Office	exposed	 that	 a	 high-quality	 randomised	 controlled	 trial	 was	 yet	 to	 confirm	 that	 the	existing	manual	screening	is	beneficial	[277].	
The	aim	of	this	work	is	not	to	develop	yet	another	type	2	DM	risk	score,	but	instead	to	investigate	the	utility	of	various	algorithms,	both	from	classical	statistics	and	machine	learning,	in	the	context	of	routinely	collected	data.	
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Of	 the	 four	 risk	 assessment	 tools	 recommended	 by	NICE,	 QDiabetes®	has	 by	 far	 the	largest	model	derivation	and	validation	base.	It	was	built	on	2.5	million	medical	records,	amounting	 to	 16,436,135	 person	 years	 of	 observation,	 during	 which	 78,081	 new	incidences	of	 type	2	DM	occurred	 [272].	The	model	 considers	11	predictor	variables:	patient’s	age,	gender,	gestational	DM,	BMI,	smoking	status,	self-assigned	ethnicity,	family	history	of	DM,	Townsend	multiple	deprivation	score	and	whether	or	not	the	patient	was	treated	for	hypertension,	had	cardiovascular	disease,	or	was	prescribed	corticosteroid	drugs.		
Despite	 their	uncontested	diagnostic	value,	BG	measurements	are	not	 included	 in	 the	computation	 model	 of	 QDiabetes®.	 The	 reason	 why	 QDiabetes®	 disregards	 this	essential	biochemical	factor	is	because	it	was	designed	with	a	vision	to	be	used	both	in	a	primary	care	environment	and	by	patients	at	home,	where	a	blood	test	for	measuring	BG	levels	may	not	be	available.	This	assumption	is	now	obsolete:	in	the	24	years	since	the	collection	 of	 the	 first	 patient	 record	 in	 the	 QDiabetes®	 study,	 point-of-care	 testing,	including	 that	 of	 BG	 in	 primary	 care,	 have	 become	 routine	 [279,280].	 	 For	 a	 model	designed	to	predict	DM	risk	at	the	point	of	care,	it	would	be	reasonable	to	use	all	available	data,	including	BG	biochemistry,	even	if	this	will	render	the	model	less	useful	outside	the	clinical	setting.	The	advances	in	point-of-care	testing	and	BG	monitoring,	coupled	with	the	recent	trends	in	personal	health	devices	[280–283]	further	stipulate	the	inclusion	of	BG	 measurements	 in	 the	 DM	 risk	 stratification	 systems	 of	 the	 future.	 The	 models	developed	in	this	chapter	consider	BG	information,	where	available.	
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 The	data	
6.2.1 Overview	
The	 data	 acquisition	 was	 funded	 by	 the	 National	 Institute	 for	 Health	 Research	 in	accordance	with	the	study	protocol	 [90].	The	data	were	obtained	through	the	Clinical	Practice	Research	Datalink	(CPRD)	and	stored	on	the	University	of	Oxford	servers.	The	data	 contained	 information	 on	 the	 incidence	 of	 type	 2	 DM	 diagnosis	 and	 associated	baseline	indicators	spanning	a	20-year	period	from	1/1/1993	to	31/10/2013.	100,000	anonymised	EMR	were	 requested	 from	primary	 care	 practices;	 these	were	 randomly	distributed	within	CPRD	in	order	to	best	represent	the	wide	UK	demographic.		Patients	who	had	already	been	diagnosed	with	DM	(either	type	1	or	type	2)	were	excluded	from	the	study.	Consistent	with	QDiabetes®,	only	patients	aged	25-79	at	the	date	of	entering	the	study	were	considered.	After	applying	the	exclusion	and	inclusion	criteria,	the	final	study	dataset	comprised	of	79,959	records,	totalling	476,333	person-years.		
In	addition	to	the	variables	considered	in	QDiabetes®	[272],	the	dataset	also	included	biochemical	 data,	 although	 the	 actual	 BG	 levels	 (fasting	 or	 otherwise)	 were	 largely	incomplete	 or	 obsolete	 (collected	 more	 than	 5	 years	 prior	 to	 the	 index	 date).	 	 The	incidence	 of	 gestational	 diabetes	 among	 women	 in	 the	 study	 was	 less	 than	 0.01%	providing	too	few	(77)	events	to	be	reliably	included	in	the	model.	Hence,	the	following	11	variables	were	used	as	model	input:	
• continuous:	patient’s	age	(years)	and	Townsend	score	(dimensionless),	most	recent	at	the	index	date	BMI	(kg/m2)	and	BG	(mmol/L)	measurements		
• binary:	 presence	 (1)	 or	 absence	 (0)	 of	 diabetic	 family	 history,	 incidents	 of	cardiovascular	 disease	 (CVD),	 treatment	 for	 hypertension,	 prescription	 of	corticosteroids	(steroid),	and	smoking	history	(smoker)	
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• nominal:	 gender	 (1=Male,	 2=Female)	 and	 ethnicity	 (1=White,	 2=Asian,	3=Black,	4=Mixed,	5=Other)	
The	outcome	variable	was	a	binary	result	of	type	2	DM	diagnosis	at	the	end	of	the	study	(0=	non-diabetic,	1=diabetic	or	missing).	The	duration	(days)	from	the	index	date	to	the	study	 end	 date	 or	 to	 the	 type	 2	 DM	 diagnosis	 date	 was	 also	 considered	 in	 survival	analysis.	 It	 is	 important	 to	note	 that	 the	diagnosis	 of	 type	2	DM	 is	merely	an	 indirect	measure	of	whether	the	person	did	or	did	not	have	type	2	DM.	The	cases	of	undiagnosed	DM	abound	as	illustrated	in	Section	6.2.2.4.	
Table	6.1	CPRD	data:	descriptive	statistics	across	the	derivation	and	validation	cohorts	Variables	Statistic	 Derivation	cohort	 Validation	cohort	Patient	N	 53306	 26653	Person	years	Mean	(std)	 6.0	(3.7)	 5.9	(3.7)	Diagnosed	type	2	DM	N		 1585	 828	Gender	female	N	(%)	 26608	(49.9)	 13260	(49.8)	Age	(years)	Mean	(std)	 44.5	(14.7)	 44.4	(14.7)	BMI	recorded	N	(%)	 30722	(57.6)	 15236	(57.2)								BMI	(kg/m2)	Mean	(std)			 26.2	(5.1)	 26.2	(5.1)	Any	blood	glucose	recorded	N	(%)	 13879	(26.0)	 7021	(26.3)								Fasting	BG	(mmol/L)	Mean	(std)	 5.1	(0.8)	 5.1	(0.8)								Random	BG	(mmol/L)	Mean	(std)	 5.1	(1.0)	 5.1	(1.0)	Townsend	score	Mean	(std)	 -0.5	(2.9)	 -0.5	(2.9)	Ethnicity	 	 								White	N	(%)	 50755	(95.2)	 25416	(95.4)								Asian	N	(%)	 1308	(2.5)	 626	(2.3)								Black	N	(%)	 564	(1.1)	 262	(1.0)								Mixed	N	(%)	 265	(0.5)	 147	(0.6)								Other	N	(%)	 414	(0.8)	 202	(0.8)	Smoker	N	(%)	 12383	(23.2)	 6292	(23.6)	Family	history	of	DM	N	(%)	 3331	(6.2)	 1678	(6.3)	History	of	CVD	N	(%)	 2157	(4	.0)	 1100	(4.1)	Treated	for	hypertension	N	(%)	 5288	(9.9)	 2604	(9.8)	Prescribed	steroids	N	(%)	 1346	(2.5)	 699	(2.6)		The	 data	 were	 divided	 randomly	 into	 derivation	 and	 validation	 cohorts:	 1/3	 of	 the	records	were	held	for	the	purposes	of	model	validation	(also	referred	to	as	‘test’	cohort),	
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and	 the	 remaining	 records	were	made	 available	 for	model	 development.	 Descriptive	statistics	across	the	derivation	and	validation	cohorts	are	presented	in	Table	6.1.		
This	 CPRD	 data	 were	 gathered	 by	 general	 practitioners	 and	 practice	 nurses	 during	routine	patient	visits	and	reflect	the	broader	challenges	of	routinely	collected	data.	The	sources	of	this	complexity	are	discussed	in	Section	6.2.2	with	illustrative	examples	from	the	79,959-sample	dataset	used	in	this	study.			
6.2.2 The	4	“C”s	of	routinely	collected	data	
6.2.2.1 Complexity	
Routinely	 collected	 data	 carry	 broad,	 often	 overlapping	 and	 at	 times	 contradictory	information	about	a	patient’s	health	and	is	inherently	complex.		
The	variety	of	possible	underlying	physiological	interactions	between	causal,	correlated	and	cofounded	factors	in	life-long	conditions	such	as	type	2	DM	are	not	fully	established.	Type	 2	 DM	 presents	 an	 intricate	 interplay	 of	 genetic	 predisposition	 and	 metabolic	processes,	where	unhealthy	diet,	smoking,	obesity,	and	physical	inactivity	combine	with	previous	 gestational	 DM,	 ethnicity,	 and	 older	 age.	 	 The	 direct	 and	 indirect	 indicators	recorded	in	the	electronic	medical	system	at	the	point	of	care	may	not	capture	all	of	this	complexity.	This	is	evident	from	retrospective	analysis	of	large	patient	databases,	where	a	number	of	patients	may	match	across	all	variables	of	 interest,	yet	 their	10-year	DM	outcome	may	differ.		
For	example,	among	the	records	in	this	study,	there	were	two	31-year	old	white	male,	non-smoking	patients	with	an	almost	identical	healthy	body	mass	(BMI	of	19.2	and	19.7),	from	 equally	 prosperous	 demographic	 areas	 (Townsend	 decile	 score	 of	 –2.17)	 and	identically	absent	histories	of	hypertension,	cardiovascular	disease,	family	DM,	previous	
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BG	measurement	or	treatment	with	steroids	at	the	time	of	joining	the	study.	Despite	their	profiles	matching	across	all	10	of	the	parameters	considered,	the	two	men	experience	opposite	outcomes:	one	goes	on	to	develop	DM	and	is	diagnosed	with	type	2	DM	after	3.5	years,	 while	 the	 other	 leaves	 the	 study	 after	 10	 years	 without	 DM.	 Such	 apparent	contradictions	are	abundant	in	the	dataset,	indicating	from	the	start	of	the	study	that	the	variables	available	for	analysis	do	not	contain	all	the	necessary	information	required	for	modelling	the	disease.	
6.2.2.2 Completeness	(or	the	lack	of)	
Routinely	collected	patient	data	could	be	described	as	sparse,	with	values	missing	across	a	 range	 of	 variables.	 The	 level	 of	 completeness	 depends	 on	 the	 mechanism	 through	which	the	data	were	collected.	For	instance,	in	the	CPRD	dataset	[90]	the	patient’s	date	of	birth	and	gender	were	known	in	all	instances,	since	the	medical	record	would	not	have	been	instantiated	without	the	two	variables.	For	variables	that	represent	conditions	or	comorbidities	that	require	diagnosis	or	clinical	intervention,	such	as	CVD,	treatment	for	hypertension,	or	prescription	for	steroids,	missing	values	imply	their	absence	and	could	be	reliably	substituted	by	zero.		
More	uncertainty	 is	 present	 around	 variables	 that	 rely	 on	patient	 disclosure,	 such	 as	ethnicity,	smoker	status	or	family	history	of	diabetes.	Among	79,959	records,	13%	did	not	have	smoking	status	on	record.	 	Family	history	of	diabetes	was	missing	 in	all	but	positive	cases	(9%).	Ethnicity	was	not	recorded	in	70%	of	patients.	Customarily,	these	missing	values	would	be	left	as	missing,	imputed	statistically	or	the	entire	patient	record	would	 be	 omitted	 from	 the	 study	 [17,284,285].	 Instead,	 in	 this	 collaborative	 study,	domain	 knowledge	 of	 practicing	 healthcare	 professionals	 and	 clinical	 statisticians	[90,286–288]	was	enlisted	to	deduce	the	missing	values	based	on	the	mechanisms	by	which	the	samples	were	recorded.		It	was	decided	to	treat	missing	family	history	of	DM	
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as	absent	(0),	unrecorded	ethnicity	as	“White”	(1),	and	to	give	benefit	of	the	doubt	to	the	unknown	smokers	 (0	 if	missing).	These	 subjective	assumptions	generate	noise	 in	 the	data,	which	adds	to	the	challenge	of	modelling	with	limited	and	uncertain	information.	
The	final	category	of	missing	input	variables	are	continuous	variables	such	as	BMI,	and	blood	 plasma	 glucose	 level:	 fasting	 (FBG)	 or	 random	 (BG).	 Any	 BMI,	 FBG	 and	 BG	measurements	 available	 up	 to	 5	 years	 prior	 to	 the	 index	 date	 were	 included	 in	 the	analysis.	Despite	this	generous	threshold,	the	measurements	were	grossly	missing:	BMI	indications	were	absent	in	43%,	BG	-	in	79%,	and	FBG	–	in	93%	of	the	patient	records	(Figure	6.1).	
		
Figure	6.1	Venn	diagram	representing	the	number	of	recorded	BMI	(aqua),	BG	(blue),	FBG	(green)	and	the	
union	of	BG	and	FBG	(red	contour)	as	a	proportion	of	the	entire	available	dataset	(white	rectangle).	The	
diagram	is	annotated	with	the	actual	numbers	of	the	records	corresponding	to	each	subset.	The	areas	of	the	
figures	are	drawn	to	scale.		Evidently,	the	FBG	was	too	scarce	to	be	reliably	incorporated	into	the	model	on	its	own.	Furthermore,	for	a	healthy	patient	a	fasting	blood	glucose	test	is	expected	to	yield	a	more	conservative	mmol/L	value	than	a	measurement	taken	at	an	arbitrary	point	in	the	day,	
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yet	it	can	be	noted	from	Table	6.1	that	the	mean	and	standard	deviation	of	the	BG	and	FBG	are	surprisingly	similar.	A	closer	analysis	revealed	that	indeed	the	distributions	of	the	BG	and	FBG	(Figure	6.2)	are	identical	(p-value	>	0.05,	Wilcoxon	rank	sum	test)	
	
Figure	6.2	Distributions	of	FBG	and	BG	values	Hence	BG	and	FBG	were	aggregated	into	a	single	predictor,	such	that:	
ΩëCE∫ = ¶Ωë,													QZ	¶Ωë	QN	å2m82																																				Ωë,																QZ	¶Ωë	QN	®QNNQ2n, Ωë	QN	å2m82							O2æ"ZQ2"æ, QZ	2"Q1ℎ"5Ωë	2m5	¶Ωë	P5"	å2m82			,	
yielding	 a	 new	 variable	with	 a	mean	 of	 5.1	mmol/L	with	 a	 standard	 deviation	 of	 0.9	mmol/L.	 This	 new	 BG	was	 known	 for	 only	 26%	 of	 the	 patients;	 a	 separate	 variable,	ΩëbE™,	was	set	to	0	for	the	remaining	74%	of	patients	for	whom	no	BG	nor	FBG	levels	
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were	 known.	When	 known,	 BG	 levels	 were	 significantly	 different	 (p-value	 <	 0.0001,	Figure	6.3)	 in	patients	diagnosed	with	type	2	DM	by	the	end	of	the	10	years	(diabetic	outcome	group,	median	BG	5.8	mmol/L)	 and	 those	who	would	have	exited	 the	 study	without	a	diabetes	diagnosis	(non-diabetic	outcome	group,	median	BG	5.0	mmol/L).		
	
Figure	6.3	Wilcoxon	rank	sum	test	for	medians	for	BG	values	in	DM,	non-DM	and	unknown	outcome	groups.			6.2.2.3 Censoring	
Another	type	of	missing	data	is	where	the	outcome	variable	is	unknown.	In	primary	care,	this	may	happen	when	a	patient	leaves	the	practice	before	the	end	of	the	longitudinal	study.	 The	 loss	 of	 follow-up	 is	 arguably	 the	most	 defining	 characteristic	 of	 routinely	collected	data.	Over	63%	of	the	patients	studied	in	this	work	left	the	study	before	the	end	of	10	years.	The	CPRD	dataset	contained	the	date	of	when	the	patient	left	the	practice	and	the	variable	“reason	for	transferring	out”,	which,	among	others,	included	death.	It	is	
unknown	whether	 those	 transferred-out	 patients	 (apart	 from	 those	who	 died)	would	have	been	diagnosed	with	type	2	DM	or	remained	disease-free	by	the	end	of	the	10	years.		
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Loss	of	follow-up	and,	therefore,	the	ability	to	ascertain	what	outcome	would	have	been	developed	by	a	patient	if	they	remained	in	the	study,	results	in	right-censored	records.	Censoring	 further	 reduces	 the	 number	 of	 records	 for	 conventional	 modelling	 with	supervised	 machine-learning	 algorithms,	 which	 inherently	 rely	 on	 known	 outcome	labels	for	training.	Let	us	recount	the	proportion	of	available	samples	with	BMI	and	BG	present	in	the	Venn	diagram	in	Figure	6.1,	taking	into	account	censoring.	The	resulting	Figure	6.4	demonstrates	the	“big	picture”	of	the	combined	effect	of	censoring	and	missing	BMI	and	BG	measurements	on	limiting	the	samples	available	for	supervised	modelling.			
	
Figure	6.4	Area	diagram	representing	the	number	of	samples	with	known	10-year	follow-up	(left)	and	
unknown	outcome	(right),	separately	in	validation	(top)	and	derivation	(bottom)	cohorts.	The	areas	of	the	
rectangles	are	drawn	in	proportion	to	their	populations.		6.2.2.4 Consistency	
Despite	numerous	attempts	 toward	standardisation,	 the	distributed	nature	of	general	practices	makes	primary	care	data	prone	to	institutional	bias:	from	one	clinic	to	another	(inter-institutional	bias),	 from	one	nurse	 to	another	 (intra-institutional	bias),	or	 from	one	 day	 to	 the	 next.	 This	 determines	 if	and	when	 certain	 baseline	 characteristics	 are	recorded	[285].	Moreover,	how	those	indicators	are	interpreted	also	depend	on	when,	
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where	and	by	whom	the	patient	was	seen	[289].	Whilst	it	is	not	the	primary	goal	of	this	research	 to	 quantify	 the	 various	 inter-	 and	 intra-centre	 biases,	 it	 is	 important	 to	acknowledge	that	inevitable	inconsistencies	influence	why	the	likelihood	of	BG	and	BMI	values	being	recorded	differs	among	DM	and	non-DM	groups,	and	why	some	patients	with	BG	levels	meeting	diagnostic	criteria	remain	undiagnosed	for	several	years.	
Firstly,	the	existence	of	bias	in	a	variable	being	recorded	for	patients	of	different	outcome	groups	directly	affects	the	utility	of	statistical	techniques	such	as	multiple	imputation	on	that	variable	(Section	3.1.3).	Table	6.2	illustrates	that	patients	who	went	onto	develop	type	2	DM	were	found	1.5	times	more	likely	to	have	their	BG	levels	measured.	Existence	of	a	BG	record	was	biased	towards	patients	in	the	DM-outcome	group	versus	non-DM	and	 unknown	 outcome	 groups.	 Whilst	 the	 mechanism	 by	 which	 a	 patient	 might	 be	referred	for	a	BG	test	was	unobservable	from	existing	data,	the	bias	indicated	that	BG	variable	 violated	 the	 Missing	 at	 Random	 (MAR)	 assumption	 required	 for	 multiple	imputation.	On	the	other	hand,	the	existence	of	a	BMI	record	was	as	 likely	 in	patients	who	would	develop	type	2	DM	as	in	patients	who	transfer	out	without	a	diagnosis.	The	absence	of	a	significant	bias,	coupled	with	a	larger	proportion	of	known	values	(57%)	provided	sufficient	ground	to	impute	BMI.	
Table	6.2	Frequency	of	BG	and	BMI	being	recorded	for	the	whole	cohort	and	separately	for	DM,	non-DM	and	
unknown	outcome	groups.	
Cohorts:	 all	 DM	 non-DM	 unknown	Is	BG	measured	uniformly	among	DM,	non-DM	and	unknown	outcome	groups?	#	samples	 79959	 2413	 26889	 50657	#		recorded	BG	 20900	 1072	 7419	 12409	%	 26%	 44%	 28%	 24%	Is	BMI	measured	uniformly	among	DM,	non-DM	and	unknown	outcome	groups?	#	samples	 79959	 2413	 26889	 50657	#		recorded	BMI	 45958	 1463	 12576	 31919	%	 57%	 61%	 47%	 63%	
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Secondly,	patients	with	BG	levels	meeting	diagnostic	criteria	may	remain	undiagnosed	due	to	inconsistencies	in	the	interpretation	of	already	existing	records	and/or	the	lack	of	monitoring	of	patients	at	risk.	Recent	studies	demonstrated	that	cases	of	undiagnosed	
type	 2	 DM	were	more	 common	 than	 previously	 acknowledged	 [286,287].	 Among	 the	patients	 analysed	 in	 this	 work,	 20900	 individuals	 had	 either	 their	 BG	 or	 FBG	 levels	recorded	at	least	once	within	5	years	before	entering	the	study.	The	records	indicate	that	for	150	of	these	patients	the	BG	or	FBG	levels	had	been	above	their	diagnostic	criteria	(Section	6.1.1)	at	the	index	date.	Table	6.3	traces	the	outcomes	for	these	patients	with	undiagnosed	diabetes	over	the	next	10	years.	
Table	6.3	Patients	with	undiagnosed	type	2	DM	prior	to	the	study	and	their	outcomes.	
Patients/year		 0	yr	 1	yr	 2	yr	 3	yr	 4	yr	 5	yr	 6	yr	 7	yr	 8	yr	 9	yr	 10	yr	N	remaining	in	the	study	 150	 130	 116	 103	 89	 85	 80	 75	 70	 60	 59	N	diagnosed	 0	 28	 36	 42	 44	 46	 48	 49	 51	 51	 53	N	remaining	undiagnosed	 150	 102	 80	 61	 45	 39	 32	 26	 19	 9	 6	%	undiagnosed	 	 78%	 62%	 53%	 44%	 44%	 38%	 33%	 25%	 13%	 10%		Out	 of	 the	 150	 patients	 who	 already	 had	 records	 of	 BG	 ≥11.1	 mmol/L	 or	 FBG	 ≥7.0	mmol/L	before	entering	 the	study,	only	28	would	be	diagnosed	by	 the	end	of	year	1,	meaning	 that	 78%	 of	 the	 undiagnosed	 patients	 would	 remain	 without	 a	 record	 of	diagnosis	with	type	2	DM	throughout	their	1st	year	in	the	study.	By	the	end	of	the	5th	year,	46	 out	 of	 the	 initial	 150	 patients	were	 given	 a	 diagnosis.	 Since	 some	 of	 the	 patients	transferred	 out,	 the	%	 undiagnosed	 (44%)	was	 calculated	 relative	 to	 the	 number	 of	patients	from	the	undiagnosed	cohort	still	remaining	in	the	study	(89).	At	the	10th	year,	10%	of	the	cohort	still	remaining	in	the	study	(59)	would	have	exited	the	study	without	ever	being	given	a	diagnosis.	 	These	estimations	only	accounted	for	patients	who	had	been	at	least	once	referred	for	a	BG	test	prior	to	the	study	start	date.	The	true	extent	of	cases	with	undiagnosed	DM	is	unknown,	since	over	70%	of	patients	in	the	study	had	no	BG	measurements.			
Chapter	6.		Diabetes	type	2	risk	stratification	from	routinely	collected	NHS	data	
136	
Finally,	the	loss	of	 follow-up	in	itself	could	be	biased.	This	happens	for	 instance	when	patients	 die	 due	 to	 complications	 of	 a	 condition,	 or	 they	 transfer	 out	 to	 a	 different	location	to	access	better	treatment.	Some	patients	may	re-enter	at	the	same	or	different	practice,	during	which	they	might	be	assigned	a	new	ID	number.	The	fact	that	the	impact	of	 these	 inconsistencies	on	 the	quality	of	 the	data	would	 remain	unquantified,	makes	working	with	routinely	collected	data	both	more	challenging	and	rewarding.	
 The	models	
The	 research	 task,	 to	 predict	 10-year	 incidence	 of	 type	 2	 DM,	 was	 approached	 with	survival	and	classification	models.	The	survival	models	included	the	classical	Cox	PH	and	ML-based	survival	DT	algorithm.		The	classification	models	considered	were:	small-data	NN,	LR,	and	NN	ensembles.	
In	 order	 to	 investigate	 whether	 or	 not	 the	 inclusion	 of	 BG	 data	 could	 improve	 the	accuracy	of	the	prognosis,	the	models	were	considered	in	two	settings:	with	and	without	BG	data.	The	predicted	output	was	 intended	 to	be	a	 continuous	variable	 [0	 to	1]	 that	represented	the	probability	of	developing	type	2	DM	by	the	end	of	10	years.	The	true	outcome	was	the	binary	variable	[0	or	1]	corresponding	to	being	diagnosed	with	type	2	DM	 (1)	 or	 being	 diagnosis-free	 (0)	 by	 the	 end	 of	 10	 years.	 In	 order	 to	 analyse	 the	confusion	matrices	and	corresponding	sensitivity	and	specificity	values,	the	continuous	predicted	 outcome	 was	 dichotomised	 into	 a	 binary	 variable.	 The	 threshold	 for	 this	conversion	was	set	to	the	75th	percentile,	in	order	to	account	for	the	model	sensitivity	to	large	class	imbalance	in	the	true	outcomes	(Section	6.4).	No	dichotomising	was	required	for	the	computation	of	concordance	measures,	which	operated	on	continuous	outputs.		
The	derivation	cohort	applicable	for	a	given	model	differed	from	one	model	to	another,	due	 to	 the	 varying	 limitations	 and	 advantages	 of	 each	 model.	 In	 order	 to	 ensure	
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consistent	comparisons	among	the	NN	ensemble,	Cox	PH,	Survival	DT	and	LR	models,	they	were	evaluated	on	the	same	cohort	of	26653	patients,	unaltered	and	as	originally	sampled.		
6.3.1 Cox	proportional	hazards	model	
Designed	to	handle	censored	samples,	a	Cox	PH	model	was	developed	with	the	entire	derivation	cohort	of	53306	samples,	 including	all	of	the	1585	DM,	17907	non-DM	and	33814	 unknown	 outcome	 records	 available	 for	 the	 model	 derivation.	 The	 model	presented	here	is	the	prototype	version	of	the	Cox	PH	model	developed	in	collaboration	with	 the	 Oxford	 group	 [90]	 which	 was	 derived	 separately	 for	 men	 and	 women	 and	included	time-varying	coefficients	and	multiple	polynomial	terms.	Despite	the	difference	in	complexity,	this	prototype	achieved	the	same	(to	2	decimal	places)	concordance	and	prognostic	 performance	 as	 the	 average	 of	 the	 male	 and	 female	 benchmark	 Cox	 PH	models.	 In	 accordance	with	 the	 collaboration	protocol	 [90],	missing	BMI	values	were	imputed	 using	 the	 MICE	 [290]	 with	 100	 iterations	 and	 the	 missing	 BG	 values	 were	imputed	 zero,	 and	 additional	 variable	 ΩëbE™	was	 supplied	 to	 indicate	 presence	 or	absence	of	BG	values.	
The	 resulting	 model	 provided	 the	 hazard	 of	 the	 event	 “diagnosis	 with	 type	 2	 DM”	happening	relative	to	the	baseline	hazard	'((1),	and	took	the	following	form:		
	 ' 1'( 1 = " #úüúo#öüöo	⋯	#øüø 	 "].	6.1	
where	:	are	predictor	variables	and	!	are	the	estimated	model	parameters.	The	values	of	!	and	corresponding	hazard	ratio	(HR)	"# 		for	the	variables	:	in	the	Cox	PH	models	with	and	without	the	inclusion	of	BG	are	provided	in	Tables	6.4	and	6.5	respectively.		
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Table	6.4	Cox	PH	model	without	blood	glucose	information	Variable	:	 Coefficient	!	 Hazard	ratio	"# 	 95%	CI	 p-value	lower	 upper	Gender	female	 -0.581	 0.559	 0.505	 0.620	 <0.001	Age	(years)	 0.039	 1.040	 1.035	 1.044	 <0.001	Family	history	of	DM	 0.509	 1.664	 1.378	 2.010	 <0.001	CVD		 0.337	 1.401	 1.195	 1.643	 <0.001	BMI	(kg/m2)	 0.130	 1.139	 1.130	 1.147	 <0.001	Hypertension	 0.452	 1.572	 1.396	 1.771	 <0.001	Ethnicity	“Asian”	 0.996	 2.707	 1.988	 3.688	 <0.001	Ethnicity	“Black”	 0.246	 1.279	 0.764	 2.140	 0.349	Ethnicity	“Mixed”	 0.087	 1.091	 0.453	 2.627	 0.846	Ethnicity	“Other”	 1.060	 2.886	 1.845	 4.516	 <0.001	Prescribed	steroids	 0.279	 1.321	 1.061	 1.646	 0.013	Smoker	 0.291	 1.338	 1.187	 1.507	 <0.001	Townsend	score	 0.064	 1.066	 1.049	 1.083	 <0.001		
Table	6.5	Cox	PH	model	with	blood	glucose	information	Variable	:	 Coefficient	!	 Hazard	ratio	"# 	 95%	CI	 p-value	lower	 upper	Gender	female	 -0.533	 0.587	 0.530	 0.651	 <0.001	Age	(years)	 0.037	 1.038	 1.033	 1.042	 <0.001	Family	history	of	DM	 0.511	 1.666	 1.379	 2.013	 <0.001	CVD		 0.253	 1.288	 1.097	 1.512	 0.002	BMI	(kg/m2)	 0.125	 1.133	 1.124	 1.142	 <0.001	Hypertension	 0.393	 1.481	 1.311	 1.674	 <0.001	Ethnicity	“Asian”	 0.874	 2.397	 1.760	 3.265	 <0.001	Ethnicity	“Black”	 0.302	 1.353	 0.809	 2.263	 0.250	Ethnicity	“Mixed”	 0.059	 1.061	 0.441	 2.557	 0.895	Ethnicity	“Other”	 1.051	 2.861	 1.829	 4.474	 <0.001	Prescribed	steroids	 0.218	 1.243	 0.998	 1.549	 0.053	Smoker	 0.318	 1.375	 1.220	 1.549	 <0.001	Townsend	score	 0.060	 1.062	 1.045	 1.080	 <0.001	BG	recorded	 -2.472	 0.084	 0.064	 0.112	 <0.001	BG	level	(mmol/L)	 0.483	 1.621	 1.552	 1.694	 <0.001		The	inclusion	of	BG	information	improved	the	prognostic	ability	of	the	model	from	?-index	= 0.809	 to	?-index	= 0.825	 on	 the	model	development	 cohort.	When	validated	with	the	independent	test	cohort	of	26653	samples,	the	Cox	model	without	BG	performed	
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with	?-index	= 0.817,	 73%	 sensitivity	 and	 74%	 specificity.	 The	 Cox	 model	with	 BG	achieved	?-index	= 	0.832,	and	was	able	to	correctly	stratify	76%	of	DM	and	74%	non-DM	groups	among	patients	with	known	outcomes.		
According	to	the	baseline	Cox	model	without	BG	levels,	the	highest	risk	factors	(HR	≥		1.5)	were:	ethnicity	“Asian”	and	“Other”,	male	gender,	presence	of	family	history	of	DM,	and	history	of	being	 treated	 for	hypertension.	 	The	 control	 group	were	patients	with	ethnic	 origin	 “White”,	 no	 family	 history	 of	 DM,	 and	 no	 history	 of	 hypertension	respectively.	 All	 variables,	 apart	 from	 those	 with	 small	 representation	 in	 the	 cohort	(ethnicity	“Black”	or	“Mixed”,	use	of	steroids)	were	statistically	significant.	
Inclusion	of	BG	information	marginally	reduced	the	HR	of	being	treated	for	hypertension	to	below	1.5.	The	Cox	model	with	BG	confirmed	the	hypothesis	that	elevated	BG	levels	were	a	high-risk	factor	for	type	2	DM.		Surprisingly,	the	presence	of	BG	measurements	was	negatively	associated	with	type	2	DM,	which	could	be	due	to	the	information	overlap	of	 BG	 levels	 with	 BG	 presence.	 To	 examine	 this	 further,	 a	 third	 Cox	 PH	 model	 was	developed	 to	 include	 only	 the	 binary	 variable	 for	 BG	 presence	 (without	 the	corresponding	BG	levels).	The	model	was	largely	similar	to	the	one	presented	in	Table	6.4,	with	the	additional	positive	association	(¿J	=1.212)	of	having	BG	recorded	with	the	type	2	DM	diagnosis	(p-value	<0.001),	which	contradicted	the	findings	in	Table	6.5,	thus	necessitating	 further	 investigation	 with	 models	 that	 could	 prove	 less	 sensitive	 to	correlated	cofactors.		
Combined,	these	findings	demonstrated	that:	
• Inclusion	of	BG	measurements	increased	the	prognostic	value	(?-index)	of	the	Cox	PH	model	from	0.809	to	0.825.	
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• Patients	of	“Asian”	and	“Other”	ethnic	origin,	patients	of	male	gender,	patients	with	 an	 existing	 family	 history	 of	 DM	 or	 a	 history	 of	 being	 treated	 for	hypertension,	and	patients	with	elevated	BG	levels	had	an	over	1.5	times	higher	risk	of	developing	type	2	DM	than	the	control	group.	
• The	relative	importance	of	the	variables	remained	inconclusive.	
6.3.2 Neural	network	ensemble	
The	NN	model	was	stipulated	by	the	CPRD	study	protocol	[90]	and	formed	a	pivotal	part	of	 this	work	with	over	1,200,000	NNs	 implemented	and	evaluated	during	 the	various	exploratory	and	model	development	stages,	amounting	to	over	138	days	of	simulation	time	alone.	As	a	result	of	this	extensive	study,	the	model	evolved	from	a	multi-node	NN	to	an	ensemble	of	100	two-layer	NNs,	where	a	single	neuron	in	the	hidden	layer	formed	a	‘bottle	neck’.		
The	model	was	trained	with	1585	DM	and	17907	non-DM	examples,	and	was	validated	on	an	independent	cohort	of	26653	patients.	With	the	ratio	of	minority	(DM	outcome)	to	majority	 (non-DM	 outcome)	 examples	 being	 approximately	 1:11,	 the	model	 suffered	from	vast	class	 imbalance	and	 initially	 failed	 to	 learn	minority	class	associations.	The	class	 imbalance	 problem	 was	 later	 addressed	 by	 combining	 ensemble	 learning	 with	majority	undersampling	as	follows:	
a) Divide	the	majority	class	into	10	non-overlapping	subsets		b) Use	one	of	the	majority	class	subsets,	plus	all	minority	class	samples	to	train	10	individual	NNs	c) Repeat	(b)	for	the	remaining	9	majority	class	subsets	to	produce	100	NNs	d) Combine	the	NNs	into	an	ensemble	by	averaging	
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It	is	important	to	emphasise	that	the	above	balancing	strategy	was	only	applied	to	the	model	derivation	 cohort,	whilst	 the	26653	validation	 cohort	 samples,	with	which	NN	ensemble	was	subsequently	tested,	retained	its	original	class	imbalance.		
Also	considered	was	minority	oversampling	with	ADASYN,	where	over	17000	synthetic	DM	 samples	 were	 created	 to	 match	 the	 number	 of	 non-DM	 samples;	 however,	 no	increase	 in	performance	over	the	proposed	strategy	with	the	majority	undersampling	was	observed.	
The	individual	NNs	in	the	ensemble	were	trained	with	a	scaled	conjugate	gradient	(SCG)	backpropagation	algorithm	(Appendix	A.2),	which	offered	higher	robustness,	albeit	at	slower	 computation	 speed	 than	 the	 Levenberg-Marquardt	 backpropagation	implemented	with	multiple	runs	strategy	in	Chapters	3	and	4.	The	two-layer	architecture	using	a	tan-sigmoid	function	in	the	hidden	layer	and	log-sigmoid	function	in	the	output	layer	was	developed	to	provide	as	much	separation	between	low-DM-risk	and	high-DM-risk	patients	in	the	interval	between	0	and	1.	The	cost	function	used	was	cross	entropy	between	 predicted	 risk	 and	 known	 binary	 outcome.	 For	 the	 purpose	 of	 computing	confusion	matrices,	 and	 the	 corresponding	 sensitivity	 and	 specificity	 values,	 a	 binary	version	of	the	predicted	outcome	was	generated	from	the	continuous	risk	value	using	a	threshold	set	at	0.5.	This	was	different	from	the	75th	percentile	threshold	used	with	Cox	PH,	since	each	NN	in	the	ensemble	was	trained	with	balanced	data.	
Four	 core	 data	 models	 representing	 various	 degrees	 of	 BG	 completeness	 were	investigated:		
1) without	any	BG	levels	(“no	BG”)		2) with	BG	presence	and	aggregate	BG	levels	imputed	zero	if	missing	(“BG	new”)	3) with	aggregate	BG	levels	imputed	with	MICE	if	missing	(“BG	imputed”)		
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4) with	random	BG	and	FBG	imputed	with	MICE	if	missing	(“BG	and	FBG	imputed”)	
Their	corresponding	performance	on	the	26653	independent	test	samples	is	provided	in	Table	 6.6.	 The	 classification	measures,	 i.e.	 sensitivity		M2,	 specificity	M3,	 and	 balanced	accuracy	?@ABACDEF ,	were	evaluated	on	9810	samples	with	known	outcomes.		
Table	6.6	NN	ensemble	performance:	concordance	and	classification	measures	
NN	ensemble	models	 ?-index	 95%	CI	 M3	 M3	 ?¡¬√¬ƒ≈∆«	lower	 upper	no	BG	 0.829	 0.816	 0.842	 0.629	 0.835	 0.732	BG	new	 0.847	 0.834	 0.860	 0.722	 0.807	 0.765	BG	imputed	 0.901	 0.891	 0.911	 0.798	 0.866	 0.832	BG	and	FBG	imputed	 0.929	 0.920	 0.938	 0.855	 0.887	 0.871		The	 first	 two	models	 (“no	BG”	 and	 “BG	new”)	 correspond	 to	 the	 two	Cox	PH	models	described	in	Section	6.3.1.		As	with	Cox	PH,	the	inclusion	of	BG	values	improved	the	NN	ensemble	performance	on	the	validation	cohort	from	?-index	= 	0.829	to	0.847.	Unlike	Cox	 PH,	 ensemble	 learning	 makes	 NNs	 largely	 a	 “black-box”	 system	 with	 no	 direct	interpretation	of	variable	importance	[21,291].		
The	two	latter	models	revealed	a	substantial	increase	in	?-index	performance:	0.901	for	“BG	imputed”	and	0.929	for	“BG	and	FBG	imputed”.	 In	other	words,	 the	NN	ensemble,	when	using	information	on	both	BG	and	FBG	values,	was	able	to	predict	the	10-year	type	2	DM	outcome	with	nearly	93%	accuracy	and	12%	more	reliably	than	the	model	without	BG.	This	finding,	initially	thrilling,	was	dismissed	following	further	consideration.	Firstly,	the	imputed	models	relied	on	the	vast	proportion	of	the	BG	(nearly	80%	missing)	and	FBG	(over	93%	missing)	values	being	synthetically	generated	by	MICE.	Secondly,	since	the	MICE	imputation	model	was	developed	separately	for	the	DM	and	non-DM	groups,	it	was	 possible	 that	 the	 NN	 was	 able	 to	 decode	 the	 DM	 and	 non-DM	 groups	 from	 the	imputed	 BG	 and	 FBG	 variables.	 Finally,	when	 re-evaluated	 on	 only	 non-imputed	 test	
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samples	(2 = 625),	the	performance	of	the	model,	at	?-index	= 	0.796,	proved	inferior	than	 that	 of	 “no	 BG”	model.	 This	 decrease	 in	 performance	 was	 due	 to	 false	 positive	samples:	i.e.	the	sensitivity	remained	high	(83%),	but	specificity	fell	to	56%,	resulting	in	70%	balanced	accuracy.	Combined,	these	outcomes	indicated	the	deceptive	effectiveness	of	imputed	data,	and	precluded	the	use	of	MICE	with	NNs	on	data	where	the	proportion	of	missing	values	is	as	high	as	80-90%.	
To	summarise,	it	has	been	demonstrated	that:	
• The	proposed	approach	of	combining	majority	undersampling	with	ensemble	learning	 offered	 a	 simple	 and	 effective	 solution,	 of	 which	 the	 performance	exceeded	that	of	state-of-the-art	synthetic	minority	oversampling	techniques.	
• The	prognostic	value	of	the	NN	ensemble	was	improved	with	the	inclusion	of	BG	measurements,	from	?-index	of	0.829	to	0.847.	
• The	 dramatic	 12%	 improvement	 to	 ?-index	 = 0.929	 achieved	 by	 the	 NN	ensemble	with	synthetically	imputed	BG	and	FBG	was	deemed	unreasonable	-	a	finding	that	revealed	the	pitfalls	of	applying	multiple	imputation	to	data	with	over	80%	missing	values.		
6.3.3 Small-data	neural	network		
One	frequently	overlooked	aspect	of	modelling	with	sparse	samples	is	that	of	a	complete-case	scenario.	The	research	question	investigated	in	this	section	was	whether	or	not	a	well-generalising	NN	could	be	developed	with	a	small,	but	high-quality	data	subset,	and	if	 so,	what	would	be	 its	 performance	on	 a	 validation	 cohort,	 given	 the	 complete-case	scenario.	
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Out	of	the	79959-patient	dataset,	there	were	only	1415	patients	(918	in	model	derivation	and	497	in	validation	cohorts),	for	whom	BG,	FBG	and	BMI	measurements	were	recorded	at	 least	 once	 during	 5	 years	 prior	 to	 the	 patient	 entering	 the	 study.	 In	 the	 model	derivation	cohort,	521	patients	were	lost	to	follow-up,	effectively	reducing	the	dataset	available	for	supervised	learning	from	over	19000	to	397	samples	(318	non-DM	and	79	DM	 examples).	 Further	 class	 balancing	would	 yield	 a	 training	 dataset	 of	merely	 158	samples.	 With	 less	 than	 7	 event	 observations	 per	 predictor	 variable,	 the	 task	 of	predicting	the	long-term	incidence	of	type	2	DM	becomes	a	small-data	problem.		
	
Figure	6.5	Small-data	performance	over	a	run	of	100	NNs	on	test	and	model	samples	(η=1,	ω=18)		The	development	of	a	NN	model	for	type	2	DM	under	the	small-data	conditions	followed	the	methodological	framework	developed	in	Chapter	3.	The	base	NN	configuration	was	similar	 to	 that	 in	 the	 NN	 ensemble	 discussed	 in	 Section	 6.3.2.	 A	 two-layer	backpropagation	NN	with	12	inputs	and	1	output	was	trained	with	a	SCG	algorithm	in	order	to	optimise	the	cross	entropy	between	predicted	and	output	values.	Early	stopping	
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was	applied	to	reduce	overtraining.	The	classification	performance	of	the	NNs	in	each	run	was	assessed	by	the	median	=>?	(defined	in	Appendix	B)	on	the	model	derivation	cohort	 and,	 separately,	 on	 independent	 tests.	 The	 method	 of	 multiple	 runs	 made	 it	possible	to	evaluate	and	optimise	the	NN	design	parameters	despite	the	output	volatility	due	to	small	data	(Figure	6.5).		
The	hidden	layer	size	η	and	the	training	duration	(as	controlled	by	the	early	stopping	criterion	ω)	were	optimised	in	an	iterative	simulation	involving	280	runs	of	100	NNs.		The	effect	of	-	varying	from	5	to	20	was	highest	at	- = 18,	but	did	not	prove	statistically	significant	(pairwise	p>0.05)	in	comparison	to	other	values	of	ω.		
	
Figure	6.6	The	small-data	NN	design	optimisation:	effect	of	the	hidden	layer	size	on	the	NN	performance	The	hidden	layer	size	varying	from	$	 = 1	to	$	 = 20	had	a	more	pronounced	effect	on	the	NN	performance	(Figure	6.6).	For	the	training	cohort,	the	median	=>?	across	the	run	increased	monotonously	with	the	increasing	$,	since	larger	networks	were	able	to	learn	the	patterns	with	greater	ease	in	the	model	cohort.	Contrary,	the	=>?	for	the	validation	
	derivation	cohort	 	validation	cohort	
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cohort	 was	 highest	 at	 $	 = 1	 and	 decreased	 with	 increasing	$,	 indicating	 that	 the	improvement	observed	in	the	model	performance	was	due	to	overtraining.	The	single	hidden	 layer	 forming	 a	 “bottleneck”	 was	 significantly	 more	 effective	 than	 any	 other	hidden	layer	size	considered	(pairwise	p	<	0.01,	Wilcoxon	rank	sum	test).		
Out	of	 the	100	small-data	NNs	 in	 the	optimal	$ = 1,	- = 18	 run	(Figure	6.5),	 the	best	performing	model	achieved	=>?	=	0.834	on	derivation	cohort	and	=>?=0.804	on	the	207	test	samples	with	known	outcome	(Figure	6.7).		
	
Figure	6.7	The	small-data	NN:	Receiver	operating	characteristic	(ROC)	curves	for	model	derivation	and	
validation	(test)	cohorts	With	$ = 1,	the	input	weights	87 	became	a	12	x	1	vector,	and	the	hidden	layer	bias	. V 		became	a	scalar.	The	resulting	NN	classifier	evaluated	score	0	of	whether	or	not	a	patient	with	 baseline	 indicators	:	would	 develop	 type	 2	DM	 in	 10	 years.	 Its	 output	 equation	could	be	written	as:	
	 0 = SmnNQn(1P2NQn :87 	+ . V 89 	+ .(,))	 "].	6.2	
Substituting	the	 logsig	and	tansig	 functions	(Appendix	A.1)	in	eq.	6.2,	the	output	takes	the	form	of:	
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	 0 = 11 + "»@(ö)»∫…Eq À	ÃÕ ú »Ep q À	ÃÕ úEq À	ÃÕ ú oEp q À	ÃÕ ú 	 "].	6.3	
where	parameters	87, 89, . V ,	and	.(,)	are	determined	during	the	NN	training.	Unlike	in	the	NN	ensemble	model,	in	this	stand-alone	NN	the	weights	could	be	traced	from	each	input	variable	 to	 the	bottle-neck	hidden	 layer	neuron,	 thus	helping	 to	reveal	a	partial	indication	 of	 how	 a	 given	 variable	 affected	 the	 predicted	 output.	 The	 input	 weights	87	were	used	as	a	measure	of	relative	variable	importance	in	the	NN	predictions	(Figure	6.8).	Unsurprisingly,	the	fasting	BG	levels	had	by	far	the	strongest	prognostic	value	in	the	NN	model,	adding	incentive	to	the	inclusion	of	BG	information	for	any	future	type	2	DM	prediction	model.		
	
Figure	6.8	The	not-so-black-box	NN:	relative	variable	importance	by	the	absolute	values	of	input	weights		When	evaluated	on	all	497	test	samples	available	for	complete-case	scenario	(both	for	missing	and	known	outcome),	 the	small-data	NN,	 trained	with	only	158	samples,	was	able	to	achieve	concordance	of	?-index	= 0.783	,	which	was	on	par	with	the	performance	
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of	the	far	more	advanced	NN	ensemble	developed	with	over	19,000	samples	and	the	Cox	model	built	on	over	53,000	samples.	
To	summarise	this	complete-case	investigation:	
• The	 methodological	 framework	 developed	 in	 Chapter	 3	 was	 successfully	applied	 to	 design	 a	 78%	 accurate	 NN	 classifier	 with	 less	 than	 7	 event	observations	per	predictor	variable.		
• Despite	 the	 selection	 bias	 associated	 with	 the	 complete-case	 scenario,	 the	model	 was	 able	 to	 generalise	 on	 497	 independent	 test	 samples,	 including	patients	for	whom	the	10-year	outcome	was	unknown.	
• In	 an	 extensive	 simulation	 involving	 28000	 NNs,	 a	 1-neuron	 hidden	 layer	“bottleneck”	design	proved	optimal	for	the	given	task.	
• The	 fasting	 BG	 level,	 followed	 by	 random	 BG	 level,	 BMI	 and	 Townsend	deprivation	 score	 had	 the	 strongest	 predictive	 value	 in	 the	 1415	 patients	included	in	the	complete-case	scenario.	
6.3.4 Logistic	regression	
The	development	of	the	LR	model	for	type	2	DM	prediction	was	motivated	by	Section	6.3.3,	 where	 it	 was	 discovered	 that	 a	 single	 tan-sigmoid	 neuron	 in	 the	 hidden	 layer	yielded	the	best	NN	model	fit.	If	we	view	the	function	implemented	by	the	hidden	neuron		
ZÅ : =	Eq À	ÃÕ ú »Ep q À	ÃÕ úEq À	ÃÕ ú oEp q À	ÃÕ ú 		as	merely	an	input	transformation,	then	"].	6.4	for	the	NN	output	becomes:	
	 0	 = 11 + "»@ ö »∫…}Œ ü 	 "].	6.4	
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where	 	.(,)	 and	89 	 are	scalars.	 It	 could	be	noted	 that	eq.	6.4	 is	 similar	 in	 form	to	 the	output	of	a	standard	LR	model:	
	 0	 = 11 + "»B(Äu~ ü 	 "].	6.5		 SmnQ1 : = !( + !V:V + !V:V + ⋯+	!b:b	 "].	6.6	
Noting	this	resemblance,	it	was	decided	to	explore	whether	the	10-year	incidence	of	type	2	 DM	 could	 be	 successfully	 modelled	 with	 a	 conventional	 LR.	 	 The	 LR	 model	 was	developed	with	1585	DM	and	17907	non-DM	examples,	and	validated	on	an	independent	cohort	of	26653	patients.	The	DM	and	non-DM	classes	were	balanced	by	SMOTE.	As	with	Cox	 PH	 and	 NN	 ensemble	 models,	 two	 scenarios	 were	 considered:	 one	 without	 the	inclusion	of	BG	information	and	one	with	the	inclusion	of	any	available	BG	level	and	the	corresponding	presence	flag.	The	set	of	β	parameters	of	the	resulting	two	LR	models	are	provided	in	Tables	6.7	and	6.8	respectively.		
Table	6.7	LR	model	without	blood	glucose	information	Variable	:	 Coefficient	!	 Odds	ratio	"# 	 95%	CI	 p-value	lower	 upper	Intercept	 -6.706	 0.001	 0.001	 0.002	 <0.001	Gender	female	 -0.722	 0.486	 0.410	 0.575	 <0.001	Age	(years)	 0.044	 1.045	 1.038	 1.052	 <0.001	Family	history	of	DM	 1.039	 2.827	 1.911	 4.236	 <0.001	CVD		 0.454	 1.574	 1.138	 2.199	 0.007	BMI	(kg/m2)	 0.154	 1.166	 1.147	 1.186	 <0.001	Hypertension	 0.458	 1.581	 1.272	 1.969	 <0.001	Ethnicity	“Asian”	 3.043	 20.971	 7.137	 89.969	 <0.001	Ethnicity	“Black”	 1.269	 3.557	 1.164	 13.375	 0.037	Ethnicity	“Mixed”	 0.048	 1.049	 0.226	 4.750	 0.950	Ethnicity	“Other”	 2.665	 14.361	 3.792	 94.494	 <0.001	Prescribed	steroids	 0.424	 1.528	 1.010	 2.335	 0.047	Smoker	 0.577	 1.780	 1.452	 2.185	 <0.001	Townsend	score	 0.082	 1.086	 1.054	 1.119	 <0.001		
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Table	6.8	LR	model	with	blood	glucose	information	Variable	:	 Coefficient	!	 Odds	ratio	"# 	 95%	CI	 p-value	lower	 upper	Intercept	 -6.428	 0.002	 0.001	 0.003	 <0.001	Gender	female	 -0.693	 0.500	 0.421	 0.594	 <0.001	Age	(years)	 0.041	 1.042	 1.035	 1.050	 <0.001	Family	history	of	DM	 1.076	 2.933	 1.965	 4.433	 <0.001	CVD		 0.352	 1.422	 1.014	 2.010	 0.044	BMI	(kg/m2)	 0.147	 1.158	 1.139	 1.178	 <0.001	Hypertension	 0.401	 1.494	 1.188	 1.880	 <0.001	Ethnicity	“Asian”	 3.030	 20.702	 7.004	 89.038	 <0.001	Ethnicity	“Black”	 1.310	 3.704	 1.209	 13.948	 0.032	Ethnicity	“Mixed”	 0.077	 1.080	 0.241	 4.743	 0.918	Ethnicity	“Other”	 2.633	 13.919	 3.683	 91.528	 <0.001	Prescribed	steroids	 0.440	 1.552	 1.020	 2.384	 0.042	Smoker	 0.563	 1.757	 1.428	 2.164	 <0.001	Townsend	score	 0.084	 1.088	 1.055	 1.122	 <0.001	BG	recorded	 -3.864	 0.021	 0.008	 0.053	 <0.001	BG	level	(mmol/L)	 0.742	 2.101	 1.777	 2.506	 <0.001		The	 inclusion	 of	 BG	 information	 improved	 the	 prognostic	 ability	 of	 the	 LR	model	 by	approximately	2%,	from	?-index	= 0.810	to	?-index	= 0.827,	on	the	validation	cohort.	The	LR	model	without	BG	was	able	 to	correctly	stratify	71%	of	DM	and	76%	non-DM	groups.	 The	 LR	model	with	 BG	 achieved	 74%	 sensitivity	 and	 77%	 specificity	 among	patients	with	known	outcome.		
The	BG	model	parameters	with	the	highest	odds	of	type	2	DM	at	10	years	were	largely	similar	to	those	established	by	Cox	PH	in	Section	6.3.1.	Patients	of	“Asian”	and	“Other”	ethnic	origin,	patients	of	male	gender,	patients	with	an	existing	family	history	of	DM,	and	patients	with	elevated	BG	levels	remained	a	high-risk	group	with	over	2	times	odds	of	developing	 type	2	DM	at	10	years.	 Similarly	 to	 the	Cox	PH	model,	 the	presence	 of	BG	measurements	in	LR	model	was	negatively	associated	with	the	outcome.	
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To	summarise,	these	findings	demonstrated	that	a	standard	LR	classifier	was	marginally	inferior	in	performance	to	the	more	complex	NN	ensemble,	which	benefited	from	tan-sigmoid	transformation	 in	the	hidden	 layer.	The	LR	model	confirmed	the	associations	previously	established	by	the	Cox	PH	model	on	the	derivation	cohort.	
6.3.5 Survival	decision	tree	
A	 survival	 DT	 model	 offered	 a	 mechanism	 for	 dealing	 with	 censored	 outcomes	 and	missing	covariates,	whilst	also	producing	a	concise	graphical	representation	of	high-risk	groups.	 The	 DT	 was	 developed	 with	 all	 of	 the	 1585	 DM,	 17907	 non-DM	 and	 33814	unknown	outcome	records	available	for	the	model	derivation.	No	imputation	of	BMI	or	BG	was	required.	Two	survival	DT	models	were	considered:	one	without	the	inclusion	of	BG	 information	 (Figure	 6.9)	 and	 one	 with	 the	 BG	 values	 and	 BG	 presence	 indicator	(Figure	6.10).			
The	survival	DTs	implemented	in	this	work	were	based	on	the	local	full	likelihood	tree	model	of		LeBlanc	&	Crowley	[292].	The	DT	partitioned	the	covariate	space	into	subsets	of	patients	based	on	 the	 log	 rank	criterion,	 so	 that	every	new	partition	 increased	 the	homogeneity	of	the	observations	within	each	patient	group.	The	proportion	of	patients	at	every	node	who	were	diagnosed	with	type	2	DM	was	then	evaluated	and	compared	with	that	at	the	root	node.	This	relative	event	rate	5	indicated	the	hazard	of	developing	type	2	DM;	the	relative	event	rate	at	the	root	was	5	=	1,	which	is	equivalent	to	the	baseline	hazard	in	Cox	PH.	The	model	output	0	was	expressed	as	5	mapped	between	0	and	1,	i.e.	5 = »–—ƒ	()–¬“  »–—ƒ	().	In	order	to	assess	the	classification	measurements,	the	output	of	the	DT	was	dichotomised	as	follows:		
	 0@uCAs = 1, QZ	5 > 10, QZ	5 ≤ 1	 "].	6.7	
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In	order	to	prevent	overfitting,	the	minimum	parent	size	was	set	to	®Q2N3SQ1	 = 100.	A	pruning	complexity	parameter	of	k3 = 	0.003		was	specified	to	control	DT	growth:	any	split	that	did	not	improve	the	fit	by	a	factor	of	0.003	was	not	attempted.		
Surrogate	splits	were	constructed	for	each	node,	which	allowed	the	handling	of	variables	with	missing	 values.	 If	 an	 observation	missed	 the	 primary	 and	 all	 possible	 surrogate	splits,	then	the	DT	sent	the	observation	in	the	majority	direction.		As	a	result	of	surrogate	splits,	a	variable	could	appear	in	the	DT	multiple	times	both	as	primary	and	surrogate.	The	relative	variable	importance	scores	were	computed	from	the	combined	node	purity	for	every	split	(surrogate	or	otherwise),	in	which	the	variable	in	question	had	featured.		
	
Figure	6.9	Survival	DT	modelled	without	the	inclusion	of	BG	(missing	values	of	BG	and	BMI	left	unaltered).		
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The	 DT	 in	 Figure	 6.9	 was	 modelled	 on	 the	 derivation	 cohort	 without	 BG	 values.	 It	consisted	of	7	branch	nodes	and	8	terminal	nodes,	numbered	1	to	15.	The	box	under	each	node	provides	 the	 value	of	5,	 the	number	of	 events/total	 number	of	 samples	passing	through	 the	 node,	 and	 the	 %	 of	 the	 derivation	 cohort	 size.	 The	 colour	 intensity	 is	associated	with	the	higher	relative	likelihood	of	being	diagnosed	with	type	2	DM.	
Without	 the	 BG	 information,	 the	 survival	 DT	 achieved	 a	 ?-index	 of	 0.786		 on	 the	validation	cohort.		The	DT	model	was	able	to	correctly	stratify	64%	of	DM	and	70%	of	non-DM	patients.		The	following	variables	(in	decreasing	order	of	importance)	were	used	by	 the	 DT	 in	 primary	 and	 surrogate	 splits:	 age,	 BMI,	 hypertension,	 gender,	 CVD,	Townsend	score	and	ethnicity.	
Of	a	particular	 interest	was	the	DT	modelled	with	BG	shown	in	Figure	6.10,	where	all	primary	 splits	 were	 based	 on	 continuous	 variables	 (age,	 BMI	 and	 BG).	 In	 the	 DT’s	surrogate	 splits,	 the	 following	 additional	 variables	were	used	 (in	decreasing	order	 of	importance):	 hypertension,	 presence	 of	 BG,	 CVD,	 steroid	 use,	 Townsend	 score	 and	ethnicity.	This	DT	stratified	patients	in	the	derivation	cohort	into	9	unequally-sized	risk	groups,	which	are	represented	by	the	terminal	nodes.		
The	10-year	risk	of	type	2	DM	was	highest	in	patients	at	nodes	15,	17,	and	11,	comprising:	
• Individuals	44	years	or	older	with	BMI	in	the	overweight	range	(≥	26	kg/m2)	(r	=	8.3,	node	15),	particularly	if	their	BG	level	≥	6.4	mmol/L	(r	=	12,	node	17);	
• Individuals	younger	than	44	years,	but	who	were	both	obese	(BMI	≥	30	kg/m2)	and	had	elevated	BG	levels	≥	6.4	mmol/L	(r	=	7,	node	11).	
Patients	 younger	 than	44	years	of	 age,	with	BMI	<	30	kg/m2,	were	 the	 least	 likely	 to	develop	type	2	DM	(r	=	0.26,	node	4).	This	group	constituted	52%	of	the	patients	in	the	derivation	cohort.	The	second	largest	stratum	(r	=	1,	node	12),	comprising	35%	of	the	
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cohort,	was	less	conclusive:	its	estimated	event	rate	was	identical	to	that	of	the	whole	cohort.	The	individuals	that	fell	into	this	stratum	were	44	years	or	older,	with	normal	BG	(<5.8	mmol/L)	and	BMI	below	obese	range	(<30	mmol/L).	With	644	events	assigned	for	the	baseline	hazard,	this	stratum	was	the	highest	producer	of	false	negatives,	signifying	that	patients	in	this	cohort	should	be	considered	with	additional	care.	As	a	result	of	the	false	negatives,	 the	classification	accuracy	of	 the	DT	model	with	BG	suffered	 from	the	imbalance	between	the	sensitivity	of	45%	and	the	specificity	of	88%,	indicating	the	need	for	more	granularity	in	the	terminal	node,	in	particular	at	node	12.			
	
Figure	6.10	Survival	DT	modelled	with	the	inclusion	of	BG	(missing	values	of	BG	and	BMI	left	unaltered).	
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Kaplan-Meyer	survival	curves	in	Figure	6.11	visualise	the	difference	in	prognosis	in	the	patient	 groups	 represented	 by	 each	 terminal	 node	 for	 the	 DT,	 with	 and	without	 BG.	Inclusion	of	BG	information	improved	the	prognostic	value	of	the	DT	by	nearly	5%	to	a	?-index	of	0.824	on	the	validation	cohort.	
	
Figure	6.11	Kaplan-Meyer	curves	for	the	terminal	nodes	of	the	DT	with	BG	(left)	and	without	BG	(right)		The	variable	importance	scores	for	the	two	DT	models	in	Figure	6.12	demonstrate	that	
age	 is	 the	 most	 important	 parameter	 for	 both	 models,	 followed	 by	 BG	 level,	 BMI,	treatment	for	hypertension,	presence	of	BG	measurements,	and	CVD.	For	the	DT	model	without	BG,	gender	and	Townsend	scores	were	also	important	factors.	Family	history	of	DM	was	not	used	in	either	survival	DT	models	(neither	as	a	primary	nor	secondary	split).	Ethnicity	played	a	smaller	role	than	in	the	Cox	PH	model	since	in	the	survival	DTs,	the	small	proportion	of	minority	ethnics	meant	that	their	relative	contribution	against	the	baseline	split	demonstrated	only	marginal	improvements.	
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Figure	6.12	Variable	importance	scores	for	DT	with	BG	(blue)	and	DT	without	BG	(orange)		To	summarise:	
• The	DT	models	were	able	to	successfully	stratify	the	10-year	risk	of	type	2	DM	without	relying	on	missing	data	imputation.			
• The	 inclusion	 of	 BG	 information	 led	 to	 a	 significant	 improvement	 in	 the	prognostic	value,	which	increased	by	nearly	5%,	from	a	?-index	of	0.786	to	a	?-index	of	0.824,	on	the	validation	cohort.	
• Despite	the	large	proportion	of	missing	values	in	BMI	and	BG	levels,	these	two	variables,	 together	 with	 the	 patient’s	 age,	 exhibited	 the	 highest	 relative	importance	 in	 the	 DT	 model,	 emphasising	 their	 prognostic	 value	 in	 the	prediction	of	type	2	DM.	
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 Model	performance	and	limitations		
Using	Cox	PH	as	the	benchmark	model,	the	prognostic	performances	of	the	NN	ensemble,	small-data	NN,	LR	and	survival	DT	models	were	evaluated	using	Harrell’s	?-index	and	Royston’s	and	Sauerbrei’s	G	and	J,K	 scores	(Table	6.9).	For	validation	cohort	samples	where	the	outcome	was	known,	standard	classification	measures,	such	as	specificity	M3,	sensitivity	M2,	and	balanced	accuracy	?@ABACDEF 	were	also	assessed	(Table	6.10).	
Table	6.9	Comparison	of	model	performance:	Harrell's	C	and	Royston’s	D	measures	of	discrimination	
		 Harrell’s	concordance	index	 Royston	and	Sauerbrei’s	D	factor	
		 ?-index	 95%	CI	 2	pairs	 G	 95%	CI	 JK, 	 2	lower	 upper	 lower	 upper	
1.	Models	without	BG	Cox	PH	 0.817	 0.803	 0.831	 28004520	 7.08	 6.32	 7.92	 0.628	 26653	NN	ensemble	 0.829	 0.816	 0.842	 28004244	 7.28	 6.52	 8.13	 0.635	 26653	Small-data	NN	 0.625	 0.550	 0.699	 33718	 2.39	 1.54	 3.71	 0.363	 497	Logistic	regression	 0.810	 0.796	 0.825	 28004520	 6.84	 6.09	 7.67	 0.620	 26653	Survival	DT	 0.786	 0.770	 0.803	 24478846	 4.86	 4.32	 5.48	 0.537	 26653	
2.	Models	with	BG	Cox	PH	 0.832	 0.819	 0.846	 28004522	 8.44	 7.53	 9.45	 0.668	 26653	NN	ensemble	 0.847	 0.834	 0.860	 28004338	 9.14	 8.17	 10.23	 0.686	 26653	Small-data	NN	 0.783	 0.724	 0.842	 33720	 6.29	 4.01	 9.87	 0.600	 497	Logistic	regression	 0.827	 0.813	 0.841	 28004522	 7.94	 7.08	 8.89	 0.655	 26653	Survival	DT		 0.824	 0.807	 0.842	 22185650	 5.92	 5.26	 6.66	 0.586	 26653	
Harrell’s	 ?-index	 measured	 concordance,	 which	 is	 defined	 in	 Appendix	 B	 as	 the	proportion	 of	 all	 comparable	 pairs	 of	 patients	 (n	 pairs)	 where	 patients	 with	 longer	survival	time	are	assigned	a	lower	risk.	It	is	also	interpreted	as	=>?	for	right-censored	data	[293].	The	most	concordant	models	were:	NN	ensemble	with	BG	(0.847),	Cox	PH	with	BG	 (0.832)	and	NN	ensemble	without	BG	 (0.829).	 	The	 inclusion	of	patient’s	BG	information	improved	all	six	models,	but	this	effect	was	most	pronounced	in	the	models	that	did	not	leverage	imputation	of	missing	variables,	i.e.	small-data	NN	(25%	increase	
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in	?-index)	and	survival	DT	(5%	increase	in	?-index).	The	improvement	in	?-index	for	Cox	PH,	NN	ensemble	and	LR	was	only	2%.		
As	discussed	in	Appendix	B,	Royston’s	and	Sauerbrei’s	G	divides	the	distribution	of	the	patient	prognostic	 indices	 into	two	equally-sized	risk	groups	at	 the	median	value	and	compares	their	relative	hazard.	This	property	allows	the	G	score	to	be	interpreted	as	the	model’s	 overall	 log	 hazard	 ratio	 [293].	 	 Another	way	 to	 reason	 about	 the	G	 score	 is	through	its	JK, 	transformation,	which	provides	a	measure	of	prognostic	separation	in	the	interval	bound	between	0	and	1.	The	highest	G	was	achieved	by	models	with	BG:	NN	ensemble	 (9.14),	 Cox	 PH	 (8.44)	 and	 LR	 (7.94).	 Notably,	 the	 largest	 disagreement	between	 ?-index	 and	 G	score	 was	 in	 the	 survival	 DT	 model.	 This	 stems	 from	 the	differences	in	the	output	distributions	produced	by	each	prognostic	model	(Figures	6.13	and	6.14).	Since	type	2	DM	was	a	rare	event,	it	meant	that	the	use	of	medians	in	Royston’s	and	Sauerbrei’s	G	score	was	less	appropriate	for	some	models	than	others.	
The	outputs	0	produced	by	each	model	should	represent	prognostic	indices	related	to	the	probability	of	being	diagnosed	with	type	2	DM,	and	hence	were	designed	to	 lie	 in	 the	common	interval	between	0	and	1.		To	achieve	this,	the	raw	outputs	0ô	of	the	Cox	PH	and	the	survival	DT	models	(which	have	no	upper	bound)	were	scaled	as	follows:	
	 0	 = 0( − min 0(max 0ô − min 0ô 	 "].	6.8	
Such	transformation	preserves	the	prognostic	separation	and	does	not	disturb	the	model	performance	measures.	The	outputs	of	the	NN	and	LR	models	were	designed	from	the	onset	to	be	between	0	and	1.	
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Four	histograms	in	Figure	6.13	correspond	to	the	prognostic	indices	0	predicted	by	the	Cox	PH,	ensemble	NN4,	LR,	and	survival	DT	models	with	BG,	where	the	sum	of	frequencies	across	the	20	bins	corresponds	to	26653	validation	cohort	samples.	To	compensate	for	loss	of	detail	due	to	the	overlaying	histograms,	the	distributions	of	0	are	also	visualised	as	smooth	density	curves,	approximated	by	a	kernel	density	function	[294]	and	scaled	to	the	 interval	 between	0	 and	1	 for	 consistent	 representation	 (Figure	6.14).	 	Unlike	 the	continuous	output	of	the	Cox	PH,	ensemble	NN	and	LR	models,	the	survival	DT	output	comprised	a	finite	number	of	discrete	values,	corresponding	to	the	number	of	terminal	nodes	in	the	tree	(8	for	the	model	without	BG	and	9	for	the	one	with	BG).		
For	the	classification	measures	in	Table	6.10,	instead	of	using	medians	for	dividing	the	prognostic	 indices	 into	DM	and	non-DM	groups,	 the	threshold	was	evaluated	for	each	model	 separately	by	accounting	how	well	 it	handled	class	 imbalance.	For	 instance,	 in	small-data	NNs,	the	class	imbalance	was	less	pronounced	and	binary	classification	was	achieved	by	using	a	rigid	threshold	of	0.5	for	assigning	the	predictions	to	DM	and	non-DM	classes.	For	Cox	PH,	NN	ensemble	and	LR	models,	 the	75th	percentile	value	was	a	more	appropriate	threshold	for	dichotomising	the	prognostic	 indices	into	non-equally	sized	DM	and	non-DM	groups.	For	surrogate	DT,	the	threshold	of	1	was	applied	prior	to	the	min-max	mapping	to	preserve	interpretability	of	the	relative	event	rate	ρ.		
The	 threshold	 for	 dichotomising	 the	 prognostic	 index	 could	 be	 tuned	 to	 allow	 for	desired	M2,	but	at	the	expense	of	lowering	M3,	and	vice	versa.	In	practice,	the	threshold	value	of	a	prognostic	system	would	depend	on	what	false	positive	or	false	negative	rates	an	individual	health	provider	is	able	to	accept,	and	requires	a	careful	consideration	of	the	morbidity	of	the	disease	and	the	costs	of	its	diagnosis.			
																																								 																					4	The	small-data	NN	was	excluded	from	this	analysis	to	avoid	misrepresentation	of	the	26653-sample	validation	cohort	with	its	subset	of	497	complete	records.	
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Figure	6.13	Distribution	of	responses	predicted	by	Cox	PH,	NN	ensemble,	LR	and	survival	DT	models	with	BG.	
	
	
Figure	6.14	Kernel	density	curve	of	the	responses	predicted	by	Cox	PH,	NN	ensemble,	LR	and	survival	DT	
models	with	BG.	
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Balanced	accuracy	?@ABACDEF 	(Table	6.10)	assessed	the	number	of	correctly	classified	DM	and	 non-DM	 patients	 from	 known	 10-year	 outcomes,	 and	 represented	 a	 more	conservative	 measure	 of	 prognostic	 discrimination	 than	 Harrell’s	 ?-index.	 When	 no	benefit	of	the	doubt	was	given	to	the	patients	who	transferred	out	of	the	study	before	the	10-year	period,	 all	models	performed	equally	with	or	without	BG.	The	exception	was	small-data	 NN	 without	 BG	 information,	 which	 performed	 marginally	 better	 than	 a	random	coin	toss.	The	remarkable	agreement	in	performance	among	the	Cox	PH,	LR,	NN	ensemble	and	small-data	NN	models	with	BG	indicates	that	?@ABACDEF 		is	a	reflection	of	the	quality	of	the	data,	rather	than	a	property	of	the	model.		
Table	6.10	Comparison	of	model	classification	performance	on	samples	with	observed	10-year	outcome	
	 Classification	measures	
	 M2	 M3	 IIß	 •Iß	 ?@ABACDEF	 2	(known	outcome)	
1.	Models	without	BG	Cox	PH	 73%	 74%	 0.205	 0.968	 74%	 9810	NN	ensemble	 74%	 76%	 0.219	 0.970	 75%	 9810	Small-data	NN	 35%	 79%	 0.392	 0.763	 57%	 207	Logistic	regression	 71%	 76%	 0.217	 0.966	 74%	 9810	Survival	DT	 64%	 70%	 0.164	 0.955	 67%	 9810	
2.	Models	with	BG	Cox	PH	 76%	 74%	 0.214	 0.971	 75%	 9810	NN	ensemble	 78%	 77%	 0.235	 0.974	 77%	 9810	Small-data	NN	 67%	 81%	 0.576	 0.865	 74%	 207	Logistic	regression	 74%	 77%	 0.228	 0.970	 76%	 9810	Survival	DT	 45%	 88%	 0.256	 0.946	 67%	 9810		The	power	of	small,	but	high-quality	data	sample	is	further	exemplified	by	the	small-data	NN.	Developed	with	only	158	complete-case	samples	and	suffering	from	a	considerable	exclusion	bias,	 this	NN	model	performed	with	?@ABACDEF		 equivalent	 to	 that	 of	 the	NN	ensemble	developed	with	over	19,000	samples	and	the	Cox	model	built	on	over	53,000	samples.			
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The	 NN	 ensemble	 model	 demonstrated	 its	 competitive	 performance	 on	 censored	observations	despite	not	being	 specifically	 trained	 to	handle	 them.	The	NN	ensemble	model	was	designed	with	1585	DM	and	17907	non-DM	examples;	33814	records	with	unknown	outcomes	were	not	suitable	for	supervised	learning.	The	drastic	reduction	in	the	 number	 of	 samples	 useable	 for	 model	 derivation	 –	 coupled	 with	 the	 potential	selection	 bias	 in	 excluding	 those	 samples	 –	was	 expected	 to	 negatively	 affect	 the	NN	performance	in	comparison	to	the	Cox	PH	model	derived	with	a	dataset	1.7	times	larger.	Yet,	when	validated	on	the	same	independent	cohort	of	26653	patients,	the	NN	ensemble	model	marginally	outperformed	Cox	PH.	
Notably,	 the	 survival	 DT	 exhibited	 poor	 sensitivity	M2,	 which	 decreased	 with	 the	inclusion	of	BG	 information.	As	explained	 in	Section	6.3.5,	 this	artefact	was	due	 to	an	inability	to	differentiate,	based	on	the	available	data,	between	DM	and	non-DM	outcomes	in	one	particular	group	of	patients	(node	12	in	Figure	6.10):	individuals	44	years	or	older,	with	normal	BG	(<5.8	mmol/L)	and	BMI	below	obese	range	(<30	mmol/L).	Patients	in	this	group	accounted	for	345	out	of	the	454	false	negatives	produced	by	the	DT	on	the	validation	 cohort.	 Should	 additional	 baseline	 indicators	 be	 available	 to	 explain	 the	variance	in	outcome	in	this	specific	group,	the	sensitivity	of	the	survival	DT	model	could	reach	the	theoretical	maximum	of	M2	 = 86.3%5	with	the	existing	structure.	The	ability	of	the	survival	DT	to	pin-point	not	only	the	groups	of	patients	with	the	highest	hazard,	but	also	the	patients	whose	data	require	further	collection	is	a	valuable	asset,	not	found	in	any	other	model.		
																																								 																					5	The	theoretical	maximum	for	the	survival	DT	in	Figure	6.10	was	calculated	by	correcting	for	the	node	12	artefact,	while	retaining	the	existing	hierarchy	of	all	the	remaining	nodes.	If	all	345	of	the	false	 negatives	 (FN)	 produced	 in	 node	 12	 were	 eliminated	 with	 hypothetical	 new	 baseline	indicators,	the	overall	number	of	FN	predictions	made	by	the	DT	would	decrease	to	454-345=109.	This	 represents	 13.2%	 of	 the	 828	 total	 type	 2	 DM	 patients	 in	 the	 validation	 cohort	 and	corresponds	to	a	model	sensitivity	of	100%-13.2%=86.8%.	In	practice,	it	is	improbable	that	all	of	the	345	FN	in	node	12	could	be	corrected	with	additional	information,	although	new	indicators	could	significantly	improve	the	predictions	in	other	nodes	of	this	tree.		
Chapter	6.		Diabetes	type	2	risk	stratification	from	routinely	collected	NHS	data	
163	
A	comparison	of	model	performance	would	not	be	complete	without	accounting	for	the	existing	 QDiabetes®	 prognostic	 model	 [272].	 Figure	 6.15	 summarises	 the	 ?-index	performance	of	every	model	developed	in	this	work,	and	that	of	the	QDiabetes®	models	(separately	for	women	and	men)	evaluated	on	the	same	validation	cohort	from	the	CPRD	data.	As	expected,	the	two	QDiabetes®	models	performed,	on	average,	the	same	as	the	Cox	 PH	 model	 without	 BG	 developed	 in	 this	 research.	 They	 were	 marginally	outperformed	by	the	NN	ensemble	model	without	BG,	and	all	four	large-data	models	(Cox	PH,	ensemble	NN,	LR,	and	survival	DT)	with	BG.	
	
Figure	6.15	Summary	of	model	performance	(?-index),	including	the	QDiabetes®	model	for	men	and	women.	
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 Chapter	conclusions	
The	key	findings	demonstrated	in	this	chapter	are	as	follows:	
(1) Routinely	 collected	 primary	 care	 data	 suffer	 from	 complexity,	 completeness,	censoring	and	consistency	challenges	(“The	4	Cs”),	which	limit	their	potential	for	data-driven	predictive	modelling.	
(2) The	 remarkable	 agreement	 in	 concordance	 and	 classification	 accuracies	 among	the	 Cox	 PH,	 LR,	 NN	 ensemble,	 and	 the	 existing	 QDiabestes®	 model	 indicate	 that	prognostic	performance	is	a	reflection	of	the	quality	of	the	data,	rather	than	a	property	of	an	individual	model.		
(3) Inclusion	of	available	blood	glucose	data	improved	all	six	models.	However,	this	effect	was	minimal	(2%	increase	in	?-index)	for	the	Cox	PH,	NN	ensemble	and	LR.	The	improvement	was	most	pronounced	for	models	that	did	not	leverage	the	imputation	of	missing	 variables,	 i.e.	 small-data	NN	 (25%	 increase	 in	?-index)	 and	 survival	 DT	 (5%	increase	in	?-index).	This	demonstrates	that	the	potential	for	using	blood	glucose	data	exists,	 but	 it	 remains	 infeasible	 until	 routine	 blood	 tests	 become	 more	 frequent	 in	primary	care.	
(4) In	 a	 complete-case	 scenario	 of	 known	 BG	 measurements,	 a	 small-data	 NN	developed	 with	 a	 balanced	 subset	 of	 158	 samples	 achieved	 the	 same	 classification	accuracy	as	the	Cox	PH	and	NN	ensemble	models	developed	on	a	cohort	of	53306	and	19492	samples,	respectively.	This	confirms	that	good	quality	data	are	more	important	than	 high	 performance	 algorithms	 or	 large	 quantities	 of	 incomplete,	 censored,	 and	imbalanced	data.	
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(5) The	survival	DT	model	was	able	to	identify	the	groups	of	patients	at	high	10-year	risk	of	type	2	DM	and	pin-point	those	whose	data	were	less	conclusive.	82.4%	of	the	DT	predictions	 were	 concordant.	 Considering	 its	 easily	 interpretable	 structure	 and	 its	ability	to	handle	missing	data,	the	survival	DT	has	the	highest	practical	value	among	the	models	explored	in	this	study	and	is	the	most	appropriate	model	for	the	complex	task	of	predicting	long-term	incidence	of	a	rare	disease	from	routinely	collected	data.	
The	task	of	developing	a	new	generation	of	dynamic	prognostic	models	for	type	2	DM	is	far	 from	complete.	The	models	prototyped	 in	 this	work	are	yet	 to	be	evaluated	using	larger	 internal	 and	 external	 data.	 The	 inherent	 ability	 of	 the	 NN	models	 to	 adapt	 to	population	dynamics	is	yet	to	be	quantified	with	more	recent	data.	Meanwhile,	we	can	rest	assured	that	the	existing	systems,	developed	with	over	2.5	million	records,	remain	appropriate	for	the	task,	until	the	time	when	advances	in	ML	for	survival	modelling	and	clinical	 practice	 for	 routine	 data	 collection	 builds	 on	 the	 foundation	 laid	 by	 this	collaborative	work.	
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Conclusions	
This	 thesis	 developed	 and	 presented	 data-efficient	 ML	 models	 for	 clinical	 outcome	prediction	and	risk	stratification	in	the	context	of	data	limited	by	size	and	quality.	The	three	domains	considered	 in	 this	 interdisciplinary	research	were:	a)	 trabecular	 tissue	engineering,	 b)	 antibody-incompatible	 renal	 transplantation,	 and	 c)	 type	 2	 diabetes	screening	 in	primary	 care.	The	 (a)	 trabecular	bone	and	 (b)	 renal	 transplant	datasets,	each	 containing	 less	 than	 10	 observations	 per	 predictor	 variable,	 exemplified	 to	 the	extreme	 the	 problem	 of	ML	modelling	 from	 small	 data.	 The	 limited	 size	 of	 available	datasets	 is	 intrinsic	 in	 surgical	 domains	 in	 general,	where	 each	 sample	 is	 a	 result	 of	costly,	 invasive,	and	(fortunately)	rare	 intervention.	However,	even	in	domains	where	large,	multi-centre	databases	are	readily	available,	more	data	do	not	necessarily	imply	proportionally-more	 information.	Routinely	collected	electronic	medical	records,	such	as	those	involved	in	(c)	diabetes	screening	in	primary	care,	suffered	from	limitations	in	quality	 that	 reduced	 the	 number	 of	 samples	 available	 for	 modelling.	 The	 “4	 Cs”	 of	routinely	 collected	 data,	 i.e.	 complexity,	 censoring,	 inconsistency,	 and	 lack	 of	
completeness,	were	shown	in	this	thesis	to	hinder	the	performance	of	classical	statistical	and	ML	algorithms	alike.	The	methods	developed	in	this	thesis	enabled	the	successful	deployment	 of	 NNs,	 DTs,	 and	 their	 ensembles	 despite	 the	 limited	 data	 and	 enabled	clinical	 applications	 that	 were	 previously	 considered	 beyond	 the	 reach	 of	 these	powerful,	yet	data-demanding	supervised	ML	algorithms.	
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 Objectives	and	the	extent	to	which	they	were	achieved	
The	objectives	of	 this	 thesis,	 as	 set	out	 in	Section	1.6	were	met	 in	 full.	The	 thesis	 (1)	identified	 effective	 strategies	 for	 managing	 data	 quality	 limitations	 in	 the	 three	abovementioned	domains;	(2)	addressed	challenges	of	learning	with	limited	information	by	 developing	 and	 validating	 a	 framework	 for	 small-data	 learning	 (less	 than	 10	observations	per	predictor	variable)	with	supplementary	strategies	for	incomplete	and	imbalanced	data;	(3)	designed,	implemented,	optimised	and	tested	practical	NN,	DT,	and	ensemble	 tools	 for	 predictive	 modelling	 in	 the	 three	 applications;	 and	 (4)	 used	 the	clinical	 insights	 gained	 from	 the	 ML	 models	 in	 order	 to	 detect	 patients	 at	 risk	 and	improve	short-	and	long-term	individual	outcomes.	
 Contributions	to	knowledge	
The	 novel	 methodological	 framework	 for	 small	 data	 developed	 in	 this	 work	 was	motivated	 by	 the	 necessity	 for	 scalable	 predictive	 models	 that	 can	 make	 accurate	predictions	on	new	observations.	The	ability	of	the	framework	to	yield	such	models	was	demonstrated	for	regression	NNs	by	using	a	large	civil	engineering	study.	A	small-data	NN	 developed	 on	 41	 samples	 using	 the	 proposed	 framework	 performed	 as	 well	 as	standard	NNs	trained	with	a	dataset	18	times	larger.	The	remarkable	generalising	ability	(J	=	0.87)	of	the	small-data	model	on	300	new	observations	confirmed	the	utility	of	the	proposed	framework	for	producing	well-generalising	learners	despite	small	data.		
The	framework	comprised:	a	method	of	multiple	runs	for	model	design	and	optimisation,	and	a	 surrogate	data	test	 for	regression	model	validation	in	the	absence	of	ample	test	samples.	 The	method	 of	multiple	 runs	 is	 based	 on	 an	 intuitive	 principle:	 rather	 than	solving	 a	 complex	 task	with	 a	 single	 learner	 trained	on	 large	 amount	of	 data,	 a	 large	
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number	of	learners	can	be	trained	with	small	amounts	of	data,	with	the	anticipation	that	one	of	 them	would	excel	at	 the	 task.	By	considering	performance	across	a	number	of	learners,	the	method	of	multiple	runs	enabled	consistent	iterative	design	optimisation	and	subsequent	model	 selection.	 In	 the	absence	of	ample	 test	data,	validating	 learner	performance	has	proven	particularly	challenging	 for	regression	models,	which,	unlike	classifiers,	 do	 not	 have	 a	 pre-defined	 minimal	 expected	 performance	 threshold.	 The	surrogate	data	test	developed	in	this	thesis	addressed	this	problem	by	quantifying	the	lowest	expected	model	performance	specific	to	each	dataset.	Combined,	the	two	methods	enabled	 the	 successful	 application	 of	 NNs	 and	 DTs	 for	 regression,	 classification,	 and	
survival	modelling	in	the	three	clinical	domains.		
 Clinical	and	engineering	impact	
In	trabecular	tissue	engineering,	the	framework	enabled	the	development	of	an	accurate	NN	model	for	osteoarthritic	hip	fracture	prediction	based	on	an	extremely	small	dataset	of	35	trabecular	bone	samples.		This	NN	estimated,	accurate	to	0.85	MPa,	the	trabecular	compressive	strength	in	patients	suffering	from	severe	hip	osteoarthritis	by	integrating	heterogeneous	bone	scan	data	with	the	patient’s	age	and	gender.	The	unique	feature	of	this	 model	 was	 that	 it	 was	 able	 to	 achieve	 98.3%	 accurate	 predictions	 of	 bone’s	mechanical	strength	from	structural	and	biological	parameters	without	 invasive	tests.	The	NN	offered	a	scalable	predictive	tool	 for	 femoral	strength	 in	osteoarthritis	with	a	potential	extension	for	other	degenerative	disorders	and	to	new	anatomical	locations.	
The	 renal	 transplant	 application	 demonstrated	 a	 successful	 extension	 of	 the	multiple	runs	method	to	small-data	DT	classification.	The	method	enabled	the	development	of	a	DT	risk	stratification	model	for	early	transplant	rejection	based	on	clinical	information	from	80	antibody-incompatible	 recipients.	This	easy-to-understand,	85%	accurate	DT	
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added	unprecedented	granularity	to	the	Cox	PH	and	LR	models,	identified	key	baseline	risk	 factors,	 and	 unveiled	 previously	 undetermined	 harmful	 antibody	 levels.	 By	integrating	known	and	novel	associations,	the	DT	classifier	provided	a	decision	support	tool	 for	 early	 risk	 stratification	 from	pre-treatment	 immunological	 indicators,	 leaving	clinicians	with	more	 time	to	make	essential	adjustments	 to	 treatment.	 	At	 the	 time	of	publication,	 this	 work	 was	 the	 first	 in	 the	 UK	 to	 use	 ML	 for	 the	 prediction	 of	 acute	rejection	 from	 immunological	 subclass	 data	 in	 antibody-incompatible	 renal	transplantation.	
The	third	and	the	final	application	considered	in	this	thesis	addressed	the	problem	of	
stratifying	the	10-year	risk	of	developing	type	2	diabetes	in	the	UK	general	population	from	routinely	collected	primary	care	data.	Several	prognostic	models,	including	Cox	PH,	LR,	survival	DT,	and	NN	ensembles	were	successfully	developed	and	validated	with	80,000	electronic	 medical	 records.	 Despite	 consistently	 achieving	 80-85%	 concordant	predictions,	 the	 Cox	 PH,	 LR,	 and	 NN	 ensembles	 grossly	 suffered	 from	 the	 “4	 Cs”	 of	routinely	collected	data,	which	reduced	the	amount	of	available	complete	samples	100-fold.	 In	 comparison,	 the	 multiple	 runs	 method	 enabled	 the	 development	 of	 a	 78%	concordant	 NN	 classifier	 from	 only	 158	 complete-data	 samples,	 demonstrating	 once	again	that,	given	adequate	data	quality,	small-data	ML	techniques	can	have	exceptional	prognostic	potential	in	healthcare.	 	The	remarkable	agreement	among	the	Cox	PH,	NN	ensemble,	 LR,	 and	 the	 existing	 QDiabetes®	 models	 evidenced	 that	 prognostic	performance	was	 a	 reflection	 of	 data	 quality,	 rather	 than	 a	 property	 of	 an	 individual	model.		
One	sobering	implication	of	this	research	for	the	current	NHS	type	2	diabetes	screening	system	is	that	substantial	improvements	to	its	prognostic	value	are	unlikely	to	be	gained	from	adopting	increasingly	more	powerful	ML	algorithms	unless	more	resources	can	be	
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dedicated	to	improving	data	collection	in	primary	care.	Rather	than	adapting	a	“store	it	all”	approach,	resources	should	be	focused	on	the	quality,	completeness	and	granularity	of	the	observations	linked	to	the	outcome	of	interest.	Of	a	particular	practical	value	is	the	survival	DT	model,	which	–	by	separating	the	groups	of	patients	at	high	and	low	risk	of	type	 2	 diabetes	 from	 those	 patients	 whose	 incomplete	 records	 required	 additional	granularity	 –	 allow	 for	 the	 targeted	 use	 of	 limited	 NHS	 resources.	 As	 repeatedly	evidenced	 in	 this	 research,	 further	 improvements	 to	 risk	 stratification	 and	 outcome	prediction	 in	 healthcare	 do	 not	 necessarily	 depend	 on	 large	 volumes	 of	 data.	 The	methodological	 significance	 of	 this	 research	 is	 that	 it	 removes	 the	 requirement	 for	substantive	volumes	of	data	for	ML.	By	lowering	the	barriers	for	the	application	of	ML	to	limited	clinical	data,	this	research	meaningfully	contributes	to	engineering	and	clinical	practice.	
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Appendix	A.	 Neural	network:	extended	methodology	
A	1		 Perceptron	transfer	functions	
The	 transfer	 function	 (TF)	 of	 a	 neuron	 represents	 the	 relation	between	 its	 input	 and	output	in	terms	of	spatial	or	temporal	frequency	[87,295].		The	definitions	of	common	TFs	in	feedforward	NNs	and	their	first	order	derivatives	are	provided	in	Figure	A.1.		The	list	is	by	no	means	exhaustive:	smooth	rectifier	(ReLU)	and	its	modifications,	logit,	probit,	complimentary	log-log	functions	could	be	used	in	NNs	if	effective	in		a	given	application	[228,295,296].		
Step-like	 functions	 produce	 highly	 efficient	 logical	 neurons,	 but	 their	 discontinuous	derivatives	 prohibit	 their	 use	 with	 gradient-based	 training	 algorithms	 [296].	 On	 the	other	hand,	sigmoidal	TFs	result	in	graded	response	neurons	with	differentiable	output.	Two	sigmoidal	TFs	were	used	for	the	final	NN	models	developed	in	this	research,	which	are	 SmnNQn : = VVoEpq	 and	 1P2NQn : = Eq»EpqEqoEpq	 .	 The	 sigmoidal	 functions	 were	particularly	suitable	for	NN	hidden	layers	as	they	cater	for	diverse	behaviours:		nearly	linear	in	the	vicinity	of	zero,	nearly	constant	in	the	saturation	range,	and	a	curvilinear	in	the	transition	zone	[17].	The	sigmoidal	TF	also	referred	to	as	‘squashing’	functions,	due	to	their	ability	to	take	a	real-valued	input	and	return	the	output	in	a	finite	interval:	[0;1]	for	SmnNQn(:)		and	[-1;1]	for	1P2NQn(:).		
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Figure	A.1	Common	perceptron	transfer	functions	A	2		 Backpropagation	
The	principles	underlying	backpropagation	have	existed	since	1960s,	but	 the	method	was	not	formalised	in	the	context	of	NNs	until	1986.	Experiments	by	Rumelhart,	Hinton	and	Williams	demonstrated	that	backpropagation	could	be	used	to	train	practical	multi-layer	 networks	 [100].	 Stuart	 Dreyfus	 is	 credited	 for	 an	 elegant	 derivation	 of	backpropagation	using	chain	rule	only	[105].	The	early	neural	networks	used	discrete	outputs,	barring	the	use	of	derivative-based	methods,	and	it	was	not	until	LeCun	[102]	and	 Rumelhart	 et	 al.	 [100]	 overcame	 this	 problem	 by	 replacing	 the	 binary-output	
Log-sigmoid Z(:) = 11 + "»ü Z′(:) = 11 + "»ü 	◊1 − 11 + "»üÿ 
Z(:) = "ü − "»ü"ü + "»ü Z′(:) = 1 − ◊"ü − "»ü"ü + "»üÿ, 
Tan-sigmoid 
Linear Z(:) = å: 
 Z′(:) = å 
Radial	basis Z(:) = "»üö 
 Z′(:) = −2:"»üö 
Z(:, Q) = "üu∑ "üuCV  Z′(:, Q) =	 Eqõ∑ Eqõ⁄ú ¤1 − Eqõ∑ Eqõ⁄ú ‹ 
Soft-max 
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neurons	with	those	using	sigmoidal	(smooth)	outputs.	The	forward	and	backward	passes	of	backpropagation	are	described	below.		
Forward	pass.		For	the	following	examples,	input	variable	:; 	is	a	scalar	that	refers	to	a	single	observation.	This	network	is	shown	in	the	diagram	in	Figure	A.2,	 for	which	the	intermediate	outputs	are	defined	as	follows:			
	 Ni = :;8;i + .i 	 "].	A.1		 	 3i = Zi(Ni)	 "].	A.2		 	 NB = 3i8iB + .B	 "].	A.3		 	 0 = 	ZB NB 	 "].	A.4		
where	 Ni 	 and	 NB	represent	 output	 of	 the	 summation	 operator	 in	 layers	 k	 and	 l,	respectively,	3i 	is	the	output	of	the	Zi 	transfer	function	with	input	sk	and	0	is	the	output	of	the	ZB 	transfer	function.	Combining	the	equations	A.1	–	A.4,	the	output	0	computed	in	the	forward	pass	is	determined	as:		
	 0 = ZB Zi :;8;i + .i 8iB + .B 	 "].	A.5		
Backward	pass.	The	cost	function	between	1	and	0		was	used	as	a	basis	for	finding	the	weighted	contributions	to	total	error	by	each	weight	and	bias	in	the	network.	This	was	achieved	by	using	partial	derivatives	at	each	step	of	the	NN	structure	in	a	chain	rule,	as	illustrated	in	Figure	A.2.	
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Figure	A.2	Backpropagation:	forward	and	backward	passes	To	 determine	 the	 gradient	 of	 the	 cost	 function	 for	 8iB ,	 	 the	 value	 of	 ›r›∫¢ﬁ	 must	 be	determined.	Using	the	chain	rule	to	find	this	derivative	gives:	
	 x/x8iB = x/x0 × x0xNB × xNBx8iB	 "].	A.6		
In	order	to	find	the	gradient	of	the	cost	function	w.r.t.	bias	.B ,	the	chain	rule	becomes:	
	 x/x.B = x/x0 × x0xNB × xNBx.B	 "].	A.7		
Let	the	cost	function	represent	a	squared-error	function:	
/ = 12 1 − 0 ,	
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Let	ZB 	represent	a	logarithmic	sigmoid	transfer	function:	
ZB = 11 + "™ﬁ 	
Differentiating	each	term	of	the	chain	rule	(equations	A.6	and	A.7):	
æ/æ0 = æ(12 1 − 0 ,)æ0 = −22 (1 − 0) = 0 − 1	
æ0æNB = æ( 11 + "™ﬁ)æNB = 11 + "™ﬁ − 11 + "™ﬁ , = 0 1 − 0 	
æNBæ8iB = æ(3i8iB + .B)æ8iB = 3i 	
æNBæ.B = æ(3i8iB + .B)æ.B = 1	
Expanding	the	chain	rule	(equations	A.6	and	A.7):	
	 x/x8iB = 3i0 1 − 0 (0 − 1)	 "].	A.8			 	 x/x.B = 0 1 − 0 (0 − 1)	 "].	A.9		
In	order	to	extend	this	method	for	finding	the	gradients	of	the	cost	function	w.r.t.	8;i 	and	.i ,	one	must	expand	the	chain	rule	to	include	the	additional	terms	›∫¢ﬁ›b¢ ,	›b¢›™¢ ,	 ›™¢›∫ù¢	and	›∫¢ﬁ›b¢ ,	›b¢›™¢ ,	›™¢›@¢	respectively:	
	 x/x8;i = x/x8iB × x8iBx3i × x3ixNi × xNix8;i	 "].	A.10			
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	 x/x.i = x/x8iB × x8iBx3i × x3ixNi × xNix.i	 "].	A.11		
Let	Zi 	represent	a	hyperbolic	tangent	sigmoid	transfer	function:	
Zi = "™¢ − "»™¢"™¢ + "»™¢ 	Differentiating	each	additional	term	of	the	chain	rule	(equations	A.10	and	A.11):	
x8iBx3i = 1	
x3ixNi = æ("
™¢ − "»™¢"™¢ + "»™¢)æNi = 1 − "™¢ − "»™¢"™¢ + "»™¢ , = 1 − 3i,	
xNix8;i = æ(:;8;i + .i)æ8;i = :	
xNix.i = æ(:;8;i + .i)æ.i = 1	
Expanding	the	chain	rule	(equations	A.10	and	A.11):	
	 x/x8;i = 3i:;0 1 − 0 (0 − 1)(1 − 3i,)	 "].	A.12			 	 x/x.i = 3i0 1 − 0 (0 − 1)(1 − 3i,)	 "].	A.13		
These	 equations	 allowed	 determination	 of	 the	 weighted	 contribution	 of	 each	 NN	parameter	to	the	resulting	error	for	a	given	sample,	which	are	required	when	calculating	the	weight	update.		
Optimisation	algorithms	(also	referred	to	as	solution	algorithms)	are	used	to	determine	the	required	update	to	the	network	parameters	from	the	cost	function	derivative	as	an	
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input	variable.	Typically,	backpropagation	NNs	use	a	gradient	descent	method	to	find	the	optimal	solution,	i.e.	minimise	the	cost	function	by	considering	the	differential	equation	of	error	with	respect	to	weight	values.	This	involves,	for	instance,	a	simple	proportional	response,	such	as	 in	the	gradient	descent	(Section	A.2.1),	or	a	more	complex,	adaptive	optimisation,	 such	 as	 in	 Levenberg-Marquardt	 algorithm	 (Section	 A.2.2),	 or	 scaled	
conjugate	gradient	(SCG)	method	(Section	A.2.3).			
Multiple	alternatives		to	backpropagation	exist	for	NN	training	[297].	These	include	now-obsolete	 techniques	 such	 as	 simulated	 annealing	 [298]	 and	 Nelder-Mead	 simplex	method	[299],	population-based	training	such	as	evolutionary	algorithms	and	particle	swarm	optimisation	[300],	and	probabilistic	methods	such	as	radial	basis	functions	and	contrastive	divergence	[301].	Extensive	work	contrasting	these	stochastic	and	gradient-free	 optimisation	methods	with	 backpropagation	 is	 described	 in	 the	 literature	 [302],	with	 the	 general	 view	 holding	 that	 any	 appropriately-tuned	method	 can	 outperform	others	in	a	given	application.	In	comparison	to	backpropagation,	where	known	output	values	 are	 used	 to	 direct	 the	 NN	 parameter	 adjustment,	 the	 stochastic	 optimisation	disregards	 this	 information	 and	 attempts	 random	 changes	 to	 the	 parameters,	 often	rendering	 them	 impractical	 for	 real-world	 applications.	 For	 those	 reasons,	backpropagation	remains	dominant	in	feedforward	NN	training	[103,303].	
A.2.1		Gradient	descent	
Gradient	descent	is	a	first-order	iterative	optimisation	algorithm	which	uses	the	gradient	of	the	cost	function	with	respect	to	each	weight	in	order	to	determine	the	direction	and	magnitude	of	the	required	change	to	the	present	weight	value.	The	weight	updates	can	then	be	calculated	as	a	step	in	the	direction	of	decreasing	error	(“descending”	the	error	gradient),	usually	with	a	magnitude	which	is	a	fraction	of	the	current	gradient.		
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The	learning	rule	specifies	the	weight	updates	with	regards	to	the	gradient	derived	by	gradient	descent.	For	a	gradient	descent	approach,	the	learning	rule	at	a	specific	weight	8;i 	 is	 given	 by	 the	 product	 of	 the	 neuron	 error,	 the	 first	 derivative	 of	 the	 activation	function	and	the	input	to	the	weight:	
∆8;i = −·	 x/ix8iB 	3i	Ni	:; 	
where	∆8;i 	is	the	weight	update	at	weight	8;i ,	·	is	the	learning	rate,	x/i 	is	the	gradient	of	the	error	function	with	respect	to	8;i ,	Ni 	is	the	sum	of	weighted	inputs	at	neuron	k,	and	x; 	is	the	input	to	the	weight	8;i .		
One	limitation	of	the	gradient	descent	algorithm	is	the	possibility	of	training	the	weights	and	 biases	 to	 reach	 a	 local	 minimum,	 hence	 constraining	 the	 potential	 gains	 of	 the	learning	process.	This	occurs	as	a	result	of	the	nature	of	the	gradient	descent,	as	it	simply	seeks	to	minimise	the	size	of	the	error,	without	general	knowledge	of	the	error	function	outside	of	the	near	vicinity	in	the	variable	space.	The	risk	of	optimising	for	local	minima	can	be	reduced	by	selecting	appropriate	learning	rates	[87,304].	
	
Figure	A.3	Effect	of	changing	learning	rate	on	saddle	point	local	minima	
E(y) 
y 
(a) E(y) 
y 
(b) 
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Figure	A.3	(a)	illustrates	the	potential	problem	of	reaching	a	local	minimum	when	using	an	inadequate	learning	rate,	while	Figure	A.3	(b)	contrasts	the	convergence	towards	a	lower	minimum	when	using	a	different	learning	rate.	It	is	also	worth	noting	that	a	high	learning	rate	may	result	in	an	unstable	oscillating	response	during	training,	while	a	low	learning	rate	may	result	in	a	very	slow	learning	process.	
Similarly	to	learning	rate,	initial	weight	and	bias	values	also	influence	the	ability	of	the	NN	to	converge	to	minimum	error	solutions,	as	they	can	cause	the	learning	algorithm	to	optimise	local	minimums	and	saddle	points.	Therefore,	the	success	of	gradient	descent	backpropagation	algorithm	depends	on	arbitrary	user-defined	learning	rate	and	initial	weight	and	bias	values.	
One	modification	of	gradient	descent	applies	the	use	of	a	“momentum	term”	in	the	weight	update	equation,	which	essentially	 transforms	an	online-learning	approach	 to	a	mini-batch	approach	using	a	moving	average	[305].		More	recent	work	has	demonstrated	the	merits	of	employing	a	gradient	descent	 learning	algorithm	with	variable	 learning	rate	[306].	This	approach	not	only	optimises	the	trade-off	between	a	 fast	 learning	process	and	an	effective	optimisation,	but	also	reduces	 the	dependency	on	selecting	adequate	starting	weight	values	[304].	
A.2.2		Gauss-Newton	and	Levenberg-Marquardt	algorithms		
Levenberg-Marquardt	 algorithm	 operates	 by	 finding	 a	 solution	 for	 a	 non-linear	 least	squares	problem.	The	algorithm	alternates	between	gradient	descent	and	Gauss-Newton	methods	depending	on	the	outcome	of	previous	iterations	using	a	variable	learning	rate	[112].		Gauss-Newton	method	can	be	described	by	considering	a	nonlinear	least-squares	optimisation	problem:	
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/ = 12 5u, !CuwV 	
where	2	is	to	the	number	of	observations,	5u ! 	is	the	error	function	between	the	target	1u 	 and	 the	 predicted	 variable,	 and	 !	 is	 the	 vector	 of	 model	 parameters	 ! = [!V,!,, … , !Ø],	where	the	model	comprises	®	parameters	and	/	represents	the	summation	of	squared	errors.	The	error	can	be	expressed	as	follows:	
	 5u ! = 1u − Z :u, ! 	 "].	A.14		
where	Z :u, ! 	represents	the	predicted	variable	resulting	from	the	model.	To	identify	the	set	of	model	parameters	that	will	minimise	the	squared	error,	an	iterative	approach	can	be	adopted,	while	taking	an	initial	assumption	for	the	parameters	! ô ,	and	modifying	this	by	a	pre-determined	step.	The	step	is	determined	using	a	Newton	method	of	finding	minima	to	a	function,	that	uses	a	Taylor	series	quadratic	approximation	[307].			
The	parameter	update	equation	takes	the	form:	
	 ! ™oV = ! ™ − n¿»V	 "].	A.15		
where	 ¿	 is	 the	 Hessian	 matrix	 of	 the	 error,	 composed	 of	 the	 second-order	 partial	derivatives	of	the	error	function,	and	n	is	the	first-order	derivative	vector.	Shown	below	is	the	Hessian	matrix	specific	to	the	error	function	defined	in	"].	A.14:	
¿ =
‚5u‚!V , + ‚,5u‚!V,CuwV ‚5u‚!V ‚5u‚!, + ‚,5u‚!V‚!,
C
uwV‚5u‚!, ‚5u‚!V + ‚,5u‚!,‚!VCuwV ‚5u‚!, , + ‚,5u‚!,,
C
uwV
⋯ ‚5u‚!V ‚5u‚!Ø + ‚
,5u‚!V‚!ØCuwV ‚5u‚!, ‚5u‚!Ø + ‚,5u‚!,‚!ØCuwV⋮ ⋱ ⋮‚5u‚!Ø ‚5u‚!V + ‚,5u‚!Ø‚!VCuwV ‚5u‚!Ø ‚5u‚!, + ‚,5u‚!Ø‚!,
C
uwV ⋯ ‚5u‚!Ø , + ‚,5u‚!Ø,
C
uwV
	 "].	A.16		
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n = 5u ‚5u‚!VCuwV , 5u ‚5u‚!,
C
uwV 	 , … , 5u ‚5u‚!Ø
C
uwV 	
For	small	steps,	the	second-order	terms	in	the	Hessian	matrix	can	be	ignored,	and	both	the	Hessian	matrix	and	the	gradient	vector	can	be	expressed	in	terms	of	the	respective	Jacobians:	
¿ = „e„	
n = „e5	
where	the	Jacobian	matrix	has	the	format:	
„ =
‚5V‚!V ‚5V‚!,‚5,‚!V ‚5,‚!, ⋯
‚5V‚!Ø‚5,‚!Ø⋮ ⋱ ⋮‚5C‚!V ‚5C‚!, ⋯ ‚5C‚!Ø
	
We	can	therefore	rewrite	the	step	change	equation	(A.14):	
	 ! ™oV = ! ™ − „e„ »V„e5	 "].	A.17		
Levenberg	Marquardt	is	effectively	a	modification	of	the	Gauss-Newton	algorithm,	and	uses	the	parameter	λ	to	blend	gradient	descent	and	Gauss-Newton	methods:	
	 ! ™oV = ! ™ − „e„ + 'ê »V„e5	 "].	A.18		
If	 the	 error	 is	 reduced	 following	 a	 weight	 update,	 λ	 is	 decreased	 to	 increase	 the	contribution	 of	 Gauss-Newton,	 therefore	 increasing	 the	 sensitivity	 of	 the	 update	algorithm.	 If	 the	 error	 increases	 after	 a	weight	 update,	λ	 is	 increased	 and	 the	weight	
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update	reversed,	allowing	gradient	descent	to	more	rapidly	guide	the	weight	update.	In	this	manner,	Levenberg	Marquardt	is	able	to	combine	the	sensitivity	of	a	Gauss-Newton	method	with	the	speed	of	convergence	of	gradient	descent,	greatly	improving	training	efficiency,	as	demonstrated	by	Rojas	[308].	
A.2.3		Conjugate	gradient	method	
Conjugate	gradient	methods	are	used	to	calculate	the	global	minimum	for	a	function	of	the	form	=: = .,	where	A	is	a	symmetric	positive	definite	n-by-n	matrix,	and	x	and	b	are	vectors	of	size	n	[115,309].	Similar	to	gradient	descent,	the	conjugate	gradient	method	takes	an	iterative	approach	to	finding	the	minimum	of	a	function,	but	additionally	uses	the	concept	of	conjugate	vectors	to	find	an	optimal	step	size	[310,311].	A	pair	of	non-zero	vectors	u	and	v,	is	said	to	be	conjugate	when:	
Oe=R = 0		
The	first	iteration	in	the	conjugate	gradient	method	is	performed	in	a	manner	similar	to	gradient	 descent,	 with	 direction	 proportional	 to	 the	 steepest	 gradient	 at	 the	 first	estimated	 solution,	 and	magnitude	 optimised	 by	 a	 line	 search.	 The	 direction	3	 of	 all	subsequent	iterations,	however,	must	be	orthogonal	to	all	previous	steps,	and	for	step	å	is	given	by	the	formula:	
	 3i = −ni + !i3i»V	 "].	A.19		
where	ni 	is	the	gradient	at	the	current	estimate,	!i 	is	an	adaptive	constant	that	ensures	the	 orthogonality	 of	 the	 gradient	 [115].	 The	 equation	 to	 calculate	 !i 	 varies	 across	different	conjugate	gradient	algorithms;	 the	one	used	 in	 this	 study	 is	Fletcher-Reeves	approach	[312],	in	which	!i 		is	given	by:	
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	 !i = nienini»Veni»V	 "].	A.20		
The	 conjugate	 gradient	 method	 relies	 on	 the	 assumption	 that	 the	 error	 in	 the	neighbourhood	of	 the	 current	 estimate	/ 8i 3i 	 can	be	 approximated	by	 a	 quadratic	equation.	 The	 step	 size	 is	 then	 calculated	 using	 a	 line	 search	 algorithm,	 which	 is	computationally	intensive.	A	modification,	called	scaled	conjugate	gradient	(SCG),	was	introduced	by	Møller	 [115],	with	 the	 aim	of	 combining	 the	 conjugate	 gradient	with	 a	model	trust	region,	similar	to	Levenberg-Marquardt.	This	approach	uses	the	following	approximation	 to	 the	 second	 order	 terms	 in	 the	 Hessian	 matrix	 of	 the	 error	function	/ 8i 3i 	with	respect	to	weights	8i 	:	
	 ‚,/ 8i 3i ≈ ‚/ 8i + *i3i − ‚/(8i)*i + 'i3i	 "].	A.21		
where	*i 	and	'i 	are	arbitrary	small	positive	constants.	This	approximation	reduces	the	complexity	of	 the	computation,	 increasing	the	training	efficiency	[313,314].	The	proof	and	detail	of	this	method	are	presented	by	Møller	[115].	
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Appendix	B.	 Performance	criteria	
The	regression	factor		J	compares	the	sum	of	squares	due	to	error	and	the	total	sum	of	squares,	and,	in	its	standard	form,	is	given	by:		
J = 1 −	 1u − 0u ,CuwV 1u − 0 ,CuwV 		
where	1u 	is	the	target	output,	0u 	is	the	output	predicted	by	the	model,	0	is	the	mean	of	0u 	and	2	is	a	total	number	of	samples	[315].		J	takes	values	between	0	and	1,	where	J	=	1	corresponds	to	a	perfect	fit,	signifying	that	the	entire	variance	in	the	dependent	output	variable	 can	 be	 explained	 by	 the	 regression	 equation.	 J		greater	 than	 0.6	 defines	statistically	 significant	 performance,	 i.e.	 JABB ≥ 0.6, J~ ≥ 0.6, J©AB ≥ 0.6,	 and	 J~E™~ ≥0.6		[84].	
JLM/,	 provides	 the	 same	 information	as	J,	 but	 is	 expressed	 in	 terms	of	 the	absolute	difference	 between	 model	 predictions	 and	 targets,	 making	 it	 particularly	 useful	 for	visualising	the	error	in	the	units	of	the	output	variable:	
JLM/ = 12 (1u − 0u),CuwV 							
In	 classification	problems,	where	 1u 	 is	 dichotomous	 (0	 or	 1),	 the	model	 accuracy	 is	expressed	by	the	proportion	of	observations	with	correctly	predicted	class		[182].	With	NN	 and	 DT	 classifiers,	 the	 predicted	 outcome	0u 	 is	 a	 continuous	 real-valued	 number	(between	0	and	1)	that	describes	a	probability	of	each	class.	In	order	to	dichotomise	0u 	into	 a	 binary	 class	 label,	 a	 cut-off	 is	 applied	 at	 a	 given	 discrimination	 threshold	 (0.5	default	value).	Receiver	operating	characteristic	(ROC)	curve	[182]	depicts	M3	versus	1 −M2	at	various	thresholds,	where	each	point	represents	a	different	trade-off	between	¶I	
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and	¶•	predictions.		This	trade-off	can	be	quantified	as	cost	ratio,	which	is	defined	by	the	gradient	 of	 the	 line	 tangent	 to	 the	 ROC	 curve.	 The	 area	 under	 the	 ROC	 curve	 (=>?)	represents	 the	performance	 averaged	 across	 all	 cost	 ratios.	On	 the	unit	ROC	 space,	 a	perfect	prediction	would	yield	 an	=>?	of	1.0.	A	 random	coin	 flipping	would	 result	 in	points	along	the	diagonal	and	the	corresponding	=>?	of	0.5.	Tracing	back	its	origins	to	World	War	II,	where	it	was	developed	to	model	FP	and	FN	radar	detections,	ROC	is	now	a	 standard	measure	 of	 discrimination	 in	medicine	 and	 clinical	 science,	 and	 its	 use	 is	becoming	increasingly	popular	in	the	ML	community	[182].	
In	survival	modelling	the	true	outcome	1u 	may	not	be	known	for	some	patients	due	to	censoring.	 A	 generalization	 of	 the	 =>?	 for	 assessing	 the	 discriminating	 ability	 of	 a	survival	model	is	known	as	concordance	–	a	rank	correlation	between	the	predicted	risk	0u 	 	and	the	observed	survival	times	§	for	all	comparable	pairs	[293].		For	time-to-event	outcomes,	pairs	of	patients	(Q, ‰)	are	comparable	(useable)	if	§u ≯ §; ,	at	least	one	of	the	patients	is	uncensored.	The	pair	is	said	to	be	concordant	when	the	patient	with	the	lowest	predicted	 risk	0	 out	 survives	 the	 other,	 i.e.	 has	 the	 longer	 survival	 time	§.	 The	most	popular	 concordance	measure	 in	 biostatistics	 and	 prognostic	 modelling	 is	 known	 as	Harrell’s	? − Q2æ":,	which	defines	the	probability	of	concordant	pairs	in	all	usable	pairs	[316]	as	follows:	
?-index	= I 0u > 0; §u < §;)	
Although	 it	 had	been	 recently	 suggested	 that	Uno’s	 or	Gonen	&	Heller’s	 concordance	measures	are	more	suitable	 for	applications	with	high	proportion	of	 censoring	 [293],	Harrell’s	?-index	was	adopted	in	Chapter	6	in	order	to	ensure	consistency	of	comparison	with	the	existing	studies,	as	specified	by	the	collaboration	protocol	[90].		
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Another	 measure	 of	 discrimination	 popular	 in	 survival	 analysis	 is	 Royston	 and	
Sauerbrei’s	G	[317].	The	G	statistic	quantifies	the	relative	gain	in	prognostic	separation	between	 two	 equally-sized	 groups	 of	 patients	with	 lowest	 and	highest	 predicted	 risk	scores	0	 defined	 at	 the	median	 value.	 This	 is	 achieved	 by	 ordering	0,	 calculating	 the	expected	 normal	 order	 statistics,	 scaling	 them	 by	 factor	 å = 	 8/Ê	 and	 performing	auxiliary	regression	on	the	scaled	values	[317].	What	makes	Royston	and	Sauerbrei’s	G	particularly	 appealing	 for	 assessing	 Cox	 PH	 survival	 models,	 is	 that	 it	 provides	 an	indication	of	the	overall	model	log	hazard	ratio.			
An	 J,-like	 form	 could	 be	 achieved	 by	 transforming	 G	 into	 JK, 	 which,	 in	 turn,	 is	interpreted	as	the	proportion	of	prognostic	separation	explained	by	the	model:	
JK, = 	 G, å,	*, + G, å,			
where	* = 	 	1		for	lognormal	models																																																					Ê, 3 	for	loglogistic	or	proportional	odds	models	Ê, 6 	for	proportional	hazard	models																								 	
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Appendix	C.	 Concrete	compressive	strength	dataset	
The	subsets	of	concrete	CS	data	were	accessed	through	a	public	repository	[164,165]	and	partitioned	as	follows	for	the	3	NN	models	considered	in	Chapter	3:	(a)	large-dataset	NN	(730	model	samples	and	300	tests),	(b)	intermediate	100-sample	NN	(70	model	samples	and		30	tests),	(c)	small-dataset	NN	(41	model	samples	and	15	tests).	The	model	samples	refer	to	the	validation	and	training	samples,	combined.			
Table	C.1	provides	the	key	statistics	on	each	model	(a),	(b)	and	(c)	with	the	breakdown	according	 to	 the	model	 and	 test	 subsets	 (number	 of	 samples	 given	 in	 brackets).	 The	frequency	distribution	histograms	for	each	of	the	9	variables	:	in	the	complete	CS	dataset	are	included	in	the	last	column.	
Table	C.1	Concrete	CS	dataset	statistics	by	individual	variable		 Model	 Subset	 min	 max	 µ	 σ	 Frequency	distribution	of	the	variable	across	all	
(1030)	samples	
Ag
e	
(d
ay
s)
	
	 all	(1030)	 1.0	 365.0	 45.7	 63.2	
	
a	 model	(730)	 1.0	 356.0	 44.6	 62.5	test	(300)	 3.0	 365.0	 48.3	 64.9	
b	 model	(70)	 3.0	 365.0	 50.5	 69.3	test	(30)	 3.0	 365.0	 41.1	 64.8	
c	 model	(41)	 3.0	 365.0	 45.5	 70.2	test	(15)	 3.0	 180.0	 43.6	 46.1		 	
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Bl
as
t	F
ur
na
ce
	S
la
g	
(k
g/
m
3 )
	
	 all	(1030)	 0.0	 359.4	 73.9	 86.3	
	
Blast	Furnace	Slag	in	the	mixture	(kg/m3)	
a	 model	(730)	 0.0	 359.4	 73.3	 86.3	test	(300)	 0.0	 342.1	 75.4	 86.4	
b	 model	(70)	 0.0	 316.1	 66.4	 81.7	test	(30)	 0.0	 239.0	 68.2	 87.3	
c	 model	(41)	 0.0	 359.4	 86.1	 84.9	test	(15)	 0.0	 250.2	 90.6	 90.4	
Ce
m
en
t		
(k
g/
m
3 )
	
	 all	(1030)	 102.0	 540.0	 281.2	 104.5	
Cement	in	the	mixture	(kg/m3)	
a	 model	(730)	 102.0	 540.0	 279.9	 103.9	test	(300)	 108.3	 540.0	 284.2	 106.1	
b	 model	(70)	 102.0	 540.0	 286.8	 117.1	test	(30)	 145.9	 525.0	 290.6	 115.9	
c	 model	(41)	 140.0	 500.0	 285.0	 111.7	test	(15)	 102.0	 522.0	 268.4	 121.1	
Co
ar
se
	A
gg
re
ga
te
		(
kg
/m
3 )
	
	 all	(1030)	 801.0	 1145.0	 972.9	 77.8	
	
Coarse	Aggregate	in	the	mixture	(kg/m3)	
a	 model	(730)	 801.0	 1145.0	 973.1	 76.9	test	(300)	 801.0	 1134.0	 972.6	 79.8	
b	 model	(70)	 822.0	 1125.0	 965.0	 83.4	test	(30)	 827.0	 1125.0	 986.4	 73.6	
c	 model	(41)	 822.0	 1125.0	 972.4	 81.4	test	(15)	 814.0	 1069.0	 930.8	 63.3	
Fi
ne
	A
gg
re
ga
te
	(k
g/
m
3 )
	
	 all	(1030)	 594.0	 992.6	 773.6	 80.2	
	
Fine	Aggregate	in	the	mixture	(kg/m3)	
a	 model	(730)	 594.0	 992.6	 774.7	 79.2	test	(300)	 594.0	 992.6	 770.8	 82.6	
b	 model	(70)	 613.0	 943.1	 779.1	 77.9	test	(30)	 594.0	 896.0	 767.0	 74.6	
c	 model	(41)	 594.0	 943.1	 772.2	 76.8	test	(15)	 594.0	 942.0	 787.6	 95.1	
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Fl
y	
As
h	
	(k
g/
m
3 )
	
	 all	(1030)	 0.0	 200.1	 54.2	 64.0	
	
Fly	Ash	in	the	mixture	(kg/m3)	
a	 model	(730)	 0.0	 200.1	 55.5	 64.3	test	(300)	 0.0	 200.1	 51.0	 63.2	
b	 model	(70)	 0.0	 194.9	 48.1	 59.5	test	(30)	 0.0	 174.2	 56.4	 63.6	
c	 model	(41)	 0.0	 174.9	 49.4	 63.1	test	(15)	 0.0	 195.0	 52.9	 72.4	
Su
pe
rp
la
st
ic
iz
er
		(
kg
/m
3 )
	
	 all	(1030)	 0.0	 32.2	 6.2	 6.0	
	
Superplasticizer	in	the	mixture	(kg/m3)	
a		 model	(730)	 0.0	 32.2	 6.3	 5.9	test	(300)	 0.0	 32.2	 5.9	 6.1	
b		 model	(70)	 0.0	 32.2	 5.7	 6.1	test	(30)	 0.0	 32.2	 7.9	 7.2	
c		 model	(41)	 0.0	 32.2	 6.1	 6.9	test	(15)	 0.0	 18.0	 6.3	 6.0	
W
at
er
	(k
g/
m
3 )
	
	 all	(1030)	 121.8	 247.0	 181.6	 21.4	
	
Water	in	the	mixture	(kg/m3)	
a	 model	(730)	 121.8	 247.0	 181.2	 21.0	test	(300)	 126.6	 228.0	 182.5	 22.1	
b	 model	(70)	 137.8	 246.9	 184.7	 19.4	test	(30)	 137.8	 228.0	 178.6	 23.8	
c	 model	(41)	 121.8	 228.0	 181.0	 22.2	test	(15)	 146.0	 228.0	 184.8	 27.2	
Co
m
pr
es
si
ve
	s
tr
en
gt
h	
(M
Pa
)	
	 all	(1030)	 2.3	 82.6	 35.8	 16.7	
	
Compressive	strength	(MPa)	
a	 model	(730)	 3.3	 82.6	 35.6	 16.2	test	(300)	 2.3	 81.8	 36.3	 17.9	
b	 model	(70)	 4.6	 72.1	 36.1	 17.5	test	(30)	 12.5	 75.0	 36.9	 15.1	
c	 model	(41)	 4.8	 80.2	 34.8	 18.9	test	(15)	 7.7	 75.0	 35.9	 19.0	
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Appendix	D.	 Bone	dataset:	real	and	surrogate	data	
Bone	data	in	Table	D.2	were	extracted	from	the	original	study	by	Perilli	et	al.	[166]	using	a	Plot	Digitiser	 tool	 [160].	Surrogate	data	 in	Table	D.3	were	synthesised	as	a	 random	normal	distribution	with	the	mean	and	standard	deviation	of	the	real	bone	data	within	the	same	range	(Section	3.4.5).	
Table	D.2	Trabecular	bone	data	Sample	 SMI	 Tb.Th	(μm)	 BV/TV	(%)	 Age	(years)	 Gender	(F=1)	 CS	(MPa)	1	 0.06	 243	 32.5	 41.8	 1	 20.9	2	 1.42	 224	 21.5	 52.0	 1	 6.91	3	 0.48	 239	 26.6	 57.0	 1	 18.2	4	 -0.82	 212	 43.5	 63.9	 1	 9.46	5	 1.22	 419	 17.9	 64.0	 1	 23.1	6	 0.64	 223	 27.6	 67.1	 1	 19.4	7	 2.10	 197	 9.82	 68.1	 1	 2.76	8	 0.38	 367	 26.9	 71.5	 1	 18.9	9	 0.80	 218	 15.4	 74.9	 1	 6.49	10	 0.54	 314	 25.0	 76.0	 1	 17.8	11	 0.30	 326	 32.4	 87.0	 1	 24.2	12	 -0.17	 287	 30.4	 41.7	 0	 21.5	13	 -0.31	 284	 37.0	 47.9	 0	 16.4	14	 0.04	 265	 38.7	 49.8	 0	 11.1	15	 0.82	 241	 22.7	 49.8	 0	 26.5	16	 -0.23	 303	 37.6	 65.8	 0	 28.8	17	 1.77	 219	 25.3	 68.0	 0	 4.91	18	 1.33	 261	 17.4	 72.9	 0	 9.81	19	 0.04	 307	 29.7	 73.9	 0	 23.7	20	 0.36	 271	 31.6	 81.8	 0	 24.4	21	 0.31	 252	 33.8	 60.9	 1	 20.5	22	 0.70	 283	 22.5	 62.9	 1	 12.2	23	 1.59	 247	 13.7	 72.6	 1	 1.93	24	 0.45	 257	 27.4	 45.7	 0	 19.6	25	 0.44	 266	 27.5	 62.9	 0	 18.5	26	 0.15	 270	 32.1	 77.8	 0	 22.2	27	 1.08	 193	 19.4	 87.0	 0	 9.12	28	 1.93	 154	 9.68	 49.0	 1	 8.22	29	 0.92	 263	 25.3	 66.0	 1	 15.4	30	 -0.43	 299	 39.7	 69.9	 1	 23.2	31	 1.04	 239	 21.0	 73.9	 1	 8.15	32	 -0.05	 288	 35.6	 46.8	 0	 24.3	33	 0.39	 246	 26.6	 64.9	 0	 19.3	34	 0.71	 178	 12.2	 68.0	 0	 14.0	35	 0.70	 234	 21.8	 84.9	 0	 13.3		
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Table	D.3	Surrogate	data	Sample	 SMI	 Tb.Th	(μm)	 BV/TV	(%)	 Age	(years)	 Gender	(F=1)	 CS	(MPa)	1	 0.06	 243	 32.5	 41.8	 1	 20.9	2	 1.42	 224	 21.5	 52.0	 1	 6.91	3	 0.48	 239	 26.6	 57.0	 1	 18.2	4	 -0.82	 212	 43.5	 63.9	 1	 9.46	5	 1.22	 419	 17.9	 64.0	 1	 23.1	6	 0.64	 223	 27.6	 67.1	 1	 19.4	7	 2.10	 197	 9.82	 68.1	 1	 2.76	8	 0.38	 367	 26.9	 71.5	 1	 18.9	9	 0.80	 218	 15.4	 74.9	 1	 6.49	10	 0.54	 314	 25.0	 76.0	 1	 17.8	11	 0.30	 326	 32.4	 87.0	 1	 24.2	12	 -0.17	 287	 30.4	 41.7	 0	 21.5	13	 -0.31	 284	 37.0	 47.9	 0	 16.4	14	 0.04	 265	 38.7	 49.8	 0	 11.1	15	 0.82	 241	 22.7	 49.8	 0	 26.5	16	 -0.23	 303	 37.6	 65.8	 0	 28.8	17	 1.77	 219	 25.3	 68.0	 0	 4.91	18	 1.33	 261	 17.4	 72.9	 0	 9.81	19	 0.04	 307	 29.7	 73.9	 0	 23.7	20	 0.36	 271	 31.6	 81.8	 0	 24.4	21	 0.31	 252	 33.8	 60.9	 1	 20.5	22	 0.70	 283	 22.5	 62.9	 1	 12.2	23	 1.59	 247	 13.7	 72.6	 1	 1.93	24	 0.45	 257	 27.4	 45.7	 0	 19.6	25	 0.44	 266	 27.5	 62.9	 0	 18.5	26	 0.15	 270	 32.1	 77.8	 0	 22.2	27	 1.08	 193	 19.4	 87.0	 0	 9.12	28	 1.93	 154	 9.68	 49.0	 1	 8.22	29	 0.92	 263	 25.3	 66.0	 1	 15.4	30	 -0.43	 299	 39.7	 69.9	 1	 23.2	31	 1.04	 239	 21.0	 73.9	 1	 8.15	32	 -0.05	 288	 35.6	 46.8	 0	 24.3	33	 0.39	 246	 26.6	 64.9	 0	 19.3	34	 0.71	 178	 12.2	 68.0	 0	 14.0	35	 0.70	 234	 21.8	 84.9	 0	 13.3		
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Appendix	E.	 Multiple	imputation	in	diabetes	data	
Imputation	accuracy	of	BG	and	BMI	values	using	MICE	(Section	3.1.3)	was	investigated	on	 a	 cohort	 of	 14922	 patients	 for	whom	 the	 BG	 and	 BMI	 values	were	 known.	 These	samples	 were	 randomly	 injected	 with	 missing	 values	 in	 BG	 and	 BMI	 columns	 to	reproduce	 the	 proportion	 of	missing	 values	 in	 the	 original	 cohort	 of	 79959	 patients	(Figure	E.1).	
	
Figure	E.4	Missing	patterns	reproduced	to	match	the	original	missing	proportions:	70%	of	BG	values	and	40%	
of	BMI	values	are	missing.	Subsequently,	 the	 deliberately	 introduced	 missing	 values	 were	 imputed	 using	 MICE	algorithm	with	m	iterations.	The	model	included	gender,	age,	family	history	of	DM,	CVD,	hypertension,	 ethnicity,	 steroid	 use,	 smoking	 status,	 Townsend	 index	 and	 type	 2	DM	outcome.		
Table	E.1	indicates	the	JLM/	values	for	BG	and	BMI	averaged	across	all	imputed	samples	for	various	m	from	1	to	100.	For	this	particular	study,	the	number	of	MICE	iterations	had	a	marginal	effect	on	the	overall	imputation	error,	which	was	equal	to	0.96	mmol/L	for	BG	and	4.7	for	BMI,	corresponding	to	19%	and	18%	relative	error,	respectively.			
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Table	E.4	Imputation	accuracy	of	MICE	at	70%	missing	BG	and	40%	missing	BMI		 JLM/	between	actual	and	imputed	values	
BG	(mmol/L)	 Ò	 Ú	 min	 max	m=1	 0.949	 NA	 0.949	 0.949	m=5	 0.962	 0.012	 0.948	 0.978	m=10	 0.957	 0.009	 0.938	 0.968	m=50	 0.959	 0.009	 0.936	 0.980	m=100	 0.957	 0.010	 0.933	 0.983		 	
BMI	(kg/m2)	 Ò	 Ú	 min	 max	m=1	 4.703	 NA	 4.703	 4.703	m=5	 4.759	 0.000	 4.759	 4.759	m=10	 4.744	 0.000	 4.744	 4.744	m=50	 4.756	 0.000	 4.756	 4.756	m=100	 4.757	 0.000	 4.757	 4.757			It	 is	 important	 to	 note	 that	 JLM/	 is	 not	 the	 only	 indication	 of	 the	 effectiveness	 of	imputation.	As	discussed	in	Section	3.1.3,	MICE	does	not	optimise	for	individual	sample	accuracy,	 but	 instead	 attempts	 to	 reproduce	 the	 overall	 resemblance	 to	 a	 complete	dataset	by	generating	multiple	datasets.	
	
